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The development of methods to produce diverse set of small molecules to be 
utilized as chemical probes in chemical biology is a continuing emerging area critical 
in the pursuit of broadening the understanding of biological pathways and search for 
new therapeutics and biological probes to improve human health. In particular, 
sultams as non-natural lactam surrogates have recently gained attention as a novel 
class of compounds with extensive chemical and biological profiles that will be 
further discussed in introduction to Chapter 1. The virtues of diversity-oriented 
synthesis (DOS) paired with “Click, Click, Cyclize” paradigm in designing methods 
and libraries for the production of novel and unique sultam compounds provide a 
facile and efficient pathway in achieving this goal. Despite these attributes, 
methodologies for the synthesis of sultams and their corresponding libraries are 
limited in literature relative to lactam surrogates. A more in detail analysis of this gap 
will be introduced in the introduction of each chapter. It is the purpose of this 
dissertation to develop novel methods and production of libraries based on scaffolds 
generated from these methods. Through these methods and libraries, we aim to 
produce various sultam compounds that present opportunities in accessing 
underexplored and underrepresented regions of chemical space with potentials for 
serving as chemical probes in search for unknown biological activities.   
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Figure A.1. Outline of method development and library production presented 
through Chapter 1–3. 
 
 
 An outline of the following chapters of this thesis is shown in Figure A.1. The 
goal of Chapter 1 is to introduce methods and library development previously 
reported from the Hanson group. The introduction reviews the libraries that utilize 
Click “3+2” Huisgen cycloaddition reaction and/or intermolecular nucleophilic 
aromatic substitution (SNAr) for peripheral diversification. Then efforts on production 
of two novel sultam libraries based on one-pot Click-aza-Michael of RCM-derived 
sultam scaffolds and one-pot Click-SNAr of “4+4” derived scaffolds. 
 Chapter 2 introduces a review of recent advances in synthesis of molecules 
containing triazole motifs via one-pot multicomponent Click reactions (MCR). This 
review is categorized into three sections, including 2-, 3-component MCR, 4-, 5-, 6-
component MCR, and development of novel catalysts for Cu-catalyzed azide–alkyne 
coupling (CuAAC) reactions. This review will be then followed by studies towards 
application of one-pot, sequential, multicomponent reaction strategy for the facilitated 
Chapter 1
Development of libraries of diverse sultams
utilizing one-pot click reaction
and orthogonal reactions
Chapter 2
Application of one-pot, sequential, multi-component
strategy for the synthesis of diverse dibenzofused
8-membered sultams
Chapter 3
Synthesis of sultam analogs of
















































synthesis of “4+4” dibenzofused 8-membered sultam scaffolds and their analogs 
produced from 3-, 4-, 5-component reactions. 
 Lastly, Chapter 3 discusses recent advances in the synthesis of various 
biologically active tetramic acids and their analogs. The review is divided into three 
sections: synthesis of tetramic acids via Dieckmann reaction, via methods other than 
Dieckmann condensation, and modification of existing tetramic acids for 
diversification and studies towards reactivity profile of tetramic acids. Subsequent 
section of this chapter includes our recent work on synthesis of sultam analogs of 
tetramic acids via intramolecular sulfa-Dieckmann cyclization. Further 
diversifications utilizing condensation with isocyanates to produce 3-carboxamide 











To my dearest family, Dad, Mom, and little brother 





First and foremost, I want to acknowledge and thank my family – Dad, Mom, 
and my little brother – for their incredible patience, love, and support during my time 
in the United States.  I left South Korea in August 15th, 2004, for my college 
education at Grinnell College in a small Iowan rural town.  Ever since, it was not 
merely my willpower to stay in the US for education but more of the support my 
family gave me that kept me going.  I just can’t thank them enough.  They were 
always there every time I needed help in many aspects. 
Next, I would also like to acknowledge all of my friends I met during my 
graduate school years here in Lawrence, Kansas.  My sincere gratitude to them for 
letting me have a good time outside of Malott and enjoy what Kansas has to offer.  In 
particular, I would like to thank all the members of Soojeong Korean Methodist 
Church for their unconditional support during the tough times I had.  The spiritual 
support is something that kept me on track.  I deeply appreciate how Pastor Han and 
his family (his wife and two children, Sujin and Dojin) have given me guidance and 
comfort when I was completely lost. 
I want to give special acknowledgement to my mentor, Professor Paul R. 
Hanson for his support, “enormous” patience, and guidance.  There were several 
occasions during my time in his group that I was derailing from my studies and 
research.  He helped me and provided numerous opportunities to get myself back on 
track.  I can’t forget the crazy times we spent on several conferences, and being 
roommate with him during the NOS conference in Princeton was by far the craziest 
 viii 
and exciting.  Paul has taught me not only what it is like to be a chemist but also how 
to deal with people, how to manage the group, and of course how to appreciate what a 
dollar is worth.  I must say my time in Paul’s group has been crazy, exciting, 
stressful, but yet fun and enjoyable at the same time.  The incredibly diverse group 
also provided a chance for me to understand and interact with people from different 
backgrounds. Paul, I am very grateful for what you have done for me and also I am 
glad that I chose you as my supervisor.   
I would like to thank Susanthi, Soma, Joanna, Jung Ho, and Naeem for the 
help, support and guidance during my Ph.D. and also former post docs including 
Alan, Thiwanka, Qin and Rambabu for their advice as well.  In particular, I would 
like to thank Alan and Thiwanka for the great time I spent with them as my mentors.  
My undergraduate students John, Junsik, and Taylor, it was my privilege working 
with you guys.  I appreciate and really am grateful to all Hanson Group members – 
past and present – I will never forget the time I spent with them going through this 
journey. 
I would also like to acknowledge my thesis committee members: Professors 
Altman, Benson, Mure and Rubin for their help and guidance during my Ph.D.  
Thank you for your patience.  In addition, special thanks to other research groups in 
Malott Hall, including all of the Tunge, Rubin, Malinakova, Clift and Prisinzano 
group members.  
Lastly, I am very thankful to Dr. Gerald Lushington, Patrick Porubsky and 
Ben Neuenswander for providing enormous help with both purification and in-silico 
 ix 
analysis as well as NMR and X-Ray personnel, Justin, Sarah and Victor for their help 
with gathering the NMR data and X-Ray structures.  In addition, I would like to 
acknowledge our front office staffs, Susan, Beth, Beverly, Ruben, Dan and Donnie 
for all the excellent help and work that they have provided.   
  
 x 
Synthesis of Novel Sultam Scaffolds: 
Method and Library Development 
 
CONTENTS             Page # 
Title Page              i 
Acceptance Page            ii 
Abstract             iii 
Acknowledgments           vii 
Table of Contents             x 
Abbreviations           xii 
 
Chapter 1: Development of Libraries of Diverse Sultams Utilizing One-Pot Click 
Reaction and Orthogonal Reactions         1 
1.1 Introduction – Sultam Libraries Generated by Peripheral Diversification 
Involving Intermolecular SNAr or Triazole Formation       2 
1.2 Library Production of RCM-Derived Scaffold via One-Pot Click-aza-Michael  14 
1.3 Library Generation of “4+4” Scaffold involving One-Pot Click-SNAr   21 
1.4 Conclusion          26 
1.5 References cited          27 
 
Chapter 2: Application of One-pot, Sequential, Multi-component Strategy for 
the Synthesis of Diverse Dibenzofused 8-Membered Sultams              34 
2.1 Introduction – Recent Advances in One-pot Multicomponent Click Reactions 
(MCR)                      35 
2.1a One-pot, 2-, 3-Component MCR                37 
2.1b One-pot, 4-, 5-, 6-Component MCR                45 
 xi 
2.1c Development of Novel Catalyst for Cu-catalyzed Azide–Alkyne 
Coupling (CuAAC) Reaction        53 
2.2 Application of one-pot, three-component strategy for the synthesis of 
dibenzo[b,g][1,4,5]oxathiazocine 5,5-dioxides                60 
2.3 Extension of one-pot strategy via SNAr for four-component synthesis              64 
2.4 Extension of one-pot strategy via CuAAC for five-component synthesis           65 
2.5 High-temperature NMR studies                  67 
2.6 Biological Activity Data                  71 
2.7 Conclusion                    72 
2.8 References cited          72 
 
Chapter 3: Synthesis of Sultam Analogs of Tetramic Acids and Their 
Derivatives                     90 
3.1 Introduction – Review of Synthesis and Modification of Tetramic Acids          91 
3.1.a Dieckmann-derived Tetramic Acids                93 
3.1.b Non-Dieckmann-derived Tetramic Acids             100 
3.1.c Derivatization of Tetramic Acids              108 
3.2 Synthesis of Sultam Analogs of Tetramic Acids via Intramolecular Sulfa-
Dieckmann Cyclization                 115 
3.3 Utilization of Cyclic Amino esters For Synthesis of Bicyclic Tetramic Acid 
Analogs                    118 
3.4 Isocyanate Addition for 3-Carboxamide Substituted Tetramic Acid Analogs   120 
3.5 Structural features and X-ray Crystallography Results             124 
3.6 Conclusion                  126 
3.7 References cited                  126 
Chapter 4: Experimental Data for Chapters 1–3              134 




ADME    absorption, distribution, metabolism and excretion 
ABPP     activity-based protein profiling  
ATP    Adenosine triphosphate 
MeCN     acetonitrile 
aq    aqueous 
BEAD    benzylethyl azodicarboxylate 
Bn    benzyl 
BnBr    benzyl bromide 
BCP    build-couple-pair 
Boc    tert-butyloxycarbonyl 
t-BuOH   t-Butanol 
CHCl3    chloroform 
CuI    copper iodide 
CAP    complementary ambiphilic pairing 
cat.    catalytic 
COSY     correlation spectroscopy 
C     carbon 
Cs2CO3    cesium carbonate 
CsF     cesium fluoride 
Cl     chlorine 
CA    chloroacetamides 
CAP    complementary ambiphile pairing 
CP    complementary pairing 
CMLD    Center of methodology and library development 
CuBr    copper bromide 
CDK2    Cyclin-dependent kinase 2 
DABCO   1,4-Diazabicyclo[2.2.2]octane 
 xiii 
DBU    1,8-diazabicycloundec-7-ene 
DCM (CH2Cl2)  dichloromethane 
Et2O    diethyl ether 
DIAD    diisopropyl azodicarboxylate 
DIC    N,N'-Diisopropylcarbodiimide 
DIPEA/Hünig’s base  N,N'-Diisopropylethylamine 
DMF    dimethylformamide 
DMSO    dimethylsulfoxide 
Boc2O    Di-tert-butyl dicarbonate 
DOS    diversity oriented synthesis 
DMAP    4-(dimethylamino)pyridine 
DTT    Dithiothreitol 
Da    daltons 
E+     electrophile 
Eq.    equivalent 
Et    ethyl 
EtOAc    ethyl acetate 
EDC (EDCI)   1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
FG    functional group 
FP    fluorophosphonate 
FDA    Food and Drug Administration 
FCMA    formimidate carboxylate mixed anhydride 
GC    gas chromatography 
GSTO1   glutathione S-transferase omega 1 
HFIP    hexa-fluoroisopropyl  
HCl    hydrochloric acid 
HPLC     high performance liquid chromatography 
HRMS    high resolution mass spectrometry 
ABHD6   α-β hydrolase-6  
 xiv 
NHS     hydroxysuccinimidyl 
h    hours 
Hsp90    heat shock protein 90 
Hz     hertz 
HCV    hepatitis C virus 
HTS    high throughput screening 
HIV    human immunodeficiency virus 
HSA    human serum albumin  
HOBt    1-hydroxybenzotriazole 
HBA    hydrogen bond acceptor 
HBD    hydrogen bond donor 
IA    iodoacetamides 
IR    infrared radiation 
IC50    inhibitory concentration at 50% 
IMDA    Intermolecular Diels-Alder 
iBu     isobutyl 
iPr    isopropyl 
Leu    Leucine 
LiOH     Lithium hydroxide 
LCMS    Liquid chromatography–mass spectrometry  
LG    leaving group 
M    molarity 
mW     microwave 
MeOH    Methanol 
MeI    methyl iodide 
MW    molecular weight 
MLPCN   Molecular Libraries Probe Production Centers Network 
MAGL   monoacylglycerol lipase  
Mmol    millimole(s) 
 xv 
MsCl     methanesulfonyl chloride 
7-mmc    7-mercapto-4-methyl-coumarin 
MCR    multi-component reactions 
MFS    multifusion similarity 
NSAIDs   Non-steroidal anti-inflammatory drugs 
NMR    nuclear magnetic resonance 
NIH    National Institute of Health 
NEP    neutral endopeptidase 24.11 
Nuc/Nu   nucleophile 
nBu    n-Butyl 
OMe     methoxy 
PMB    para-methoxybenzyl 
ppm    parts per million 
PBPs    penicillin binding proteins 
Ph    phenyl 
PTSA    p-toluenesulfonic Acid 
XLogP    partition coefficient 
PI3K    phosphoinositide 3’OH kinase  
K2CO3    potassium carbonate 
PCA    principal component analysis 
PMI    principal moments of inertia 
PEM    protein epitope mimics  
PKC    protein kinase C 
RCM    ring closing metathesis 
rt    room temperature 
S     sulfur 
Sat’d     saturated 
SAR    structure activity relationship 
SHs    serine hydrolases 
 xvi 
Si    silicon 
NaN3    sodium azide 
NaOtBu    sodium tert-Butoxide 
NaHMDS   sodium hexamethyldisilazide 
SL-PTC   solid-liquid phase transfer catalysis 
SPE    solid phase extraction 
SM    starting material 
SAR    structure-activity-relationship 
TACE    TNF-α converting enzyme  
TBAF    Tetrabutyl ammonium fluoride 
nBu4NBr   tetra-n-butylammonium bromide  
TBS    tert-butyldimethylsilyl 
TFA    trifluoroacetic acid 
K3PO    tripotassium phosphate 
PPh3    triphenylphosphine 
TLC    thin layer chromatography 
tBu    tert-butyl 
Et3N    triethylamine 
TEBA    triethylbenzylammonium chloride 
THF    tetrahydrofuran 
THIQ    tetrahydroisoquinoline 
TLC    thin layer chromatography 
TLR4    Toll-like receptor 4 
TopoPSA   topological polar surface area 
TPP    triphenylphosphine 
TOS    target oriented synthesis 
Val    valine 
VEGF-R2   vascular endothelial growth factor receptor-2 










Development of Libraries of Diverse Sultams  
Utilizing One-Pot Click Reaction  
and Orthogonal Reactions 
 
 2 
Chapter 1: Development of Libraries of Diverse Sultams Utilizing One-Pot Click 
Reaction and Orthogonal Reactions 
 
1.1 Introduction – Sultam Libraries Generated by Peripheral Diversification 
Involving Intermolecular SNAr or Triazole Formation 
 
1.2 Library Production of RCM-Derived Scaffold via One-Pot Click-aza-Michael 
 





The need for discovery of new pharmaceutical leads and small molecule probes has 
led to efforts focusing on the production of small molecule libraries to be utilized in high-
throughput screening (HTS).  High-throughput screening of libraries of small molecules has 
recently emerged as a viable means of detecting less well-characterized targets, either 
individually or as a group of targets.1  In this regard, diversity-oriented synthesis (DOS) 
presents an attractive pathway in accessing underexplored and underrepresented regions of 
chemical space in search for novel chemical probes that could aid in the detection of both 
known and unknown targets.2  Efforts in DOS have been driven by the development and 
emergence of new methods, protocols and technologies to access diverse collections of 
small molecules in a rapid and facilitated manner.3  
Sultams (cyclic sulfonamide analogues) represent a class of non-natural lactam 
surrogates that have surfaced in recent years as important targets in drug discovery due to 
their extensive chemical and biological profiles (Figure 1.1).4  Biological activities include 
anti-inflammatory, anti-HIV, and inhibition of HIV to name a few.  However, a literature 
 3 
search in 2015 revealed that sultams are highly underrepresented relative to lactams.5  To 
date, there are only two previous reports on synthesis of chemical libraries of sultams 
(Figure 1.2). 6   This presents opportunities in further producing varieties of sultam 
compounds that can reside in a relatively unoccupied chemical space and advance studies 
towards probing novel biological targets and activities. 
 
Figure 1.1. Representative examples of bioactive sultams.   
 
 








































































Inhibitors of papain, falcipain-2 





















In this regard, efforts have focused on the development of methods involving rapid 
and facilitated protocols for the synthesis of diverse sultam scaffolds provides means for 
accessing novel structures to probe relatively unoccupied chemical space (Figure 1.3).7 
Figure 1.3. Representative sultams prior to 2010 from the Hanson group.. 
 
To date, the Hanson group has focused their attention on methods development to novel S- 
and P-heterocycles (Figures 1.4 and 1.5, P-heterocycles not shown)8 with biological and 
synthetic utility, as well as the corresponding library synthesis to access varied sultams.  
This thesis is centered on two scaffolds, namely dibenzo-oxathiazocine dioxide and 
isothiazolidin-4-one 1,1-dioxide (Figure 1.6), as well as subsequent library production to 
generate analogs.  Previous method work had developed a facile route to formal name (then 
parenthetically 4+4 scaffold).  In the context of this thesis, we evaluated the uniqueness, 
vide infra (see Chp 2, page 59), as well as diversity (PMI analysis Chp 1, page 25) for this 
scaffold, which in turn inspired the design of libraries around it.  Before detailing our library 
work regarding the “4+4” scaffold, this chapter will review libraries reported by the Hanson 
group utilizing Click reactions and/or intermolecular SNAr reactions is introduced.  
Subsequently, the design and production of two libraries involving one-pot Click-aza-



















































presented in Sections 1.2 and 1.3 (Figure 1.7).  These two scaffolds contain electrophilic 
positions that may be readily utilized for further diversification.  Sultam 1.7.A contains α,β-
unsaturated sulfonamide, which is a Michael acceptor that possesses potentials in adding 
various heteroatom nucleophiles, and also a terminal alkyne that is utilized in “3+2” 
Huisgen cycloaddition to attach various triazoles.  Sultam 1.7.B contain aryl fluoride moiety 
that can be functionalized via Cu-catalyzed N-arylation, and also a terminal alkyne as well. 
Figure 1.4 Summary of benzofused sultams developed by the Hanson group. 
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Figure 1.6. Two main scaffolds to be discussed in this thesis. 
 
Figure 1.7. Overview of two library scaffolds and their diversification plan. 
 
 
The following libraries will be discussed in the subsequent section: 
- SNAr diversification of scaffolds derived from epoxide ring opening-SNAr cascade 
sequence. 
- Pd-catalyzed Suzuki-Miyaura coupling and [3+2] Huisgen cycloaddition of 
thiadiazepan-1,1-dioxide-4-ones 
- Alkylation/SNAr diversification of amino-benzothiaoxazepine-1,1-dioxide scaffolds 
- SNAr diversification for the production of chiral benzothiaoxazepine-1, 1-dioxides 
- Application of OTP reagent for synthesis of chiral sultams with triazole moieties 
- Library of triazolated 1,2,5-thiadiazepane-1,1-dioxides via Click diversification 































In 2010, Hanson, Rolfe and coworkers reported the preparation of library 
compounds based on scaffolds derived from an epoxide ring opening-SNAr cascade 
sequence.9  By having a fluoro-substituent on the 6-position of benezenesulfonyl chloride, 
the group envisioned that it is possible to diversify the 6-position via SNAr with various N-, 
O-nucleophiles.  The SNAr reaction of sultam 1.1.1 with N-nucleophiles proceeded 
successfully in the presence of Cs2CO3 and DMSO in microwave heating for 30 minutes at 
150 °C, whereby purification of excess amines was done by simple silica SPE after reaction 
(Scheme 1.1).  However, SNAr with phenol nucleophiles required 3 equiv. of the 
nucleophile and purification via silica SPE was not possible, making it difficult to be 
applied to a parallel library synthesis platform due to requirement of aqueous workup.  
Application of previously reported high-load, soluble scavenger oligomeric dichlorotriazine 
(ODCT50) derived from ring-opening metathesis polymerization (ROMP) was envisioned to 
remove unreacted excess phenols from the crude reaction mixture.10  Original scavenging 
conditions required 10 hours and thus were not ideal for parallel format.  These conditions 
were modified so that ODCT50 could be used in microwave conditions and thus the reaction 
time was reduced to 30 minutes at 50 °C, which yielded final crude purity over 95 %.  With 
these results in hand, the authors reported the synthesis of a 78-member library.  Overall, 59 
of 78 members provided the desired products in 12-82 % yield with 47 compounds in 90 % 
or higher purities. 





In 2011, Hanson, Fenster, Long and coworkers reported an automated synthesis of 
184-member library of thiadiazepan-1,1-dioxide-4-ones.11  Sultam scaffolds 1.2.1 were 
generated based on a strategy that was previously reported, where a sequence termed “Click, 
Click, Cyclize” was employed en route.12  By applying 4-bromobenzyl bromide as the 
alkylation reagent and propargylamine as the aza-Michael partner, two handles for 
peripheral diversification were generated for their use in Pd-catalyzed Suzuki-Miyaura 
coupling and [3+2] Huisgen cycloaddition, respectively (Scheme 1.2).  Initial studies 
revealed that the two reactions could be performed in a sequential fashion, whereby usage of 
immobilized copper catalyst on Amberlyst (A-21•CuI) for [3+2] Huisgen cycloaddition 
allowed for facile removal of copper catalyst by simple filtration.13  Subsequent removal of 
solvent through concentration in vacuo, followed by addition of palladium catalyst in a 
mixture of DME/H2O and cesium carbonate, and the addition of boronic acids resulted in 
formation of desired peripherally diversified sultams 1.2.2.  This sequential two-step 
reaction was applied to automated Chemspeed Accelerator SLT-100 synthesizer for the 
production of 225 compounds,14 whereby 184 compounds passed through preparative/mass-





































yields and substrates, although it was evident that reactions involving thiopene boronic acid 
resulted in very little or no presence of products. 




In 2011, Hanson, Rolfe and coworkers reported a library synthesis based on scale 
out of amino-benzothiaoxazepine-1,1-dioxide scaffolds utilizing a microwave-assisted SNAr 
protocol that was followed by peripheral diversification using SNAr with various cyclic 
amine nucleophiles. 15  Generation of the core amino-benzothiaoxazepine-1,1-dioxide 
scaffolds was enabled by facilitated process involving microwave-assisted, continuous-flow 
organic synthesis (MACOS) protocol.16 With this technology in hand, scale out of the 
desired scaffolds 1.3.2 was achieved via intramolecular SNAr in the presence of tBuOK as 
base in DMSO, under microwave irradiation at 80 °C, 40 W power, and flow rate of 100 
µLmin-1 (Scheme 1.3). Subsequent alkyation of sulfonamide nitrogen of 1.3.2 with Cs2CO3 
as base in DMF at 50 °C, followed by SNAr of the resulting alkylated scaffold with various 
cyclic amine nucleophiles 1.3.3 in DMSO under microwave conditions at 180 °C for 50 min 
furnished library compounds 1.3.4 in good overall yields. 









R2–N3, CH2Cl2, rt, 14 h
1.
2. R3–B(OH)2, Pd(dppf)Cl2
    Cs2CO3, DME/H2O











R1 = Me, i-Pr, i-Bu
R2 = MOM-OCH2CH2,, furfuryl, 
        1,3-dioxane-CH2CH2, Cy-CH2
R3 = Ph, 4-F-Ph, 4-Pyr, 4-Cl-Ph, 2-Thiophene,
        4-MeO-PH, 4-Me-Ph, 3,4-diMeO-Ph,
        3-(NMe2)-Ph, 3,4-diCl-Ph, 
        CH3CH2CH2CHCH, 4-MeO-3-Pyr, 
       4-F-3-Pyr, 3-(CH2OH)-Ph, 4-Cl-3-Pyr
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 In 2011, Organ, Hanson and coworkers reported scale out of stereochemically rich 
sultams via MACOS and their corresponding library compounds involving intermolecular 
SNAr.17  The authors designed a collection of stereochemically rich benzofused sultams that 
can be rapidly generated by commercially available chiral starting materials.  A two-step 
procedure was designed whereby a combination of chiral 2° sulfonamides, epoxides, and 
amino alcohols are utilized for the synthesis of core benzothiaoxazepine-1,1-dioxides via an 
epoxide opening/SNAr cyclization sequence from a previously reported method (Scheme 
1.4a).18 Sequential intermolecular SNAr diversification then would allow for a generation of 
a stereochemically-rich sultam library (Scheme 1.4b).  Applying the optimized conditions 
from the previous report,18 reaction conditions for application to MACOS setting was 
investigated. Epoxide ring opening/SNAr sequence of sulfonamide 1.4.1 and epoxide 1.4.2 
in the presence of DBU as base at 180 °C with a flow rate of 100-200 µLmin-1 furnished 
scaffold 1.4.3 in gram quantities.  Chiral, non-racemic sultam 1.4.4 was then reacted with 
various chiral cyclic amines in DMSO under Anton Parr Synthos 3000® microwave 
platform19 at 180 °C for 50 min, followed by dilution, filtration, and purification via column 
chromatography to afford a collection of chiral benzothiaoxazepine-1, 1-dioxides 
compounds in good yields (Scheme 1.4.b).  
Scheme 1.4. Scale out synthesis of scaffold 1.4.3 via MACOS and library production 
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 In 2012, Hanson, Faisal and coworkers demonstrated a combination of MACOS 
technology with ring opening metathesis polymerization (ROMP)-derived oligomeric 
triazole phosphates (OTPn) for the synthesis of a library of chiral sultams with triazole 
moieties. 20   As shown in examples above, much attention has been focused on the 
development of facilitated methods for rapid access to a variety of core sultam scaffolds for 
HTS.   ROMP-derived reagents have been reported in variety of synthetic applications due 
to the numerous beneficial attributes such as being bench stable, free-flowing solids, and 
readily soluble in variety of solvents. 21  Building upon these efforts, the authors 
demonstrated the application of ROMP-derived OTP reagents for facilitated installation of 
triazole moieties on scaffolds readily prepared via MACOS technology (Scheme 1.5).  
Scaffold 1.5.1, which was produced in large quantities through MACOS platform, was 
reacted with OTP reagent 1.5.2 in the presence of Cs2CO3 and NaI in DMF at 90 °C to 
produce (triazolyl)methylated sultam 1.5.3 in good yields.  Upon completion, the work up 















































SPE and sequential evaporation afforded clean products without the need for purification via 
column chromatography. 
Scheme 1.5. Application of MACOS and OTP reagents for the library production of chiral 
sultams via purification-free method. 
 
 
This method was next further extended to generation of library based on scaffolds 
synthesized from the double aza-Michael sequence in 2012.  Hanson, Zang and coworkers 
reported production of a library of triazolated 1,2,5-thiadiazepane-1,1-dioxides utilizing 
scaffolds generated by the double aza-Michael pathway.22  Building upon the previous 
report,23 using two routes based on usage of propargylamine or propargyl bromide afforded 
two types of triazolated 7-membered sultams with the triazole moieties in different positions 
(Scheme 1.6).  The first route employed propargyl bromide as the alkylating reagent on the 
sulfonamide nitrogen 1.6.1 to afford propargylated sulfonamide 1.6.2.  Subsequent 
elimination/double-aza-Michael sequence, followed by Cu-catalyzed [3+2] Huisgen 
cycloaddition furnished N-triazolated sultam scaffold 1.6.3.  The alternate route then 
involves alkylation of the secondary sulfonamide 1.6.1 to furnish 1.6.4, followed by 
addition of propargylamine as the double aza-Michael partner to attach a propargyl moiety 
in a different position.  Subsequent [3+2] Huisgen cycloaddition afforded triazolated 7-
membered sultam 1.6.5 bearing the triazole functionality in an alternate location. The 




































(SLT-100)14 to produce a 96-member library, where 94 compounds passed with an average 
of 58 mg and average purity of 94 %.  
Figure 1.6. Click diversification on DaM-derived scaffolds. 
 
 In 2012, Hanson, Loh and coworkers reported synthesis of 80-member library of 
unique chiral benzoxathiazocine 1,1-dioxides by a microwave-assisted, intermolecular SNAr 
diversification pathway.24   Gram quantity synthesis of eight proposed scaffolds were 
achieved through the use of sulfonylation, Mitsunobu alkylation, and SNAr to generate all 
stereoisomers of each core following previous reports (Scheme 1.7).  Each scaffold was 
prepared in 2.5 g scale.  A variety of chiral amine/amino alcohol nucleophiles were utilized 
for peripheral diversification via intermolecular SNAr with benzoxathiazocine 1,1-dioxides 
1.7.1 and 1.7.2 to produce a library of chiral sultams in good yields.  Optimized reaction 
condition was obtained in absence of base, with 5 equiv. of amine 1.7.A-J, at a 
concentration of 0.5 M in DMSO under microwave irradiation at 180 °C for 50 min. 
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In summary, Hanson and workers have demonstrated the development of novel 
methods for the production of library compounds based on sultam scaffolds.  Building upon 
these accounts, the following sections details our efforts in this regard by utilizing the Click 
reaction and its corresponding orthogonal reactions.  
 
1.2 Library Production of RCM-Derived Scaffold via Click-aza-Michael 
Amongst numerous bioactive sultam compounds, β-amino sultams and their 
corresponding sulfonate analogues are a relatively new chemotype that has shown 
interesting biological properties.  Such reports include the inhibition of HIV-1 replication 
and antibacterial activity (Figure 1.2).25  However, reports of methods to generate these 
cores are rather limited in the literature. In this regard, the production of library of 
compounds bearing β-sultam cores would allow to access a more diverse array of this class 
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diverse β-sultam, isothiazolidine 1,1-dioxide, bearing triazole moieties and tertiary amines 
are introduced.26 
Figure 1.2. Representative examples of bioactive β-sultams and sulfonates. 
 
 The synthesis of β-sultam libraries was envisioned by the diversification of core 
dihydroisothiazole 1,1- dioxide scaffold 1.8.4 via a one-pot, multicomponent protocol 
pairing an aza-Michael diversification reaction with other orthogonal reaction pathways 
(Scheme 1.8b). The corresponding core scaffold 2-(prop-2-yn-1-yl)-2,3-dihydroisothiazole 
1,1-dioxide 1.8.4 was rapidly generated on multigram scale via a previously reported 3-step 
sulfonylation, RCM, propargylation protocol starting from 2-chloroethane sulfonyl chloride 
1.8.1 (Scheme 1.8a). 27  Notably, the addition of metathesis catalyst 
[(IMesH2)(PCy3)(Cl)2Ru=CHPh; G-II],28 in 5 equal portions of 0.5 mol % (total 2.5 mol %) 
every 30 min was essential for maintaining the observed high conversion of the RCM 





























Scheme 1.8. Gram synthesis of core scaffold 1.8.4 via RCM and proposed Click/aza-
Michael (ClaM) strategy. 
 
 
With the desired core sultam 1.8.4 in hand, initial efforts focused on the 
diversification of the core via an aza-Michael or Click reaction separately.  After successful 
diversification of 1.8.4 utilizing either reaction in high yields, the combination of both 
reactions in a one-pot protocol was investigated.  In this regard, preliminary studies for one-
pot Click/aza-Michael protocol with azide G and pyrrolidine 6 was investigated (Table 1.1). 
An initial attempt combined both reaction conditions into the same pot (Table 1.1, entry 1) 
that yielded the desired product in 62 % yield.  This yield was improved to 96 % after 
increasing the CuI catalyst load to 30 mol % (Table 1.1, entry 2), while additional 
optimization led to the use of lower equivalents of amine and base without affecting the 
















































Table 1.1. Optimization of one-pot click/aza-Michael reaction conditions. 
 
entrya azide {G} (equiv.) 
amine 6 
(equiv.) CuI (mol %) DBU (mol%) yield (%) 
1 2 2 10 mol% 10 mol% 62 % 
2 2 2 30 mol% 10 mol% 96 % 
3 1 1 30 mol% 10 mol% 78 % 
4 2 1.2 30 mol % 50 mol% 95 % 
5 2 1.2 30 mol% 10 mol% 96 % 
aReactions carried out utilizing 1.8.4 (50 mg, 0.318 mmol, 1 equiv.) in 0.5M EtOH at 60 ºC for 12 hrs. 
 
With these optimized conditions in hand, a validation library was investigated for the 
diversification of dihydroisothiazole 1,1-dioxide 1.8.4 with a variety of 2º amine 
nucleophiles (Scheme 1.9).  Reactions were performed in 1-dram vials using reaction 
blocks, and resulting crude reaction mixtures were diluted in EtOAc, filtered through silica 






















Scheme 1.9. Prototype library synthesis utilizing core scaffold 1.8.4. 
 
entrya yield  final purityc Mass
  entryb yield  final purityc mass 
2{G} 52 % 99 % 89.3 mg 2{O} 43 % 100 %  22.9 mg 
4{G} 45 % 99 % 75.4 mg 12{O} 41 % 98 %  22.3 mg 
5{G} 42 % 92 % 56.2 mg 13{O} 40 % 97 % 19.4 mg 
6{G} 47 % 99 % 63.9 mg 15{O} 43 % 98 % 22.3 mg 
a Reaction conditions: Dihydroisothiazole 1,1-dioxide 1.8.4 (50 mg, 1 equiv.), azide (2 equiv.), amine (1.2 
equiv.), CuI (30 mol%), DBU (10 mol%), dry EtOH (0.5 M), 60 ºC, 12 hrs.  bReaction conditions: 
Dihydroisothiazole 1,1-dioxide 1.8.4 (20 mg, 1 equiv.), azide (2 equiv.), amine (1.2 equiv.), CuI (30 mol%), 
DBU (10 mol%), dry EtOH (0.5 M), 60 ºC, 12 hrs.  cPurified by an automated preparative reverse phase HPLC 
(detected by mass spectroscopy).  Purity was determined by HPLC with peak area (UV) at 214 nm and % 
rounded up to nearest 1%.   
 
With the successful synthesis of the 8-member validation library, two libraries, A 
and B, were proposed for the synthesis of 180-triazole-containing isothiazole 1,1-dioxides 
derivatives via the diversification of dihydroisothiazole 1,1-dioxide 2.  For both libraries A 
and B, a full matrix library was designed using in-silico analysis, literature precedence, and 
observed synthetic results.28  A virtual library incorporating all possible building block 



































property filters were applied, guiding the elimination of undesirable building blocks that led 
to products with undesirable in-silico properties (Full in-silico data and detailed calculation 
information is available in Ch. 4).  These metric filters included standard Lipinski Rule of 5 
parameters (molecular weight <500, ClogP <5.0, number of H-acceptors <10, and number  
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of H-donors <5), in addition to consideration of the number of rotatable bonds (<5) and 
polar surface area.  Absorption, distribution, metabolism, and excretion (ADME) properties 
were calculated along with diversity analysis using standard H-aware 3D BCUT descriptors 
comparing against the MLSMR screening set (ca. 7/2010; ∼330,000 unique chemical 
structures).  Guided by this library design analysis, the corresponding amines 1-15 and 
azides {A-R} (Figure 1.3) were chosen for sultam libraries A and B.  
Utilizing the optimized conditions, library A (132-member) was generated utilizing 
azides A–L with amines 1–11 via a one-pot click/aza-Michael transformation.  Library B 
(48-member) was also generated utilizing azides A–L with piperazines 12–15 via a 
sequential 2-step click/aza-Michael protocol, instead of the previously used one-pot method.  
This 2-step sequence was necessary to efficiently remove the Cu catalyst from the crude 
material without the need of an aqueous work-up due to increased affinity to the SiO2 SPE 
of the corresponding final compounds bearing both a triazole and piperazine moiety.  
Overall, all 180-triazol-isothiazole 1,1-dioxide members of library A and B were 
successfully generated, with 167 out of the 180 compounds possessing >90% final purity 
after purification by automated mass-directed LCMS. 
Within the 132-member library A is a unique set of 12 bis-triazole-containing 
isothiazole 1,1-dioxides A–L{11} which were generated through a bis-click/aza-Michael 
due to the use of N-methyl propargyl amine {11} in the presence of 2 equiv. of the 
corresponding azide (Scheme 1.10). 
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Scheme 1.10. One-Pot bis-click/aza-Michael to produce compounds A–L{11}. 
 
 
1.3 Library Generation of “4+4” Scaffold involving Click-SNAr 
 Building upon the importance of generating diverse sultams as drug-like molecules 
and a variety of biological activities shown in the previous section, we selected novel 
dibenzofused sultam scaffolds as a new target for library production.  Sultam 1.11.4 is a 
unique compound that displays interesting physiochemical properties with skeletal and 
stereochemical diversity (Scheme 1.11a). 29   More in depth analysis of its chemical 
properties and known biological activities will be introduced in Chapter 2.  We initially 
designed a set of library compounds by incorporating Cu-catalyzed N-arylation of the aryl-
Br moiety and Cu-catalyzed Click reaction of terminal alkyne derived from sulfonylation of 
propargyl amine (Scheme 1.11b). 
 The desired core scaffold 1.11.4 was produced in 4.5 g quantities following a 
previously reported method.29  Sulfonylation of propargyl amine using substituted ortho-
fluorobenzene sulfonyl chloride afforded secondary sulfonamide 1.11.2 in excellent yields 
(Scheme 1.11a).  Subsequent “4+4” cyclization of 1.11.2 via sequential aza-Michael/SNAr 
with ortho-quinone methide precursor 1.11.3 produced 8-membered dibenzofused sultam 

























Scheme 1.11. Gram synthesis of core scaffold 1.11.4 and design of one-pot, multicomponent 
synthesis of triazole-containing sultam library. 
 
 
With these scaffolds in hand, we initially focused our attention on finding optimal 
conditions for Cu-catalyzed N-arylation using 4-Br scaffold 1.12.1 and o-anisidine 1.12.2 
(Scheme 1.12a).  Reaction of sultam 1.12.1 with o-anisidine 1.12.2 in the presence of 
K2CO3, 1,10-phenanthroline, and CuI as catalyst in EtOH as solvent at 60 °C produced 
aminated sultam 1.12.3 in 29 % yield.  No reaction occurred when azide 1.12.4 was 
included into the same reaction conditions (Scheme 1.12b).  When this reaction was applied 
to microwave conditions, decomposition of starting material was observed.  These low 
yields and/or decomposition led us to search a different pathway for peripheral 
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Initial investigation for application of SNAr diversification started with 4-F 
substituted sultam 1.13.1 (Scheme 1.13a).  Adopting the conditions shown in previous 
examples from the Hanson group in the introduction section, sultam 1.13.1 and pyrrolidine 
1.13.2 were reacted in DMSO in the presence of DBU as base under microwave irradiation 
at 180 °C for 50 min.  To our delight, 4-pyrrolidine-substituted sultam 1.13.3 was produced 
in 95 % yield.  Encouraged from this result, application of one-pot three-component 
SNAr/Click sequence was probed (Scheme 1.13b).  Sultam 1.13.1 was reacted in one-pot 
with pyrrolidine 1.13.2 and azide 1.13.4 in the presence of DBU as base and CuI catalyst in 
DMSO under microwave irradiation at 180 °C for 50 min.  Gratifyingly, three-component 
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Scheme 1.13. Utilization of SNAr for diversification and application to one-pot Click-SNAr. 
 
 With these optimized conditions in hand, a 60-member library was designed based 
on two core scaffolds 1.4.A and 1.4.B, commercially available amines 1.4.C-J, and benzyl  
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azides 1.4.K-Q (Figure 1.4).  Using the aforementioned one-pot, three-component reaction 
conditions, the reactions were carried out in parallel synthesis format using Anton Parr® 
Synthos 3000 microwave system.19  Resulting reaction mixtures were diluted in EtOAc, 
filtered through SiO2 SPE, concentrated in vacuo, and were purified by automated mass-
directed LCMS.  Overall, 54 out of 60 compounds were synthesized possessing >90% final 
purity, with average yield of 60 %. 
 
Table 1.2. Select one-pot Click/SNAr Library representative results. 








1.4.A.FN 75 % 99 % 134.5  1.4.B.HO 57 % 92 % 51.1 
1.4.A.HN 67 % 99 % 120.5 1.4.B.HP 38 % 93 % 34.2 
1.4.A.DQ 61 % 98 % 54.7 1.4.B.JN 59 % 99 % 108.9 
1.4.A.EQ 95 % 99 % 36.1 1.4.B.IL 62 % 99 % 53.2 
 
Principle moments of inertia (PMI) analysis was conducted for the produced library 
compounds for assessment of molecular diversity.30 PMI analysis is based on analyzing 
shape-based descriptors: the minimum energy conformation of each compound is resolved, 
the corresponding PMI ratios are calculated and normalized, and the resulting data is 
represented by a triangular plot depicting the molecular shape diversity (Figure 1.5).  The 
results were plotted against a set of FDA approved drug molecules shown in black dots. The 
results show that the 60-member library compounds occupy a region that is closer to being 
rod-like and disc-like 3-D shape.  This region is in accordance to the region that the FDA 
 26 
approved drug molecules occupy, thus providing a rudimentary insight that these library 
compounds may have beneficial biological activities. 






In conclusion, two libraries of triazole-containing isothiazolidine 1,1-dioxides were 
prepared utilizing a one-pot Click/aza-Michael protocol for utilization in HTS screening 
collections. Core dihydroisothiazole 1,1-dioxide scaffold was prepared rapidly on multi-
gram scale via RCM and rapidly diversified via a one-pot multi-component click/aza-
Michael protocol to generate a 180-triazole-containing isothiazole 1,1-dioxide library (A 
and B). All 180 compounds were successfully generated, with 167 possessing >90% final 
purity after purification by automated mass-directed LCMS. 
Another set of 60-member library of triazole-containing dibenzofused sultams was 
prepared utilizing a one-pot Click/SNAr protocol.  The core 
 27 
dibenzo[b,g][1,4,5]oxathiazocine 5,5-dioxide scaffolds were prepared in gram quantities via 
coupling of 2° sulfonamides with ortho-quinone methides, then rapidly diversified via one-
pot three-component Click/SNAr sequence to furnish a library of structurally unique 
sultams.  Overall, 54 out of 60 compounds were synthesized with average yield of 60 % 
possessing >90% final purity after purification by automated mass-directed LCMS. 
This screening set of sultams represent a diverse motif not currently reported in the 
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Chapter 2: Application of One-pot, Sequential, Multi-component Strategy for the 
Synthesis of Diverse Dibenzofused 8-Membered Sultams 
 
2.1:  Introduction – Recent Advances in One-pot Multicomponent Click Reactions (MCR) 
2.1a One-pot, 2-, 3-Component MCR 
 2.1b One-pot, 4-, 5-, 6-Component MCR 
 2.1c Development of Novel Catalyst for Cu-catalyzed Azide–Alkyne Coupling 
(CuAAC) Reaction  
2.2  Application of one-pot, three-component strategy for the synthesis of 
dibenzo[b,g][1,4,5]oxathiazocine 5,5-dioxides 
2.3  Extension of one-pot strategy via SNAr for four-component synthesis 
2.4  Extension of one-pot strategy via CuAAC for five-component synthesis 
2.5  High-temperature NMR studies  
2.6  Biological Activity Data 
2.7  Conclusion 
 
2.1 Introduction 
Triazoles and their derivatives have been increasingly found in literature due to their 
interesting biological profiles and physiochemical properties. A number of triazole-
containing molecules are known to exhibit various biological activities, such as anti-HIV,1 
antibacterial,2 anticancer,3 and antifungal4 activities (Figure 2.1).  The abundance of triazole 
derivatives in combinatorial drug discovery5 is related to the inherent stabilizing structural 
features leading to bioorthogonality, thus serving as excellent peptidomimetics6 and protein 
foldamers.7  Moreover, the stability of triazoles extends to its resistance towards enzyme 
degradation in living systems.8  In spite of these attributes, sultams containing triazole 
moieties are relatively limited in literature.  Building upon the sultam-triazole libraries we 
generated in Chp 1 (Figure 2.2), we have designed one-pot sequential multicomponent 
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reactions to produce new sultam compounds with triazole moieties in a facile manner to 
provide scaffolds joining the two motifs together in order to screen for novel biological 
activities.  In this regard, we herein report one-pot, sequential, 3-, 4-, and 5-component 
reactions to furnish dibenzo[b,g][1,4,5]oxathiazocine 5,5-dioxides and their corresponding 
analogs with triazole motifs (Figure 2.2). 
Figure 2.1. Representative examples of bioactive triazoles and drug candidates. 
 
Figure 2.2. Summary of sultam-triazole scaffolds from Chp 1 and proposed one-pot, 
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Sultam-triazole Library from Chp 1




The introduction in this chapter will focus on reviewing recent advances in synthetic 
method developments of one-pot, multicomponent copper-catalyzed azide alkyne coupling 
(CuAAC) reactions for the synthesis of triazole derivatives.  In part, this review section is 
categorized into three subsections: (i) one-pot, 2-, 3-component MCRs, (ii) one-pot, 4-, 5-, 6-
component MCRs, and (iii) development of novel catalysts for one-pot CuAAC. 
 
2.1a  One-pot, 2-, 3-Component MCR 
 In 2014, Sun and coworkers reported the synthesis of triazoloquinazolinones by 
employing a one-pot, two-component tandem Click and intramolecular C–H amidation 
strategy. 9   Triazoloquinazolinones are a class of nitrogen-containing heterocycles with 
several known to have biological activities such as anticancer and antihypertensive 
properties.10  Despite these attributes, direct synthetic methods to produce this motif are 
limited in literature.  By pairing triazole synthesis with intramolecular C–N bond formation 
through C–H amidation, the synthesis of biologically relevant triazoloquinazolinones 2.1.3 
was achieved (Scheme 2.1).  Reaction of N-methoxybenzamide 2.1.1 with phenyl acetylene 
2.1.2 in the presence of catalytic CuI and DIPEA in THF under aerobic conditions at room 
temperature yielded the desired triazoloquinazolinones 2.1.3 in 80% yield.  The copper 
catalyst-enabled Click reaction enabled formation of triazole intermediate 2.1.4, and 
subsequently catalyzed the intramolecular C–H amidation to afford the desired triazole 2.1.3. 
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Scheme 2.1. One-pot two-component synthesis of triazoloquinazolinone derivatives. 
 
In 2011, the Müller group reported formation of triazolyl-substituted N-Boc protected 
heterocycles via three-component Sonogashira coupling–TMS-deprotection–Click 
sequence. 11   This sequence enables facile assembly of diverse nitrogen-containing 
heterocycles such as indole, indazole, 4-, 5-, 6-, and 7-azaindoles, 4,7-diazaindole, 7-
deazapurine, pyrrole, pyrazole, and imidazole.  Starting from iodo-N-Boc N-heterocycles 
2.2.1,12 sequential addition of trimethylsilylacetylene (TMSA) in the presence of palladium 
and copper catalysts (Sonogashira coupling), followed by deprotection of the acetylene 
moiety using TBAF, and addition of benzyl or aryl azide (Click reaction), afforded the 






































Scheme 2.2. One-pot three-component Sonogashira coupling–TMS-deprotection–Click 
sequence towards various N-heterocycles. 
 
 In 2012, Schoch and coworkers reported a three-component MCR strategy involving 
CuAAC and inverse electron-demand Diels-Alder reaction (DAinv) for site-specific dual 
labeling of DNA.13  CuAAC has recently merged as an important tool in the field of 
bioorthogonal tagging/labeling.14  Another method that has recently gained attention is 
DAinv,15 which is known to be rapid, does not require transition metals, and allows for 
efficient functionalization of oligonucleotides at ambient temperature.  Concurrent 
bioorthogonal site-specific double-modification of oligonucleotides without protection or 
intervening protection had not been reported yet.  This report demonstrated the first 
successful attempt at combining CuAAC and DAinv for one-pot labeling of DNA 
oligonucleotides.  Doubly-modified oligonucleotides 2.3.1 containing both a terminal alkyne 
and a dienophile were reacted with tagged dansyl tetrazines 2.3.2 and tagged azides 2.3.3 in 
the presence of Cu2SO4, tris(3-hydroxypropyltriazolylmethyl)amine (THPTA), and sodium 







2 mol% PdCl2(PPh3)2, 4 mol% CuI
1.5 eq TMSA
2.0 eq NEt3, THF, rt, 1-23 h
then, 1.5 eq TBAF, rt, 0.5 h
then, 1.0 eq BnN3 or PhN3,











































 In 2013, Fang and coworkers demonstrated the use of one-pot three-component 
CuAAC for the production of novel triazolyl substituted tetrahydrobenzofuran derivatives to 
study their inhibitory activies of H+/K+-ATPase.16  Development of H+/K+-ATPase inhibitors, 
also known as gastric proton pump inhibitors (PPIs), provides clinical benefits coping against 
gastroesophageal reflux disease (GERD), peptic ulcer, and other acid-related disorders.17 
However, currently existing PPIs possess limitations such as insufficient efficacy and hepatic 
toxicity. 18   A concise and efficient method for the synthesis of triazolyl substituted 
tetrahydrobenzofurans 2.4.4 was developed in search for novel PPIs (Scheme 2.4). 
Preparation of 4-azido substituted tetrahydrobenzofuran intermediate 2.4.3 was achieved by 
reduction of ketone 2.4.1 followed by azide substitution following the method of Haynes.19  
Intermediate azide 2.4.3 next underwent one-pot, three-component CuAAC with propargyl 
bromide and primary amine in water without other co-solvents at room temperature to 

















Scheme 2.4. One-pot three-component CuAAC for the synthesis of novel triazolyl substituted 
tetrahydrobenzofuran derivatives 2.4.4. 
 
 
In 2013, the Varma group reported the synthesis of 1,2,3-triazole substituted 
unnatural amino acids via microwave-assisted using a one-pot three-component method.20 
Known methods to produce triazole-based unnatural amino acids follow the same strategy.21 
Previously reported procedures utilize the Mitsunobu reaction, which involves usage of 
highly toxic and explosive dry hydrogen azide for the generation of the azide intermediate.  
In order to circumvent this problem, one-pot three-component CuAAC with sulfamidate 
2.5.1, terminal alkyne 2.5.2, and sodium azide was developed (Scheme 2.5).  The reaction 
was performed in 1:1 mixture of tBuOH and water under 120 °C microwave irradiation for 
20 minutes, which furnished the desired triazole-substituted unnatural amino acid 2.5.3.  




 In 2012, Crowley and coworkers demonstrated the application of one-pot three-
component CuAAC for the preparation of exo-functionalized pyridiyl-1,2,3-triazole 















































Mild and functional group tolerant triazoles have become a viable alternative to pyridine-
containing macrocycles that are used for synthesis of mechanically interlocked architectures 
(MIA).23  In this regard, the authors report employment of one-pot multi-component CuAAC 
for the facile production of triazole-containing macrocycles.  Dialkyne 2.6.1 poses a threat in 
the sense that the resulting diazide may be explosive (Scheme 2.6).  However, the in situ 
generated diazide moiety is readily captured by copper catalyst to yield the desired Click 
macrocycle 2.6.3 in good yields.  The resulting macrocycle proved to be unsuccessful in 
attempts to utilize it in both passive and active metal template syntheses of rataxanes due to 
the coordinating ability of the 1,2,3-triazole units within the macrocycle. 




In 2013, Naeimi and coworkers reported utilization of sonochemical synthesis for the 
production of 1,4-disubstituted 1,2,3-triazole derivatives via one-pot three-component 
CuAAC in 1:1 mixture of water and ethanol.24  Recently, ultrasound has been gaining interest 
as an efficient green and sustainable tool for synthetic processes.25  Building upon a previous 
report by Priebe in 1984 on the synthesis of organic azides from the corresponding activated 














1. NaN3 (3 eq), DMF, 90 °C, 48h
2. CuSO4•5H2O, ascorbic acid




envisioned applying this method towards the synthesis of 1,2,3-triazoles in a one-pot fashion.  
At room temperature, aliphatic/benzyl halide 2.7.1, terminal alkyne 2.7.2, and sodium azide 
were reacted in the presence of 3 mol% CuI under ultrasonic irradiation power of 70 W for 5 
min to furnish the desired 1,4-disubstituted 1,2,3-triazole 2.7.3 in excellent yields (Scheme 
2.7).  The authors hypothesized that the observed effects of ultrasonic irradiation is due to 
formation of cavities, which are known to act as microreactors for volatile molecules by high 
temperature and pressure produced during cavitation break.25  
Scheme 2.7. Sonochemical one-pot three-component CuAAC process for the production of 
1,4-disubstituted 1,2,3-triazole derivatives. 
 
 
 In 2013, Li and coworkers reported preparation of 5-halo-1,2,3-triazoles via one-pot 
three-component tandem oxidative halogenation and CuAAC.27  Generation of more diverse 
and highly substituted 1,2,3-triazoles has been a desirable target due to its known benefits in 
various areas.  In this regard, development of 5-halo-1,2,3-triazoles, which are known 
precursors to other functional groups28 and also are widely used analogs for SAR studies, 29 
provide a center for further diversification.  However, direct halogenation is unsuccessful due 
to the deficient electron density of the 1,2,3-triazole system.  The authors demonstrated the 
first effective one-pot tandem aerobic oxidative halogenation and CuAAC involving azide 
2.8.1, alkyne 2.8.2, and CuX (X = I, Br) under O2 atmosphere at room temperature in the 











2.7.1 2.7.2 2.7.3H2O/EtOH (1:1)
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It was found that TBSCl activates aerobic oxidation of CuX to produce X2 and Cu+, which in 
turn undergoes aerobic oxidative halogenation and catalyze the Click reaction, respectively. 




 In 2014, Jiang and coworkers demonstrated the development of a simple, efficient 
thermally-promoted protocol for one-pot three-component CuAAC catalyzed by 
CuSO4•5H2O in water.30  Until this work, reports of utilizing Cu(II) salts as catalysts for 
CuAAC reactions require additional reducing agent such as sodium ascorbate, metallic 
copper, hydrazine monohydrate, among others.31  Moreover, the reactions require longer 
times for completion.  In this regard, this report focuses on development of conditions using 
Cu(II) salts as catalysts for CuAAC without the need of reducing agent and expedited 
reaction times.  Optimization studies revealed 1 mol% CuSO4•5H2O as catalyst at 100 °C in 
water as optimal conditions, and showed that the reaction was greatly accelerated to be  
Scheme 2.9. Thermally promoted protocol for one-pot three-component CuAAC catalyzed by 




1. 0.5 eq. TBDMSCl
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complete in 30 min when using alkyne 2.9.1 and organic azide 2.9.2 (Scheme 2.9a).  When 
this method was applied to one-pot, three-component synthesis of triazoles using alkyl 
bromide 2.9.4, NaN3, and terminal alkyne 2.9.5, the reactions were complete in 50–70 min to 
afford triazoles 2.9.6 in excellent yields (Scheme 2.9b). 
 
2.1b  One-pot, 4-, 5-, 6-Component MCR 
In 2011, Qian and coworkers reported one-pot four-component synthesis of triazolyl-
pyridazone libraries via a “Click and Activate” strategy.32  This strategy entails usage of 
CuAAC step in mid-stage of one-pot reaction sequence, which is considered to be a rather 
unexplored sector of one-pot Click reaction processes.  Regioselective azide substitution at 
the 5- over 4-position of 2-substituted-4,5-dichloropyridazinone 2.10.1 allows for preparation 
of CuAAC partner 2.10.2 (Scheme 2.10).  Subsequent CuAAC reaction with terminal 
alkynes 2.10.3 attaches substituted triazole at the 5-position to afford 2.10.4.  By attaching 
the triazole, the starting material that is rather neutral or deactivated for nucleophilic attack 
has been “activated” electronically by the presence of triazole at the 5-position.  At the last 
stage, various amine and carbon nucleophiles were used for substrate scope studies to 
achieve diverse 2,4,5-trisubstituted-3(2H)-pyridazinones 2.10.5. 
 
Scheme 2.10. One-pot four-component synthesis of triazolyl-pyridazone libraries via “Click 










































 In 2012, Niu and coworkers demonstrated application of grouping copper-free three-
component cycloaddition with CuAAC in a one-pot four-component fashion for the synthesis 
of unsymmetrical bis(1,2,3-triazole) derivatives and their corresponding peptidomimetics.33 
Conventional methods to generate unsymmetrical bis(1,2,3-triazoles) utilize double-Click 
strategy.34  However, the necessity for protection-deprotection sequence renders this strategy 
to be cumbersome.  By utilizing a previously reported method for the synthesis of triazoles in 
the absence of copper catalyst,35 the authors envisioned three-component reaction of azide 
2.11.1, diketene 2.11.2, and alkyne-containing amine 2.11.3 as linker to generate triazole 
2.11.4 (Scheme 2.11).  Optimization studies revealed DBU as catalyst and MeOH as solvent 
to be optimal in generating the desired product.  After completion of the initial formation of 
triazole 2.11.4, sequential addition of copper catalyst with the second azide furnished the 
desired unsymmetrical bis(1,2,3-triazole) 2.11.5 in excellent yields. 
Scheme 2.11. One-pot four-component CuAAC for preparation of unsymmetrical bis(1,2,3-
triazole) derivatives and their corresponding peptidomimetics. 
 
 
In 2012, Salehi and coworkers reported one-pot, four-component condensation of 
phthalhydrazide 2.12.1, aromatic propargyloxy aldehydes 2.12.2, active methylenes 2.12.4 
(dimedone/1,3-cyclohexanedione), and azides 2.12.3 in the presence of copper catalyst for 























2.11.1 2.11.2 2.11.3 2.11.4
2.11.5
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derivatives 2.12.5 (Scheme 2.12).36  Phthalazine derivatives have gained attention from the 
synthetic community due to their biological properties including anticonvulsant, 37 
vasorelaxant,38 and cardiotonic properties.39  The four components, in the presence of 
Cu(OAc)2•H2O, PTSA, and sodium ascorbate as catalysts in EtOH as solvent at 80 °C 
afforded the desired triazole-attached phthalazine-trione product 2.12.5 in good yields.  
Through scope studies, both electron-rich and electron-deficient aromatic propargyloxy 
aldehydes afforded high-to-excellent yields. 




 In continuation of the previous work,36 in 2012 Dabiri and coworkers reported one-
pot pseudo-five-component synthesis of triazolyl methoxyphenyl 1,8-dioxo-
decahydroacridines.40  Acridine derivatives are known to possess a wide variety of biological 
activities, including antimalarial,41 antitumor,42 antiprion,43 anti-Alzheimer,44 antileishmanial, 
and antitrypanosomal activities,45 and thus various routes to their syntheses have been 
developed by the synthetic community. 46   In this report, the authors focus on the 
development of a facile and expedient method for the production of these acridine derivatives 
bearing triazole moieties.  Propargylated aldehyde 2.13.1, organic azide 2.13.2, primary 
amine 2.13.3, and two equivalents of dimedone 2.13.4 in the presence of catalytic amount of 


























2.12.1 2.12.2 2.12.3 2.12.4 2.12.5
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H2O/EtOH (1:1 by volume) at 100 °C for 6 h provided acridine product 2.13.5 in good yields 
(Scheme 2.13).  This one-pot sequential Click-Knoevenagel condensation-Michael addition-
cyclocondensation method achieved simple and efficient syntheses of desired acridine 
derivatives. 




 In 2012, the Wang group demonstrated a concise synthesis of chiral 2(5H)-furanone 
derivatives possessing 1,2,3-triazole moieties via one-pot four-component strategy. 47 
Compounds with 2(5H)-furanone moieties, a type of α,β-unsaturated lactone substructure 
that is often found in various natural products, have received attention due to their variety of 
biological activities.48  However, combining 1,2,3-triazole moiety into 2(5H)-furanones with 
various amino acids as linkers have not been previously reported.  In this work, a one-pot 
four-component strategy involving asymmetric Michael addition-elimination, substitution, 
and cycloaddition starting from (5S)-5-menthoxy-3,4-dibromo-2(5H)-furanone 2.14.1 (where 
R1 = menthyl) afforded the desired chiral 2(5H)-furanone derivative 2.14.7 bearing 1,2,3-
triazole moiety (Scheme 2.14).  Initial attempts showed that usage of EtOH is necessary for 
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2.13.5
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solvent system utilized a mixture of EtOH and CH3CN in 1:8 ratios, one-pot four-component 
reaction was achieved in a sequential manner. 
Scheme 2.14. One-pot four-component strategy towards synthesis of chiral 2(5H)-furanone 
derivatives possessing 1,2,3-triazole moieties. 
 
 
In 2013, Quan and coworkers applied one-pot four-component CuAAC for the 
synthesis of functionalized 1,2,3-triazoles with 3,4-dihydropyrimidinone or amide group.49 
Recently, 3,4-dihydropyrimidinones (DHPMs) have emerged as attractive targets for 
synthesis due to their interesting pharmacological properties, where the N3-substituted 
analogs bear the most attraction as active forms.50  In this regard, one-pot MCR involving 
CuAAC for the generation of N3-substituted DHPM analogs bearing 1,2,3-triazole moiety 
was achieved.  In continuation of previous work on synthesis of N3-substituted DHPM 
analogs by reacting with paraformaldehyde in presence of TMSCl,51 reaction conditions were 
modified to be applied to one-pot MCR strategy.  Sequential addition of paraformaldehyde in  
Scheme 2.15. Synthesis of functionalized 1,2,3-triazoles with 3,4-dihydropyrimidinone or 
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2. NaN3,               , Et3N
   Cu(OAc)2•H2O / NaAsc, 35 °C, 8 h
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CH2Cl2 in the presence of TMSCl to DHPM 2.15.1, followed by addition of NaN3, terminal 
alkyne, and Et3N in the presence of Cu(OAc)2·H2O/NaAsc furnished the desired product 
2.15.2 in excellent yields (Scheme 2.15). 
 In 2014, the Santillán group demonstrated one-pot pseudo-four-component synthesis 
of mono- and di-benzylated 1,2,3-triazoles derived from anilines. 52   In regards to 
investigation of usage of 1,2,3-triazoles as steel corrosion inhibitors and/or transition metal 
ligands, synthesis of triazole derivatives containing aniline moiety was achieved.  In the 
initial stages, CuAAC reaction with propargylated benzyl amine 2.16.1, benzyl bromide 
2.16.2, and NaN3 in the presence of 5 mol% Cu(OAc)2•H2O, 5 mol% 1,10-phenanthroline, 
and sodium ascorbate at room temperature resulted in mixture of mono- and di-benzylated 
triazole derivatives 2.16.3 and 2.16.4 (Scheme 2.16).  By increasing the amount of benzyl 
bromide to 2 eq, the reaction solely furnished di-benzylated triazole 2.16.4. 
Scheme 2.16. One-pot pseudo-four-component synthesis of mono- and di-benzylated 1,2,3-
triazoles 2.16.3 and 2.16.4. 
 
 In 2014, Dabiri and coworkers reported the synthesis of (1,2,3-triazol-4-yl)methyl-3-
amino-5,10-dihydro-5,10-dioxo-1H-pyrazolo[1,2-b]phthalazine-2-carboxylate derivatives via 
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exhibit diverse biological activities.36  Building upon previous work, preparation of novel 
phthalazine derivatives bearing an enamine moiety was demonstrated (Scheme 2.17).  One-
pot four-component condensation/CuAAC reaction involving benzaldehyde 2.17.2, active 
methylene compound 2.17.3 (prop-2-ynyl-2-cyanoacetate), azide 2.17.4, and phthalhydrazide 
2.17.1 in the presence of Cu(OAc)2 and sodium ascorbate as catalysts and 1-methyl-1H-
imidazolium trifluoroacetate ([Hmim]TFA) as an ionic liquid medium provided the desired 
phthalazine derivatives 2.17.5 in excellent yields.  
Scheme 2.17. Synthesis of (1,2,3-triazol-4-yl)methyl-3-amino-5,10-dihydro-5,10-dioxo-1H-
pyrazolo[1,2-b]phthalazine-2-carboxylate derivatives via one-pot four-component CuAAC. 
 
 
 In 2015, the Kaushik group reported development of a facile one-pot five-component 
synthesis of glycoside annulated DHPM derivatives with 1,2,3-triazole linkage via 
transesterification/Biginelli/CuAAC reactions in aqueous medium. 54   As noted earlier, 
dihydropyrimidinones (DHPMs) have gained much attention from the synthetic community 
due to their potential pharmacological and biological activities.50  By combining DHPMs 
with glycosides, which are the most abundant molecules in nature and play a major role in 
cellular metabolism, physiology, and signal transduction,55 it will enable search for novel 
bioactivities by incorporating both advantages.  One-pot five-component reaction of tert-
butyl β-ketoester 2.18.2, arylaldehyde 2.18.4, urea 2.18.1, propargyl alcohol 2.18.3, and 
glycosyl azide 2.18.5 via transesterification, Biginelli reaction, and CuAAC in the presence 
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 52 
of 10 mol% CuI (relative to aldehyde) in water provided the optimal condition (Scheme 
2.18). It is noteworthy that choice of solvent was crucial in performing this sequence, as 
shown by the results in Scheme 2.18.  
Scheme 2.18. One-pot five-component synthesis of glycoside annulated DHPM derivatives 




In 2014, Shaabani and coworkers reported application of CuAAC in one-pot six-
component reaction to produce triazole-containing coumarin-3-carboxamides.56  Recently, 
several works have revealed that compounds with coumarin backbones in junction to some 
nitrogen-containing heterocycles, such as azetidine, thiazolidine, and thiazoles, display 
significantly enhanced antimicrobial efficiency and broadened antimicrobial spectrum.57  In 
attempts to combine the beneficial biological activities of coumarins and triazoles, one-pot 
six-component diversity oriented synthesis of coumarin-3-carboxamides with triazole ring 
was achieved via tandem Knoevenagel/Ugi/CuAAC (Scheme 2.19).  Reaction of 
salicylaldehyde 2.19.2, aromatic propargyloxy aldehyde 2.19.4, aniline 2.19.5, isocyanide 
















































furnished the desired product 2.19.7 in excellent yields.  Various derivatives were 
synthesized to produce a library of compounds with motifs that may exhibit interesting 
biological activities. 





2.1c  Development of Novel Catalyst for CuAAC 
In 2012, the Reddy group reported development of novel CuII-hydrotalcite (CuII-HT) 
catalyst for its usage in one-pot MCR to generate β-hydroxy triazoles via regioselective 
epoxide opening followed by Click cyclization in water at room temperature.58   The 
significance of this work, is that there are not many reports of studies on catalysts for the 
preparation of β-hydroxy triazoles, and the majority of previously reported syntheses utilize 
conditions with a wide array of drawbacks: low reactivity, use of organic solvents, use of 
additives, elevated reaction temperatures, low yields, and formation of by-products.59  The 
authors focused their attention on hydrotalcites as potential novel catalyst to be utilized in the 
desired reaction sequence due to the known beneficial properties in catalysis.60  Optimization 
































produce of β-hydroxy triazoles 2.20.4 revealed catalyst mole ratio (Cu:Al) of 3:1 to be 
optimal in the presence of water as solvent at room temperature (Scheme 2.20).  The CuII-HT 
catalyst was found to be easily recoverable via simple filtration, and displayed no significant 
loss of activity up to five runs, thus presenting potential for recyclability and use in large-
scale applications. 




 In 2012, García-Álvarez and coworkers reported utilization of 
(iminophosphorane)copper(I) complexes as novel catalysts for one-pot MCR involving in 
situ generated azides and alkynes in water.61  Although there are known examples of one-pot 
MCR in water as solvent, there is only one previously reported catalytic system that utilizes 
1-iodoalkynes in a chemo- and regioselective fashion.62  The authors report synthesis and 
application of a novel copper(I) complex that is applied to one-pot three-component synthesis 
of triazoles 2.21.3 involving alkyne 2.21.1, alkyl bromide 2.21.2, and NaN3 (Scheme 2.21). 
The novel complex displayed stability in water and air, and provided chemo- and 
regioselectivity.  Also, it is the first example of isolated Cu(I) catalyst system that is also 
active with internal alkyne, 1-iodoalkyne.  The presence of iodo moiety in the resulting 


































 In 2012, Megia-Fernandez and coworkers reported a one-pot, three-component 
CuAAC method under microwave irradiation and heterogeneous catalysis for the synthesis of 
(alkyl sulfate)- and (alkyl sulfamidate)-1H-1,2,3-triazoles.63  The authors envisioned three-
component reaction of cyclic sulfates/sulfamidates 2.22.1 in the presence of sodium azide 
and terminal alkynes 2.22.2 would produce the desired products 2.22.3 in a facile manner.  
Aiming to simplify the isolation procedure, previously reported robust and efficient 
heterogeneous Click catalyst, Si-BPA•Cu+ or Si-BPMA•Cu+, was employed (Scheme 2.22).64  
Adding all the components and the heterogeneous catalyst in a mixture of t-BuOH and water 
and reacting under microwave irradiation for 15 min at 60 °C provided the targets in 
excellent yields over 85%.  The workup procedure involved only simple filtration of the 
catalyst and evaporation of the solvent mixture.  The scope of this protocol was studied using 
various cyclic sulfates derived from glycerol and α-D-glucofuranose, highlighting the 
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 56 
Scheme 2.22. One-pot three-component (alkyl sulfate)- and (alkyl sulfamidate)-1H-1,2,3-
triazoles using novel heterogeneous catalysts. 
 
 
 In 2013, the Ranu group reported a solvent-free one-pot three-component CuAAC 
catalyzed by Cu/Al2O3 surface under ball-milling conditions for the synthesis of 1,2,3-
triazole derivatives.65  Ball-milling (intense mechanical grinding) has recently emerged as an 
efficient and green method to perform chemical reactions.66  In efforts to further enhance the 
eco-friendliness of CuAAC, a solvent-free one-pot three-component CuAAC was achieved 
with alkyl/benzyl halides 2.23.1 or aryl boronic acids 2.23.2, sodium azide, and terminal 
alkynes 2.23.3 over Cu/Al2O3 surface under ball-milling conditions to afford triazole 
derivatives 2.23.4 (Scheme 2.23).  The group observed that aryl halides do not undergo 
CuAAC in these conditions, so aryl boronic acids were utilized in place of aryl halides 
successfully.  The three components were inserted into a ball-milling device, and optimal  
Scheme 2.23. Solvent-free one-pot three-component CuAAC catalyzed by Cu/Al2O3 surface 
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conditions were found to be 10 mol% of Cu/Al2O3 catalyst, ball-milling device running at 
600 rpm in the presence of 6 balls for 1 h.  The resulting reaction mixture was extracted with 
ethanol, and no chromatographic purification was required. 
In 2013, Mittapelly and coworkers reported a one-pot three-component synthesis of 
1,4-disubstituted 1,2,3-triazoles involving coupling of alcohol, azide, and alkynes using CuO 
nanoparticles.67  In attempt to broaden the scope of one-pot MCR in combination with Click 
chemistry, the group utilized benzylic and allylic alcohols 2.24.1 and 2.24.2 as starting 
materials for the synthesis of 1,2,3-triazoles 2.24.4 and 2.24.5 (Scheme 2.24).  In the 
presence of CuO nanoparticles, nucleophilic substitution with TMS azide of the alocohol 
moiety, followed by sequential capture of the resulting organic azide with terminal alkynes 
2.24.3, furnished the desired 1,4-disubstituted 1,2,3-triazoles 2.24.4 and 2.24.5 in good to 
excellent yields.  Notably, this report enabled the use of unactivated alcohols, which 
generally requires preactivation of alcohol groups in order to substitute to azides.68  Also, by 
capturing the reactive organic azide in situ, potentially unstable low molecular weight 
organic azides were handled safely.69 
Scheme 2.24. One-pot three-component synthesis of 1,4-disubstituted 1,2,3-triazoles 2.24.4 



























 In 2013, Zhang and coworkers demonstrated the application of porous copper catalyst 
one-pot three-component CuAAC in water.70  As shown in this section, major advances have 
been made in methodology development for production of triazoles.  However, the 
development of heterogeneous immobilized copper catalysts that are inexpensive, readily 
available, easy to use, have high efficiency, and recyclable still remains a major challenge.  
In this regard, porous metals containing a large surface-to-volume ratio and are lightweight 
have recently attracted significant attention and have found wide range of applications in 
chemistry, mechanics, and nanotechnology.71  Utilizing commercially available sintered 
copper porous material, one-pot three-component synthesis of triazoles 2.25.3 involving 
aliphatic/benzyl halide 2.25.1, terminal alkyne 2.25.2, and sodium azide was demonstrated 
(Scheme 2.25).  The optimized conditions were 5 mol% catalyst loading in water at 55 °C.  
The catalyst was recyclable up to five times without loss of significant catalytic activity. 




 In 2014, the Astruc group reported utilization of novel, highly active, and 
magnetically recoverable tris(triazolyl)–CuI catalyst for CuAAC synthesis of triazoles.72  The 
catalyst was supported on iron oxide nanoparticles and displayed excellent monodispersity, 
recoverability, and reusability.  This nanoparticle-supported catalyst 2.26.4 was then applied 
towards one-pot three-component CuAAC reactions involving benzyl bromides 2.26.2, 
alkynes 2.26.1, and sodium azide to furnish triazole 2.26.3 (Scheme 2.26).  This process was 
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performed at room temperature in water for 24 h, with 0.5 mol% catalyst loading.  The 
catalyst was next easily recovered by using an external magnet, and reusability was observed 
up to five times with no significant loss of catalytic activity.  ICP analysis revealed that 
amount of copper leached to reaction mixture is negligible around 1.5 ppm.  
Scheme 2.26. Magnetically recoverable tris(triazolyl)–CuI catalyst for one-pot CuAAC 
synthesis of triazoles. 
 
 
 In 2014, Nasr-Esfahani and coworkers reported development of copper immobilized 
on nanosilica triazine dendrimer (Cu(II)-TD@nSiO2)-catalyzed regioselective synthesis of 
various triazole derivatives via one-pot three-component CuAAC reaction.73  Building upon 
previous work on preparation of Cu(II)-TD@nSiO2,74 the catalyst system was applied to 
production of wide range of 1,4-disubstituted 1,2,3-triazoles 2.27.6-9 (Scheme 2.27). 
Optimization studies revealed mixture of H2O/EtOH (2:1), 0.3 mol% catalyst loading, and 5 
mol% sodium ascorbate at room temperature for 20 min to be optimal.  After the reactions 
were complete, the reaction mixture was diluted with H2O and EtOAc, and the catalyst was 
separated by simple filtration.  Upon drying, reusability of the catalyst was tested and showed 
no significant loss of activity up to five times.  Leaching of copper from the catalyst system 



























Scheme 2.27. Cu(II)-TD@nSiO2-catalyzed regioselective synthesis of various triazole 




2.2 Application of one-pot, three-component strategy for the synthesis of 
dibenzo[b,g][1,4,5]oxathiazocine 5,5-dioxides 
 
The employment of various facilitation approaches, such as Build-Couple-Pair75 and 
function group pairing (FGP)76 paradigms, for the development of single-pot, multistep 
reaction processes in sequential fashion for the generation of functionalized heterocyclic 
scaffolds represents a method of high value for enabling DOS platforms and high-throughput 
screening (HTS).  The ability of one-pot multistep reaction processes to generate core 
scaffolds in a quick and facile manner allows for producing scaffolds and its analogs, making 
use of step,77 atom,78 and pot economy.79  The key feature of one-pot, sequential multistep 
protocol is moving through multi-reaction transformations without the need for workup or 
purification in between, both facilitating the process and saving resources.  
Sultams (cyclic sulfonamides) are a non-natural class of heterocycles that have 
























































eight membered benzofused sultams bearing oxygen in the core skeleton are limited to four 
reports to the best of our knowledge.81,82  More detailed SciFinder and PubChem substructure 
searches show that these motifs containing hydrocarbon 2.2.B or other heteroatoms such as 
nitrogen 2.2.C or sulfur 2.2.D are in fact relatively scarce (Figure 2.2).  Dibenzofused 
sultams 2.2.E and their corresponding lactam analogs 2.2.F are even less abundant.  In this 
regard, development of facile methods towards production of these structurally unique 
scaffolds may provide benefits to further study various biological activities involved with 
sultams. 
Figure 2.2. SciFinder and PubChem substructure searches as of 04-06-2015. 
 
The development of formal “4+4” CAP heterocyclization strategy to generate 
dibenzofused sultams was recently reported.82  In the previous chapter, we described library 
synthesis of sultam compounds utilizing one-pot three-component Click/SNAr protocol.  
Building on these efforts, we herein report the development of one-pot, sequential, 



































sultams employing in situ generated ortho-quinone methides (o-QM) in a formal “4+4” 
heterocyclization reaction. 
Initial studies focused on optimizing the conditions for sulfonylation of primary 
amine 2.28.2 using ortho-fluorobenzenesulfonyl chloride 2.28.1 to generate secondary 
sulfonamide 2.28.3 as a precursor for the sequential “4+4” cyclization (Scheme 2.28).  
Originally, the reported conditions for sulfonylation required usage of K2CO3 as base in a 
biphasic 1:1 mixture of water/CH2Cl2 for overnight reaction at room temperature.  However, 
we envisioned that if the sulfonylation were to proceed in THF, the reaction conditions might 
then be compatible with the following step.  Reaction in THF and Et3N as base at room 
temperature gratifyingly provided quantitative yield of the desired secondary sulfonamide 
2.28.3 at a much faster rate of around 1 h, after purification through column chromatography.  
In efforts to streamline this process, monitoring of this process was carried out with TLC.  
After the disappearance of the starting materials, o-QM precursor 2.28.4 was next added, 
along with 3 equivalents of TBAF and exposed the reaction vessel to microwave irradiation 
at 100 °C for 40 min to afford 8-membered dibenzofused sultams 2.28.5.  The final crude 
reaction mixture was washed with H2O and extracted with EtOAc, and after concentration in 
vacuo, the mixture was purified by column chromatography.  To our delight, the desired 
cyclized products 2.28.6-13 were achieved in yields from 77–99 %, completing the one-pot 




Scheme 2.28. One-pot sequential three-component method for synthesis of 
dibenzo[b,g][1,4,5]oxathiazocine 5,5-dioxides 2.28.6-13. 
 
 
Compound X R Yield (%)a 
2.28.6 4-F propargyl 99 
2.28.7 4-F n-butyl 80 
2.28.8 4-F benzyl 47 
2.28.9 4-F 2-ethanol 15 
2.28.10 4-F cyclopropyl 80 
2.28.11 4-F Gly•OEt 9 
2.28.12 6-F 2-ethanol 11 
2.28.13 4-Br propargyl 99 
a Final isolated yield after flash chromatography. 
 
 It is important to note that the aqueous workup was necessary at the final stage to 
facilitate purification of the reaction mixture.  This step is deemed necessary due to the 
existence of various by-products such as both organic and inorganic salts that are present in 
the reaction mixture.  When the crude reaction mixture was put through column 
chromatography after concentration in vacuo without the aqueous workup, the process failed 


































2.3 Extension of one-pot strategy via SNAr for four-component synthesis 
From the conditions we developed for the library production of 
dibenzo[b,g][1,4,5]oxathiazocine 5,5-dioxides, we investigated the potential of further 
extending the utility of one-pot sequential MCR pathway.  As mentioned earlier, nucleophilic 
aromatic substitution (SNAr) is commonly used to further functionalize a halogen containing 
aromatic system.  As introduced at the beginning of Chapter 1, previous reports from our 
group demonstrate how SNAr reactions may add peripheral diversity to existing scaffolds.83 
The reported conditions employ primary or secondary amines with either Cs2CO3 or 1,8-
diazabicycloundec-7-ene (DBU) in DMSO in microwave conditions at 150-180 °C for 50 
min.  
In order to apply this useful reaction for the development of one-pot sequential 
pathway, a different condition was utilized.  Following the one-pot, sequential, three-
component strategy, benzenesulfonyl chloride 2.28.1 was reacted with primary amine 2.29.1 
to produce secondary sulfonamide 2.29.2, which was then reacted with o-QM precursor 
2.28.4 to afford sultam 2.29.3 (Scheme 2.29).  At this stage, without workup or change of 
solvent from previous reactions (THF), an excess of primary or secondary amine 2.29.4 and 
0.1 equivalents of DBU were added to the reaction mixture.  The vessel was then exposed to 
µW conditions at 100 °C for 1 h.  After an aqueous workup and silica SPE to remove excess 
amines, the reaction mixture was then purified via column chromatography. The 
corresponding SNAr adducts 2.29.5 were isolated in excellent yields.  Relative to previous 
harsh conditions at high temperatures in DMSO, the workup is cleaner since decomposed 
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DMSO can be avoided.  The results demonstrate the scope of various primary and 
secondary/cyclic amines that may be incorporated to these reaction conditions.  




Compound R1 R2 position R2 yield %a 
2.29.6 propargyl 4- pyrrolidine 86 
2.29.7 propargyl 4- morpholine 96 
2.29.8 propargyl 4- N-methyl-2-
ethanol amine 
28 
2.29.9 n-butyl 4- morpholine 64 
2.29.10 n-butyl 4- pyrrolidine 68 
2.29.11 propargyl 6- isobutyl amine 39 
2.29.12 propargyl 6- N-methyl-2-
ethanol amine 
27 
a Final isolated yield after flash chromatography. 
 
2.4 Extension of one-pot strategy via CuAAC for five-component synthesis 
With these encouraging results in hand, we envisioned incorporating one more step in 
this sequence of reactions.  An emerging functional handle that is commonly utilized in 
adding diversity to a scaffold is the triazole moiety, as seen earlier in this chapter.  Moreover, 
it was demonstrated in Chapter 1 that SNAr and Click reactions are orthogonal to each other, 
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propargyl amine was selected as the amine for the initial sulfonylation reaction.  This 
propargyl moiety will be then available for a late stage-[3+2]-Huisgen cyclization reaction, 
commonly referred to as Click reaction. 
Initially, we started our methodology studies by adding benzyl azide 2.30.4 with a 
copper source to perform Click reaction after the fourth (SNAr) reaction is complete, in a 
sequential manner (Scheme 2.30).  However, after considering the orthogonality of SNAr and 
Click reaction, we investigated the possibility of executing the two reactions in a  











































































































multicomponent reaction fashion.  Without any purification or solvent change, after 
completion of the three-component reaction, 2 equivalents of benzyl azide 2.30.4, 5 
equivalents of amine 2.30.3, 0.3 equivalents of DBU, and 0.1 mol% of CuI were added to the 
reaction mixture. Then, the mixture was exposed to µW conditions at 100 °C for 1 h. After 
an aqueous workup and silica SPE, purification was done via column chromatography. To 
our delight, we were able to achieve one-pot, sequential, 5-component multi-step/multi-
component reaction products 2.30.5 in excellent overall yields (Scheme 2.30). 
 
2.5 High-temperature NMR studies  
Previous stepwise synthesis of the desired 8-membered dibenzofused sultams 
revealed that there are a set of rotamers seen in the 1H NMR spectra as evident by the 
appearance of the two split peaks for the –OMe residing at the periphery on amino ester-
derived scaffolds (Figure 2.3).82  Initially, this phenomenon was viewed as a minor by-
product (two –OMe peaks at 2.28 ppm and 3.52 ppm).  The relative intensities suggested  




















4.43 d 16.0 1.0
3.85 d 15.9 5.96
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that there is an approximately 7:1 ratio of the two conformers in the case of valine•OMe-
derived scaffold shown in Figure 2.3.  X-ray crystallographic analysis of a single crystal 
confirmed the non-flat and cup-like architecture of this unique sultam,84 but solution 1H-
NMR data also revealed that we have two conformers, plausibly rotamers about the N–Cα 
bond or two ring conformers (oxygen up as in X-ray or down in ring-flipped structure) 
(Figure 2.4). 
Figure 2.4. X-ray crystal structure of Val•OMe-derived sultam. 
 
In considering rotamer vs ring conformer mentioned in the previous paragraph, 
consideration of innate properties of sulfonamides should be in order.  In this regard, 
discussion among colleagues, as well as recent analysis detailed in Dr. Joanna Loh’s thesis 
and Dr. Kyu Ok Jeon’s thesis,85 have shed light on the unique conformational control 
imparted by the preferred conformation of sulfonamides, which places the nitrogen lone pair 
anti-periplanar to the S–Ar bond to maximize the σ* orbital delocalization.  This 
conformation effectively allows the orientation of the lone pair to bisect the O=S=O 
internuclear angle.86  In amino ester derived sultams, such as valine•OMe derived sultam 







provides additional stabilization to plausibly partition two potential rotameric structures.  
These features could potentially influence both aforementioned rotamers and ring-flipped 
structures. 
In order to shed additional light on this matter, variable temperature NMR 
experiments were carried out to establish the barrier to rotation about the N–C bond. This 
phenomenon was explained by the hindered rotation around the bond between sulfonamide 
nitrogen and carbon substituent.  Two scaffolds, alanine methyl ester-derived and valine 
methyl ester-derived scaffolds were selected based on the steric bulk attached to the 
sulfonamide nitrogen.  The A-values of methyl and isopropyl substituents are 1.70 and 2.15 
kcal/mol, respectively.  We hypothesized that by heating the compound to higher 
temperatures, the two split –OMe peaks will slowly coalesce by overcoming the rotational 
barrier between the existing rotamers.  At the same time, we hypothesized that the magnitude 
of steric bulk will have a linear relationship with barrier of rotation between the two 
rotamers. 
 High-temperature NMR studies were performed with the two scaffolds.  The two 
compounds were dissolved in d6-DMSO, and the peaks representing the –OMe of the methyl 
esters at the periphery were measured (Figure 2.5, 2.6).  By heating from room temperature 
up to 110 °C, the two rotamer peaks were measured at each temperatures.  As expected, we 
observed the slow coalescence of the two –OMe peaks as the temperatures increased.  Based 
on the measured peaks, the barriers of the two conformers were calculated.87  Alanine•OMe-
derived scaffold’s barrier was 16.2 kcal/mol, and that of valine•OMe-derived scaffold was 
21.0 kcal/mol.  The significance of these values led us to tentatively assume that this is most 
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likely a ring-flip phenomenon and not a rotational barrier issue, which is more likely to be 
around 10 kcal/mol.85 
Figure 2.5. High-temperature NMR study of alanine•OMe-derived scaffold. 
 
Figure 2.6. High-temperature NMR study of valine•OMe-derived scaffold. 
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2.6 Biological activity data 
 After submission of produced compounds to NIH Molecular Libraries Probe 
Production Centers Network (MLPCN) depository to be sent to Molecular Libraries 
Screening Centers Network (MLSCN), we were able to access the screening results in 
PubChem database.  Gratifyingly, four compounds displayed various biological activities 
when screened against diverse biological assays (Figure 2.7).  Sultam 2.7.A exhibited agonist 
activity against both human cholinergic receptor, muscarinic 1 (CHRM1) and trace amine-
associated receptor 1 (TAAR1).  Sultam 2.7.B was found to be positive allosteric modulators 
of both human CHRM1 and CHRM4, and also inhibitors of tim23-1 yeast. Sultam 2.7.C 
displayed modulating activity against peroxisome proliferator-activated receptor gamma 
coactivator (PGC-1α) at IC50 of 14.33 µM.  Notably, sultam 2.7.D, which was generated 
from one-pot, sequential, five-component reaction protocol, was identified as exosite 
inhibitors of a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10). 
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Active in 1 of 18 BioAssays
• exosite inhibitors of ADAM10
2.7.A 2.7.B 2.7.C 2.7.D
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2.7 Conclusion 
 In conclusion, development of one-pot sequential three-, four-, and five-component 
reactions for the synthesis of diverse dibenzo[b,g][1,4,5]oxathiazocine 5,5-dioxide 
derivatives inspired from the method developed in Chapter 1 have been achieved.  From the 
resulting scaffolds derived from alanine and valine methyl esters, rotational barriers between 
the two existing rotamers were studied through high-temperature NMR analysis.  Biological 
data was also obtained from PubChem and has shown promising activities.  The developed 
one-pot sequential methodology is highly efficient and yielding, and will enable further 
production of analogs in a highly facilitated manner for ultimate screening in a broad range 
of assays.  
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3.1 Introduction – Review of Synthesis and Modification of Tetramic Acids 
Tetramic acids are well known in the literature for their existence in numerous natural 
products and biologically active compounds. Bioactivities include, but are not limited to, 
antibiotic, antiviral, cytotoxicity, and cell cycle inhibition (Figure 3.1).1 The broad bioactivity 
of tetramic acids has attracted much attention from the synthetic community, spawning 
various types of library syntheses and their corresponding structure-activity relationships 
(SARs).  
In contrast, the corresponding sultam (cyclic sulfonamide) derivatives of tetramic 
acids are relatively limited in the literature. As shown in Figure 3.2, the number of sultam 
analogs 3.2.C and tautomer compounds 3.2.D listed in SciFinder and entries in PubChem 
database are drastically scarce relative to tetramic acid cores 3.2.A and their tautomers 3.2.B. 
In this regard, the development of methods to produce sultam analogs of tetramic acids will  
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Figure 3.1. Select examples of natural products containing tetramic acid core. 
 
be beneficial to occupy underdeveloped chemical space in search for novel compounds with 
potential biological activities. We herein report the synthesis of monocyclic and bicyclic 
sultam analogs of tetramic acids, and further derivatization to generate analogues of known 
biologically active compounds via “Click, Click, Cyclize” methodology.2 Further discussion 
of “Click, Click, Cyclize” methodology will be introduced in Section 3.2. 
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This introduction in this chapter will focus solely on review of recently developed 
synthetic methodods towards the production of tetramic acids and their modifications for the 
synthesis of derivatives, from 2010 to-date.  For methods developed prior to 2010, the reader 
is referred to two review articles published in 20083 and 2010.4  Moreover, recent efforts 
towards the total synthesis of natural products containing tetramic acid moieties are described 
in the following references.5 
In large, this review section is categorized into three subsections: (i) synthesis of 
tetramic acids via Dieckmann-related chemistry, (ii) synthesis of tetramic acids via non-
Dieckmann-type chemistry, and (iii) modification of tetramic acids for peripheral diversity. 
 
3.1a Dieckmann-derived Tetramic Acid Synthesis 
In 2010, Deng and coworkers6 reported synthesis of tetramic acid analog, which has a 
photosensitive moiety that was used for binding studies to undecaprenyl pyrophosphate 
synthase (UPPS).  UPPS is a bacterial enzyme that catalyzes the condensation of eight 
molecules of isopentenyl pyrophosphate (IPP) with farnesyl pyrophosphate (FPP) to produce 
C55 undecaprenyl pyrophosphate (UPP).  UPP then functions as a lipid carrier for 
peptidoglycan synthesis that is involved in bacterial cell wall construction. Starting from 
commercially available 4-aminobenzophenone 3.1.1, acylation with methyl malonyl chloride 
3.1.2 afforded 3.1.3 (Scheme 3.1).  Hydrolysis of the ester moiety with NaOH, followed by 
EDCI coupling with ethyl-2-homophenylalanine yielded compound 3.1.5, which is ready for 
intramolecular Dieckmann condensation.  Dieckmann condensation of 3.1.5 in the presence 
of 21% NaOEt in EtOH produced tetramic acid 3.1.6.  The synthesized tetramic acid was 
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employed as a photoprobe in studying the binding mode of tetramic acids in the FPP binding 
site. 
Scheme 3.1. Synthesis of tetramic acid derivative bearing photosensitive moiety.  
 
In 2010, Yang and coworkers 7  reported synthesis of novel (E)-3-(1-
(alkyloxyamino)ethylidene)-1-alkylpyrrolidine-2,4-dione derivatives (Scheme 3.2).  In 
building the Dieckmann cyclization precursor 3.2.5, ethyl bromoacetate 3.2.1 was reacted 
with primary amine 3.2.2 to afford 2-(alkylamino)acetate 3.2.3.  Subsequent reaction with 
diketene 3.2.4 installed the dicarboxyl moiety to generate 3.2.5 that participates in the 
cyclization to form the tetramic acid core.  Dieckmann cyclization of 3.2.5 with sodium 
methoxide furnished 3-acyl tetramic acid 3.2.6. Formation of oxime ether moiety at the 3-
position was achieved by exposing the 3-acyl tetramic acid 3.2.6 to O-alkyl hydroxylamine 
3.2.7 in presence of NaOH to afford 3-oxime-ether-substituted tetramic acid 3.2.8. 






















































































In 2010, Schobert and coworkers8 reported the synthesis of precursors and analogs of 
aburatubolactam A and macrocidin A.  Starting material aburatubolactam fragment 3.3.1 was 
prepared in six steps following literature precedent (Scheme 3.3a).  Compound 3.3.1 was 
then acylated with 2,2-dimethyl-6-[(1E,3E)-penta-1,3-dienyl]-4H-[1,3]-dioxin-4-one 3.3.2 to 
afford amide 3.3.3.  Subsequent Dieckmann cyclization with NaOMe furnished 
aburatubolactam precursor 3.3.5.  A different route was employed in making analogs of 
macrocidin A (Scheme 3.3b).  Starting from a simple tetramic acid 3.3.5, Yoshii acylation 
with carboxylic acid to install the side chains at the 3-position yielded 3-acyl tetramic acid 
3.3.6. Deprotection of N-Boc moiety and subsequent removal of allyl group at the phenol 
position produced macrocidin A precursor 3.3.7. 
Scheme 3.3. Synthesis of precursors of aburatubolactam A and macrocidin A. 
 
In 2011, Moloney and coworkers built upon previous work,9  and reported the 
synthesis of a stereochemical library bearing tetramic acid cores.  Starting from simple 
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the oxazolidine motif 3.4.3 (Scheme 3.4).  Subsequent acylation with carboxylic acid 3.4.4 
followed by Dieckmann ring closure yielded the desired tetramic acid core 3.4.6.  This core 
then was further diversified through peripheral modification.  The highlight of this strategy 
was the ability of generating a stereochemically diverse set of compounds starting from a 
simple starting material.  The authors reported that the chiral heterocyclic libraries generated 
from tetramic acid cores exhibited antibacterial activity. 
Scheme 3.4. Synthesis of stereochemical library bearing tetramic acid cores. 
 
In 2011, Moody and coworkers10 utilized a Diels-Alder approach in synthesizing 
spirotetramate cores of naturally occurring antibiotics.  The synthesis of exocyclic methylene 
unit 3.5.8 that participates in Diels-Alder reaction as the dienophile is generated from a 
sequence of reactions starting from S-methylcysteine 3.5.1 (Scheme 3.5).  2,4- 
Scheme 3.5. Utilization of Diels-Alder approach in synthesizing spirotetramate core of 






































































































dimethoxybenzyl (DMB) protection of S-methylcysteine 3.5.1 with the corresponding 
aldehyde 3.5.2 and acylation with thioester 3.5.4 afforded Lacey-Dieckmann precursor 3.5.5.  
The precursor 3.5.5 was then subjected to Lacey-Dieckmann conditions to yield tetramc acid 
3.5.6.  Oxidation of the thioether of tetramic acid 3.5.6 with hydrogen peroxide, followed by 
thermal elimination produced the dienophile 3.5.8.  Diels-Alder reaction with various dienes 
3.5.9 furnished spirotetramate 3.5.10. 
In 2013, Moloney and coworkers 9 reported synthesis of chiral bicyclic tetramic acid 
derivatives via chemoselective Dieckmann cyclization.11  Starting from L-cysteine 3.6.1, 
reaction with various aldehydes 3.6.2 afforded the corresponding thiazolidines 3.6.3 (Scheme 
3.6).  Subsequent coupling with monoethyl malonate 3.6.4 afforded the Dieckmann precursor 
3.6.5, predominantly the cis-isomer.  Chemoselective Dieckmann cyclization with KOt-Bu 
successfully produced bicyclic tetramates 3.6.6.  This method was then extended to utilizing 
α-methyl serine 3.6.7. Interestingly, only the trans-isomer  
















































































underwent Dieckmann cyclization to afford chiral α-methyl substituted bicyclic tetramates 
3.6.11.  
In 2014, Liu and coworkers12 reported the synthesis of 4-amino derivatives of 
tetramic acids.  Diethyl malonate 3.7.1 was modified to yield monoethyl malonate 3.7.2, 
which then was coupled with various commercially available amino esters 3.7.3 (Scheme 
3.7a).  Next, treatment with NaOMe in refluxing toluene afforded the Dieckmann 
cycloadduct 3-acyl tetramic acid 3.7.5.  The subsequent decarboxylation was performed by 
refluxing the reaction in a mixture of acetonitrile and water to afford tetramic acid 3.7.6.  
With tetramic acid 3.7.6 in hand, the authors then reported the transformation of the hydroxyl 
group to an amine by reacting with various primary amines 3.7.7 (Scheme 3.7b). In addition, 
tetramic acid 3.7.9 reacted with benzaldehyde to form an exocyclic olefin-containing 
tetramic acid 3.7.10.  However, they observed a mixture of the desired target and  
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a 4-ethoxy tetramic acid 3.7.11.  In an alternate attempt to form 4-amino tetramic acids, the 
authors utilized 3-acyl tetramic acid 3.7.12 and reacted with benzyl amine in THF or EtOH at 
room temperature (Scheme 3.7c).  Instead of proceeding to the desired 4-amino substrate 
3.7.14, they observed that the reaction stops at the salt formation at the 3-hydroxy position to 
yield 3.7.13. However, when the mixture was refluxed in THF the desired amination product 
3.7.14 was formed. When the amine partner is switched to aryl amines, they observed 
formation of 3-carboxamide tetramic acid 3.7.15.  
In 2014, Moloney and workers reported further modification to generate 3-acyl 
tetramic acids.13  3-Acyl side chains have been identified on numerous bioactive natural 
products containing tetramic acid cores, and thus became a target for further studies.  By 
utilizing previously synthesized bicyclic tetramic acids, the authors utilized O-
acylation/rearrangement procedure to attach 3-acyl moieties.  Treatment of tetramic acid 
3.8.1 with acetic acid in the presence of DCC-DMAP furnished 3-acyl tetramic acid 3.8.2 
(Scheme 3.8).  The resulting 3-acyl tetramic acid 3.8.2 was then subjected to aromatic  
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aldehydes using secondary amines (piperidine or dibenzyl amine) as base to produce enamine 
3.8.3.  Depending on which secondary amine was used, the enamine was directly hydrolyzed 
under alkaline conditions or deprotected to form 3.8.4 and then hydrolized to afford 3-acyl 
substituted tetramic acid 3.8.5.  
 
3.1.b Non-Dieckmann/Non-traditional Dieckmann Section 
In 2010, Alcaide and coworkers reported utilization of 2-azetidinone-tethered allenols 
in the synthesis of tetramic acids and spirocyclic seleno-β-lactams.14  Screening of various 
halogenating reagents resulted in N-bromosuccinimide (NBS) as the optimal source of 
brominating the external allene 3.9.1, which subsequently underwent selective 1,2 C–C bond 
migration to afford the desired tetramic acid 3.9.3 (Scheme 3.9).  On the other hand, 
employing N-phenylselenophthalimide went through a different transition state 3.9.4, which 
then led to oxycyclization with the loss of a proton to yield spirocyclic seleno-β-lactam 3.9.5. 
Scheme 3.9. Synthesis of chiral tetramic acids and spirocyclic seleno-β-lactams. 
 
In 2010, the Dittmer group reported the usage of telluride-triggered Dieckmann 
cyclization for the synthesis of tetramic acids.15  Telluride-triggered Dieckmann precursor  
α-bromoacyl amide ester 3.10.3 was prepared by acylating amino ester 3.10.1 with α-
































of lithium or sodium telluride in THF at room temperature, affording lithium enolate 3.10.4, 
which then underwent Dieckmann cyclization to yield tetramic acid 3.10.5. The authors 
noted that several of tetramic acid derivatives were unstable, and thus required conversion to 
the corresponding silyl enol form 3.10.6. 




In 2010, Prousis and coworkers reported synthesis of chiral 5-carboxymethyl tetramic 
acids via intramolecular cyclization of (S)-N-Ac-L-aspartic anhydrides.16  Regioselective 
addition of β-ketoester carbon nucleophile 3.11.2 into the more hindered, more electron-
deficient carbonyl at the C-2 position of anhydride 3.11.1 resulted in the ring-opened product 
3.11.3 (Scheme 3.11).  After aqueous workup and acidification, the reaction mixture was 
next exposed to NaOEt in EtOH to afford the desired 3-acyl-5-carboxymethyl tetramic acid 
3.11.4.  
Scheme 3.11. Synthesis of chiral 5-carboxymethyl tetramic acids. 
 
In 2010, the Avendaño group demonstrated use of pyrazino[1,2-b]isoquinoline-1,4-
diones in the synthesis of tetramic acid derivatives.17  Previous reports have shown that N-
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that promoted base-mediated ring contraction reaction to generate various tetramic acids 
3.12.2 and 3.12.3 (Scheme 3.12a).18  Building upon this reactivity, Avendaño and coworkers 
expanded this methodology to utilizing pyrazino[1,2-b]isoquinoline-1,4-diones 3.12.4 to 
afford tetramic acids 3.12.5 containing benzo[f]indolizine skeleton (Scheme 3.12b).  
Scheme 3.12. Pyrazino[1,2-b]isoquinoline-1,4-diones in the synthesis of tetramic acid 
derivatives. 
 
Markopoulos and Igglessi-Markopoulou group reported the synthesis of exocyclic 
olefin-containing tetramic acids for the utilization in ruthenium-catalyzed selective 
hydrogenation processes.19  Through a one-pot C-acylation reaction with N-acetylglycine 
3.13.1 and dimethyl or diethyl malonate 3.13.2 in the presence of N-hydroxysuccinimide 
(NHS) and N,N’-dicyclohexylcarbodiimide (DCC) followed by cyclization afforded 3-acyl 
substituted tetramic acid 3.13.3 (Scheme 3.13).  The resulting tetramic acid 3.13.3 was then 
reacted with 4-substituted benzaldehydes to produce mono- and bis-arylidene tetramic acids 























    THF, rt
2. H3O+
1. LiHMDS
    THF, -78 °C
2. R4X
when R1  = R3 = Boc, Bzwhen R1  = R3 = Boc




















OHH1. KtBuO, THF, rt, 12 h
2. H3O+
                    or







Scheme 3.13. Synthesis of exocyclic olefin-containing tetramic acids. 
 
 
In 2011, Ďuriš and coworkers showcased a novel approach in producing constrained 
tetramic acids via a sequence of amidation followed by intramolecular Wittig olefination.20 
Aminobutanolide 3.14.1 was reacted with phosphorous ylide 3.14.2, which undergoes a 
sequential amidation of the exocyclic secondary amine with the ester followed by Wittig 
cyclization of the phosphorous ylide with lactone ester furnishing bicyclic tetramic acid 
3.14.3 (Scheme 3.14).  Hydrogenation of 3.14.3 with Pd/C and H2 in EtOAc produced 
tetramic acid 3.14.4.  Subsequent reduction with excess amount of sodium in a mixture of 
liquid ammonia and THF afforded N- and O-debenzylated product 3.14.6. Interestingly, the  
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authors noted that by switching the solvent to protic solvent, MeOH, during the Pd/C and H2 
reduction step, they were able to isolate the ring-opened product 3.14.5 in one step. 
In 2010 and 2012, Liu and coworkers reported the synthesis of tetramic acids via 
intramolecular aza-anti-Michael addition.21  En route to studying routes to utilize cinnamoyl 
ketene dithioacetal 3.15.1, exposure to sodium hydride in open-air conditions unexpectedly 
afforded a mixture of intramolecular aza-anti-Michael adduct 3.15.2 and 3.15.3, an oxidative 
rearrangement product (Scheme 3.15).  In order to drive the reaction towards the synthesis of 
the unexpected succinimide derivatives, further studies and optimizations revealed a 
sequence of intramolecular aza-anti-Michael, oxidation/1,2-benzyl migration to furnish the 
rearranged product 3.15.4 in 70% yield.  
Scheme 3.15. Synthesis of tetramic acids via intramolecular aza-anti-Michael addition. 
 
Building upon a previous report, the Burgess group reported the synthesis of 
omegatides, analogs from contiguous tetramic acids in 2012.22  Starting with N-Boc-alanine 
3.16.1, coupling with Meldrum’s acid via a C-acylation pathway, followed by 
decarboxylation, afforded the N-Boc protected tetramic acid 3.16.2 (Scheme 3.16).  
Subsequent deprotection with TFA furnished tetramic acid 3.16.3.  Through a similar 







































Scheme 3.16. Synthesis of omegatides bearing contiguous tetramic acids. 
 
In 2012, Xu and coworkers demonstrated a strategy towards the synthesis of tetramic 
acids employing SmI2-mediated coupling of nitrones and tert-butanesulfinyl imines with 
allenoates.24  Initial work on coupling nitrones 3.17.1 with allenoates 3.17.3 afforded β-
methylenyl-substituted γ-amino esters 3.17.4 (Scheme 3.17).  Subsequent zinc reduction of  
N-hydroxy amines furnished exo-β,γ-unsaturated lactam 3.17.5, which was stable under both 
neutral and acidic conditions towards double bond migration.  With this result an asymmetric 
version was investigated, and by using chiral sulfinyl imines 3.17.2, optically active lactams 
3.17.7 were synthesized by acid hydrolysis of the resulting ester 3.17.6.  The exocyclic olefin 
was then cleaved by ozonolysis to yield tetramic acid 3.17.8. 
Scheme 3.17. Synthesis of tetramic acids employing SmI2-mediated coupling strategy. 
 
In 2013, Mao and coworkers reported the first synthesis tetramic acids using 
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presence of Brønsted acids.25  Various 1-acetyl N-aryl carboxamide derivatives 3.18.1 
containing cyclopropane or cyclopentane were utilized in intramolecular sp3 C–H amination 
(Scheme 3.18).  Optimization studies revealed that PhI(OPiv)2 has shown the best reactivity, 
and the presence of propanoic acid was crucial in obtaining higher yields of tetramic acid 
3.18.2.  Due to the nature of this mechanism that involves a N-iodane species, the authors 
noted that annulation of alkyl amines failed due to instability. 
Scheme 3.18. Synthesis tetramic acids using intramolecular sp3 C–H amination mediated by 
hypervalent iodine (III) reagents. 
 
In 2014, the Yamada group reported the usage of silver-catalyzed carbon dioxide 
incorporation into propargyl amine and intramolecular rearrangement for the synthesis of 
tetramic acid derivatives.26  Selection of base was critical for this reaction sequence, and 
DBU was identified as the appropriate base from screening studies.  In the presence of 10 
mol% AgOAc in acetonitrile under 0.1 MPa CO2 pressure, the silver catalyst activated the 
alkyne 3.19.1 to incorporate a CO2 moiety to form an oxazolidinone intermediate 3.19.2 
(Scheme 3.19). Intermediate 3.19.2 readily underwent intramolecular rearrangement initiated 
by removal of N–H proton by DBU to generate an isocyanate intermediate 3.19.3, followed 
by cyclization to furnish tetramic acid 3.19.4.  This sequence was performed in a one-pot 
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Scheme 3.19. Synthesis of tetramic acids via Ag-catalyzed CO2 incorporation into propargyl 
amines and intramolecular rearrangement. 
 
 
Cherian and coworkers reported syntheses of N-acyl, 3-acyltetramic acids as analogs 
of reutericyclin.27  The objective of this study was to establish structure-activity relationship 
(SAR) reutericyclin, an antibiotic from membrane-active Lactobacillus reuteri. Modification 
of the tetramic acid core of reutericyclin was streamlined (Scheme 3.20).  Amino acid benzyl 
esters 3.20.1 were reacted with the Bestman ylide and hydrogenated to yield tetramic acid 
core 3.20.2.  A further sequence involving acylation to generate intermediate 3.20.3 followed 
by acyl migration by addition of acetone cyanohydrin 3.20.4 to the reaction mixture 
produced the 3-acyl motif 3.20.5.  Subsequent N-acylation with NaHMDS and acid chloride 
3.20.6 furnished the desired N-acyl, 3-acyltetramic acid 3.20.7. 
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In 2014, the González-Muñiz group demonstrated the utilization of copper-catalyzed 
coupling of iodiphenyl-2-trifluoroacetylamine with β-ketoesters derived from amino acids en 
route to tetramic acid synthesis.28  Under milder coupling conditions at room temperature in 
DMSO, the coupling of β-ketoester 3.21.1 with aryl iodide 3.21.2 in the presence of CuI and 
Cs2CO3 yielded coupled product 3.21.3 (Scheme 3.21).  Further heating in MeOH/H2O and 
addition of Cs2CO3 at 80 °C afforded the cyclized tetramic acid 3.21.4.  With this result in 
hand, the authors carried out the Cu-catalyzed coupling reaction at elevated temperature and 
4 equivalents of Cs2CO3 and achieved the synthesis of tetramic acid 3.21.4 in one pot without 
isolating intermediate 3.21.3. 
Scheme 3.21. Utilization of copper-catalyzed coupling of iodiphenyl-2-trifluoroacetylamine 




3.1.c Derivatization of TA Section  
In 2010, the Kozmin group reported a library synthesis of various 7-membered 
heterocycles containing tetramic acid cores to be screened against proliferation of A549 cell 






















F3COCCuI (0.2 equiv), L-Pro (0.4 equiv)Cs2CO3 (4 equiv), DMSO, 50 °C
CuI (0.2 equiv), L-Pro (0.4 equiv)








condensing o-phenylenediamine 3.22.2 and tetramic acid 3.22.1 in benzene in the presence of 
catalytic amount of PTSA (Scheme 3.22). Then a one-pot transformation of urea 3.22.3 via 
Mannich reaction with aldehyde 3.22.4 followed by acylation with acid chloride 3.22.5 
sequence was developed to furnish the desired tetramic acid-fused 7-membered heterocycle 
3.22.6. 





In 2010, McNab and coworkers reported the modification of pyrrolizine-1,3-dione to 
afford diverse heterocyclic compounds (Scheme 3.23).30  Pyrrolizine-1,3-dione 3.23.1, a 
pyrrole-fused tetramic acid, was conveniently synthesized from previously reported 
method.31  Hydrogenation of tetramic acid 3.23.1 under hydrogen atmosphere with Pd/C 
afforded 3.23.2. Dimethylaminomethylene product 3.23.6 was conveniently produced by 
reacting the starting material in solution of chloroform with DMF dimethyl acetal 3.23.5 at 
room temperature.  Reaction of tetramic acid 3.23.1 with methoxymethylene Meldrum’s acid 
3.23.3 in the presence of trace amounts of Hünig’s base, furnished product 3.23.4.  Finally, 



















































Building upon their previously reported method,14 the Alcaide group reported the 
Suzuki-Miyaura reaction of bromoalkene substituted tetramic acids.32  In investigating 
different reactivities of scaffolds generated from previously reported methods for the 
production of potentially bioactive heterocycles, the authors envisioned application of 
Suzuki-Miyaura reaction for further diversification.  The exocyclic bromoalkene moiety of 
tetramic acid 3.24.1 was subject to Suzuki-Miyaura conditions in refluxing mixture of 
toluene/ethanol/water (18:1:1) in the presence of Pd catalyst and aryl boronic acids 3.24.2 to 
afford aryl substituted tetramic acid 3.24.3. 
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Building upon previous work, the Moloney group published studies on the 
development of conditions for modifying tetramic acids to their corresponding O-acyl and 3-
acyl tetramic acids.33  O-Acylation conditions were initially studied, and optimization 
process identified two sets of conditions (Scheme 3.25).  Condition A, which uses the 
corresponding carboxylic acids in the presence of DCC and catalytic amount of DMAP, 
furnished O-acyl tetramic acids 3.25.2 in excellent yields.  An alternate condition, B, utilized 
the corresponding acid chlorides with Et3N to give the O-acylated products 3.25.2 as well.  
With the O-acyl tetramic acids synthesized, conditions to transform them into 3-acyl tetramic 
acids 3.25.3 were reported.  They envisioned a Fries-type acyl migration using catalytic 
amount of acetone cyanohydrin in the presence of Et3N to produce 3-acyl tetramic acid 
3.25.3. In case where R2 was decanoyl, simple treatment with DMAP in CH2Cl2 afforded 
acyl-migrated product 3.25.3 (Condition D), where as the condition only showed  
Scheme 3.25. Development of conditions for modifying tetramic acids to their corresponding 
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decomposition when R2 is phenyl.  In case of using linear carboxylic acids, increase in 
amount of DMAP to 1.3 equivalents directly produced 3-acyl tetramic acids 3.25.3 in good 
yields (Condition E).  
In 2012, Castellucci and coworkers reported a one-pot synthesis of tetramic acids for 
the preparation of putative turn mimics.34  The group focused on the skeleton of 1-acyl 3-
carboxy tetramic acids being analogous to constrained β-amino acids.  Benchmarking the 
method developed by the Igglessi-Markopoulou group,19a synthesis of poly-substituted 
tetramic acids and their 6-membered analogs 3.26.3 were demonstrated in a one-pot method, 
starting from benzyl malonate and N-hydroxysuccinimide esters of Boc-protected amino acid 
3.26.1 (Scheme 3.26a).  The resulting γ-amino β-oxo benzyl ester 3.26.2 then cyclized in 
situ, leading to polysubstituted tetramic acid and its 6-membered analog 3.26.3.  The authors 
then demonstrate modification of 6-membered tetramic acid analog 3.26.4 (Scheme 3.26b).  
Methylation of 4-enol followed by debenzylation afforded free carboxylic acid 3.26.6, which 
was then coupled with alanine methyl ester to produce polysubstituted tetramic acid 3.26.7.  
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In 2014, the Pettus group demonstrated various modifications of tetramic acids 
prepared from the Jones’ protocol.35  Aldol adducts at the 5-position of tetramic acids are 
found in various natural products, including tetrapetalone B,36 cylindramide A,37 militarinone 
B,38  paecilosetin, 39  and cryptocin.40   By utilizing three different one-pot protocols for 
silylation to generate the intermediate silylated pyrrole 3.27.2 followed by addition of 
aldehyde in the presence of Lewis acid additive, they achieved diastereoselective vinylogous 
aldol reaction at the 5-position to afford substituted tetramic acid 3.27.3 (Scheme 3.27).  
Through optimization studies they identified SnCl4 to be the optimal catalytic Lewis acid 
“additive.”  Exposure to IBX followed by DIBAL-H resulted in enhanced diastereoselectivity 
when linear aldehydes were used to produce 3.27.4.  Various transformations were 
performed, including exposure of 5-substituted tetramic acid 3.27.3 to argentic oxide with 6N  
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A: crude pyrrole in THF with LiHMDS
B: crude pyrrole in toluene without KHMDS














HNO3, which resulted in aminal 3.27.5.  Acylation of alcohol moiety adjacent to the 5-
position followed by treatment with the aforementioned condition produced deprotected 
tetramic acid 3.27.6.  For the case of R2 = Br, coupling under Molander’s conditions afforded 
3-substituted tetramic acid 3.27.8.  The same 3-bromo-tetramic acid was also converted to its 
corresponding aldolate 3.27.7 by hydrogenolysis.  
Recently in 2014, the Yoda group published their studies on using chiral, non-racemic  
L-phenylalanine-derived tetramic acids for the synthesis of chiral C2- and pseudo C2-
symmetric diols that may be utilized as novel asymmetric ligands (Scheme 3.28).41  They 
envisioned that tandem Knoevenagel condensation of tetramic acid 3.28.1 with aldehydes 
3.28.2 followed by Michael addition with second equiv of tetramic acid 3.28.1 would 
produce the desired chiral tetramic acid dimers 3.28.4.  Optimization studies revealed L-
proline to be the optimal catalyst for the initial Knoevenagel condensation performed in 
ethanol at room temperature for 1 h.  Michael addition of the second equivalent of starting 
tetramic acid 3.28.1 furnished the desired chiral diol.  This method enables readily 
availability of custom designed chiral diols in gram quantities that may be further utilized as 
versatile chiral ligands. 
Scheme 3.28. Application of chiral L-phenylalanine-derived tetramic acids for the synthesis 




























3.2 Synthesis of Sultam Analogs of Tetramic Acids via Intramolecular Sulfa-Dieckmann 
Cyclization 
 
Our group has previously utilized vinyl and ortho-halobenzene sulfonamides as the 
initial linchpin that is readily available from the corresponding sulfonyl chlorides (Figure 
3.3).  The linchpins contain orthogonal functional groups that serve as handles for both facile 
cyclization and peripheral diversification reactions.  Through this process, sultams are 
synthesized in a quick and facile manner through a “Click, Click, Cyclize” strategy.2  Some 
features of “Click” chemistry include high yields, simple reaction conditions, and formation 
of benign byproducts.42  By streamlining a series of “Click” reactions and performing 
cyclization of the resulting linchpin with orthogonal functional groups, generation of diverse 
scaffolds with multiple functional groups as handles can be greatly facilitated.  In this report, 
we introduce a novel mesyl amino ester linchpin that undergoes intramolecular sulfa-
Dieckmann condensation to form a novel 5-membered β-keto-sultam. 




The utilization of carbanions adjacent to sulfur for cyclization was first reported by 
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form the corresponding sultones and sultams 3.29.3 via carbanion-mediated 
sulfonate/sulfonamide intramolecular cyclization reaction (CSIC reaction).43  The CSIC 
reaction entails the usage of nitriles as the functional group that participates in the cyclization 
with carbanion 3.29.2 generated from the methyl group on the mesylated alcohol or amine to 
form a five-membered sultone or sultam (Scheme 3.29). 
Scheme 3.29. Carbanion-mediated sulfonate/sulfonamide intramolecular cyclization 
reaction. 
 
A similar strategy was also introduced in 1984, where an alkyl sulfonamide was 
utilized in synthesizing five-membered β-γ-diketo sultams 3.30.3/3.30.4 (Scheme 3.30).44  
Condensation of diethyl oxalate 3.30.2 with primary sulfonamide 3.30.1 followed by base-
catalyzed intramolecular cyclization yielded both tautomers of β-γ-diketo sultams 
3.30.3/3.30.4, depending on the R1 substituent. 




 In efforts to devise a synthetic route towards synthesis of sultam analogs of tetramic 
acids, we developed a novel route involving “Click, Click, Cyclize” strategy.  The first click 
reaction involves mesylation of commercially available chiral amino esters 3.31.2 in the 









































mesylated amino ester 3.31.3 in good yields (Scheme 3.31).  The second click reaction 
involves benzylation of 3.31.3 with K2CO3 as base in CH3CN as solvent at 70 °C to afford 
benzylated tertiary sulfonamide 3.31.4.  Subsequent sulfa-Dieckmann condensation with 
LiHMDS as base furnished the desired tetramic acid analogs 3.31.6 in good to excellent 
yields.  This reaction involves the generation of carbanion that is adjacent to the sulfonamide 
sulfur, which subsequently undergoes intramolecular cyclization by attacking the ester 
moiety resulting in the desired product and methanol. 
Scheme 3.31. Development of route towards synthesis of sultam analogs of tetramic acids. 
 
 Substrate scope studies were next investigated in order to survey a variety of starting 
materials that could be utilized in this reaction sequence.  Amino esters derived from natural 
amino acids bearing alkyl side chains (alanine, valine, leucine, isoleucine), aromatic side 
chains (phenylalanine, tryptophan), and cyclic side chain (cyclohexyl) were utilized and 
























































3.3 Utilization of Cyclic Amino esters For Synthesis of Bicyclic Tetramic Acid Analogs 
 The method was further extended to incorporate cyclic amino esters for the synthesis 
of bicyclic tetramic acid analogs.  We envisioned that although this excludes one functional 
handle, namely the sulfonamide N–H, the resulting bicyclic core of tetramic acid analogs 
could occupy a unique chemical space.  The modified reaction sequence involved  




mesylation of cyclic amino ester 3.32.2, which then underwent intramolecular sulfa-




OO R = Ph           3.A.1   65 %
    = 2-F-Ph    3.A.2   72 %
    = 2-Cl-Ph   3.A.3   73 %
    = 4-Me-Ph 3.A.4   67 %
    = 4-Br-Ph   3.A.5   69 %





OO R R = Ph             3.A.7     61 %
    = 2-Br-Ph     3.A.8     37 %
    = 4-Me-Ph    3.A.9     67 %
    = 4-F-Ph       3.A.10   96 %











R = 2-prop-1-ene   3.A.12   63 %
    = vinyl                3.A.13   65 %
    = 4-F-Ph            3.A.14   53 %
    = 3-Cl-Ph           3.A.15   42 %
R = 4-F-Ph    3.A.18  66 %
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 Several commercially available cyclic amino esters were selected for validation 
(Figure 3.4).  Both R- and S-proline-2-carboxylic acid methyl esters 3.4.A and 3.4.B, and 
TBS-protected 4-hydroxyproline methyl ester 3.4.C were chosen for production of 5,5-fused 
bicyclic tetramic acid analogs.  Piperidine methyl ester 3.4.D and several other heterocylic 
derivatives, such as N-Boc-piperiazine methyl ester 3.4.E, were selected for synthesis of 5,6-
fused tetramic acid analogs.  
Figure 3.4. Select examples of commercially available cyclic amino esters. 
 
Initial optimization started by searching for an appropriate base for the generation of 
the carbanion of the methyl group from the mesyl moiety.  Several bases were surveyed such 
as LDA, KHMDS, and LiHMDS.  Gratifyingly, it was found that 2 equivalents of LiHMDS 
at -78 °C provided the best yield without racemization at the amino ester stereogenic center. 
However, it is noteworthy that initial attempts at intramolecular sulfa-Dieckmann 
condensation resulted in low yields.  It was hypothesized that the low yield resulted from the 
solubility of sultam 3.33.2 in the aqueous layer during work up.  An initial workup procedure 
was performed by quenching the reaction with NaHCO3 and extracting with EtOAc.  In order 
to improve the yields of this reaction, we modified the workup procedure by using 10 % HCl 




















3.4.D 3.4.E 3.4.F 3.4.G
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of 3.33.5 (Scheme 3.33).  Unfortunately, neither the original, nor the modified procedures, 
were successful in synthesizing thiomorpholine derivative 3.33.8.  
Scheme 3.33. Sulfa-Dieckmann condensation involving cyclic amino esters. 
 
 
3.4 Isocyanate Addition for 3-Carboxamide Substituted Tetramic Acid Analogs 
 
There has been an increasing interest in making 3-carboxamide tetramic acids in the 
recent years.  These structures have been identified as suitable templates for new small 
molecule inhibitors to overcome undesirable physiochemical properties of known active 
compounds (Figure 3.5).45  Moreover, high-throughput screening and docking studies have 
shown 3-carboxamide tetramic acids to be fruitful targets in chemical biology.46  Unlike 
other known tetramic acids, the exocyclic NH is forming an intramolecular H-bond to 
stabilize the conformation of the molecule.  In this regard, a brief summary of recent 
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Figure 3.5. Known bioactive 3-carboxamide substituted tetramic acids. 
 
In 2002, Folkes and coworkers reported the synthesis of amido-substituted tetramic 
acid derivatives.45 By reacting the substituted amino ester 3.34.1 with methyl malonyl 
chloride 3.34.2, the precursor 3.34.3 to Dieckmann cyclization was afforded (Scheme 3.34). 
The precursor 3.34.3 was then exposed to NaOMe in MeOH for Dieckmann cyclization to 
yield 3-methoxycarbonyl tetramic acids 3.34.4. Reaction with amines in refluxing xylene 
yielded the corresponding 3-carboxamide tetramic acids 3.34.5.  
Scheme 3.34. Synthesis of amido-substituted tetramic acid derivatives. 
 
Moloney and coworkers reported a slightly different route towards 3-carboxamide 
tetramic acids in 2013.47  Starting from N-alkyl-glycine methyl ester 3.35.1, monoethyl 
malonate 3.35.2 was attached using DCC coupling reaction (Fig 3.35a).  The resulting N-
alkyl-N-malonyl glycine methyl ester 3.35.3 was subject to Dieckmann cyclization using 
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to the previous work, the ethyl ester 3.35.4 was then substituted with amines in refluxing 
toluene to afford the desired 3-carboxamide tetramic acids 3.35.5.  Another route involved 
the attachment of the ester portion post cyclization with butyl chloroformate 3.35.7 to 
tetramic acid 3.35.6 (Fig 3.35b).  Then, the resulting ester 3.35.8 was transformed to its 
corresponding amide 3.35.9 by refluxing amine in toluene.  Alternatively, a direct attachment 
of the amide moiety was achieved by reaction of the tetramic acid 3.35.6 derivative with 
phenyl isocyanate in the presence of DMAP to yield 3-carboxamide tetramic acid 3.35.10.  
This opened up an area where the amide moiety could be inserted at a late-stage modification 
allowing for more diverse peripheral diversity.  This method was extended to produce a 
library of natural product inspired polysubstituted tetramic acids.48 
Scheme 3.35. New synthetic route towards 3-carboxamide substituted tetramic acids. 
 
However, there are very limited reports regarding sultam analogs of tetramic acids. 
To the best of our knowledge, sultam analogs of 3-carboxamide tetramic acids have not been 





































































 Towards the aforementioned goal of accessing sultam analogs of 3-carboxamide 
tetramic acids, the synthesis plan involves generation of carbanion by deprotonating the most 
enolizable proton that is in the alpha position of both sulfonamide and ketone moieties 
(Scheme 3.36).  Subsequent addition of phenyl-substituted isocyanates results in formation of 
the desired carboxamide functionality at the 3-position of sultam 3.36.2.  This method was 
then applied to a variety of sultams generated from the previous section, including the 
bicyclic sultams 3.36.3. The results are summarized in Scheme 3.36 below. 
Scheme 3.36. Isocyanate addition to form 3-carboxamide variants. 
 
 One notable aspect of the resulting 3-carboxamide substituted tetramic acid analogs is 
that the compounds are partially water-soluble.  Due to this solubility, it was not feasible to 
perform aqueous work up to remove excess Et3N and the resulting salt byproducts generated 














































O R = H        3.36.5  43 %
    = OMe  3.36.6  62 %
    = F        3.36.7  48 %

























R = H        3.36.9    51 %
    = OMe  3.36.10  53 %
    = F        3.36.11  48 %
    = Me     3.36.12  30 %
R = H        3.36.13  70 %
    = OMe  3.36.14  59 %
    = F        3.36.15  69 %
    = Me     3.36.16  28 %
R = H        3.36.17  37 %
    = OMe  3.36.18  30 %
    = F        3.36.19  35 %
    = Me     3.36.20  27 %
R = H        3.36.21  99 %
    = OMe  3.36.22  53 %
    = F        3.36.23  23 %
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preparative/mass-directed HPLC purification in order to utilize reverse phase 
chromatography conditions. 
3.5 Structural features and X-ray Crystallography Results 
 X-ray crystallographic analysis of 3-carboxamide substituted sultam 3.36.18 
substantiated its formation (Figure 3.6).  To our surprise, the crystal structure revealed that 
the compound existed in a salt form with triethylammonium ion, after going through 
preparative/mass-directed LCMS purification.  Notably, unusually short hydrogen bonding 
interactions between the –OH functionalities between two molecules was observed at bond 
lengths of 2.414 and 2.424 Å.  Common hydrogen bonding lengths between O–O are 
reported at around 2.8 Å, and when the distance decreased to roughly 2.5 Å it is considered a 
low-barrier hydrogen bond (LBHB), albeit being a controversial concept.49,50  Potentially, 
this existence of LBHB may play a role in the partial solubility in water.  
Figure 3.6. X-ray crystal structure of 3.36.18 suggesting presence of LBHB. 
 
Principle moments of inertia (PMI) analysis was conducted for the compounds 
generated from this project for assessment of molecular diversity, as shown in Chapter 1.51 
Bond Length: 2.414 Å












As mentioned earlier, PMI analysis is based on analyzing shape-based descriptors: the 
minimum energy conformation of each compound is resolved, the corresponding PMI ratios 
are calculated and normalized, and the resulting data is represented by a triangular plot 
depicting the molecular shape diversity (Figure 3.7).  The results were plotted against a set of 
FDA approved drug molecules shown in black dots, and also set of NCI’s NeXT screening 
collection shown in purple dots.  Monocyclic and bicyclic tetramic acid analogs are 
represented in blue spheres, and 3-carboxamide tetramic acid analogs are in red spheres.  The 
results show that the core monocyclic and bicyclic scaffolds (blue spheres) occupy the region 
that is slightly closer to the sphere-like area.  As expected, the scaffolds containing 
carboxamide substituents at the 3-position (red spheres) result in the area that is relatively 
close to rod-like shape region.  Interestingly, the region that 3-carboxamide substituted 
scaffolds occupy overlaps more with the reported bioactive compounds.  




 In conclusion, we have successfully developed a route towards the synthesis of 
sultam analogs of tetramic acids.  This method was further extended for the production of 
bicyclic scaffolds, allowing for occupation of novel chemical space and search for novel 
biological activities.  Scaffolds generated from this methodology were then further 
functionalized by addition of isocyanates to generate 3-carboxamide substituted tetramic acid 
analogs, which are novel compounds that have been gaining attention due to their unique and 
attenuated biological activities.  Compounds generated through these efforts will provide 
opportunities in searching for novel biological activities, and future efforts will focus on 
studying chemical reactivity profiles of these entities and submission to biological screening. 
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Chapter 4:  
Supporting Information 




4.1: Experimental for Chapter 1 
All air and moisture sensitive reactions were carried out in flame- or oven-dried 
glassware under argon atmosphere using standard gas tight syringes, cannulae, and septa.  
Stirring was achieved with oven-dried, magnetic stir bars. The solvents Et2O, THF and 
CH2Cl2 were purified by passage through the Solv-Tek purification system employing 
activated Al2O3 (Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, 
F. J. Organometallics 1996, 15, 1518–1520).  Et3N was purified by passage over basic 
alumina and stored over KOH.  Flash column chromatography was performed with SiO2 
from Sorbent Technology (30930M-25, Silica Gel 60A, 40-63 um).  Thin layer 
chromatography was performed on silica gel 60F254 plates (EM-5717, Merck).  Deuterated 
solvents were purchased from Cambridge Isotope laboratories.  1H and 13C NMR spectra 
were recorded on a Bruker Avance operating at 500 MHz and 126 MHz respectively.  High-
resolution mass spectrometry (HRMS) and FAB spectra were obtained in one of two 
manners: (i) on a VG Instrument ZAB double-focusing mass spectrometer and (ii) on a LCT 
Premier Spectrometer (Micromass UK Limited) operating on ESI (MeOH). All library 
syntheses were carried out in 1 dram vials utilizing Anton Parr ® Synthon 3000 microwave 
platform with parallel evaporations were performed using a GeneVac EZ-2 plus evaporator. 
Automated preparative reverse-phase HPLC purification was performed using an Waters 
Mass-Directed Fractionation system (Prep Pump 2525, Make-up pump 515, Sample 
Manager 2767, UV-DAD detection 2996, Micromass ZD quadrapole spectrometer) and a 
Waters X-Bridge C18 column (19 x 150mm, 5um, w/ 19 x 10mm guard column).  Samples 
were diluted in DMSO and purified utilized an elution of water (modified to pH 9.8 through 
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addition of NH4OH) and CH3CN, with a gradient increasing to 20% in CH3CN over 4 
minutes at a flow rate of 20ml/min.  The preparative gradient, triggering thresholds, and UV 
wavelength were selected based on the HPLC analysis of each crude sample.  Analytical 
analysis of each sample after purification employed a Waters Acquity system with UV and 
mass detection (Waters LCT Premier).  The analytical method utilized a Waters Aquity 
BEH C18 column (2.1 x 50mm, 1.7um) eluting with a linear gradient of 5% water (modified 
to pH 9.8 through addition of NH4OH) to 100% CH3CN at 0.6 mL/min flow rate were purity 
was determined using UV peak area at 214 nm. 
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4.1.1 Library Production of RCM-Derived Scaffold via Click-aza-Michael 
2,3-Dihydroisothiazole 1,1-dioxide (1.8.3). 
 
Into a r.b flask was added allyl amine (6.57 mL, 87.6 mmol, 1.1 equiv.), dry DCM (160 mL, 
0.5 M), and Et3N (36.6 mL, 262.2 mmol, 3 equiv.).  The stirring solution was cooled to 0 ºC 
to which was added dropwise 2-chloroethanesulfonyl chloride (8.32 ml, 79.6 mmol, 1 
equiv.).  After addition, the reaction was warmed to rt and stirred for an additional 4 hrs.  
Upon completion, the reaction was quenched with 10% HCl aq. (60 ml), the organic layer 
extracted and washed with 10% HCl aq. (60 ml), H2O (60 ml) and brine (60 ml).  The 
combined organic was dried over MgSO4, filtered and concentrated. 
To the crude material, N-allylethenesulfonamide (11.5 g, yellow oil) in a r.b flask was added 
Ar degassed dry DCM (0.07M, 111 ml), and the reaction was heated at 45 ºC.  Over the 
required 3 hr reaction period at 45 ºC, G-II [(IMesH2)(PCy3)(Cl)2Ru]CHPh] (2.5 mol%) 
was added in 5 equal portions every 30 mins, essential for complete conversion of the 
starting material to product.  After such time, the reaction was concentrated and purified by 
flash chromatography to yield the desired product as a brown oil (8.35 g, 70 mmol, 88% 
over 2 steps). 
FTIR (neat): 3552, 3274, 1386, 1274, 1151, 1103 cm-1; 
1H NMR (500 MHz, CDCl3) δ 6.89 (dt, J = 6.5, 2.3 Hz, 1H), 6.71 (dt, J = 6.5, 2.3 Hz, 1H), 
5.23 (br s, 1H), 4.10 (dt, J = 4.4, 2.3 Hz, 2H); 





HRMS calculated for C3H6NO2S (M+H)+ 120.0119; found 120.0121 (TOF MS ES+). 
 
2-(Prop-2-yn-1-yl)-2,3-dihydroisothiazole 1,1-dioxide (1.8.4). 
 
Into a 500 ml rb flask under Ar, was added 2,3-dihydroisothiazole 1,1-dioxide 1.8.3 (4.05g, 
33.9 mmol, 1 equiv), dry CH3CN (170 mL, 0.2 M) and K2CO3 (9.36 g, 67.8 mmol, 2 equiv).  
To the stirring slurry was added propargyl bromide ([80% in tol.], 7.58g, 50.9 mmol, 1.5 
equiv), after which the reaction was heated at 60 ºC for 5 hrs [TLC monitoring (7:3 
EtOAc:hexane, Rf 1.8.4 = 0.5, Rf 1.8.3 = 0.3].  After such time the reaction was cooled to rt, 
filtered through a SiO2 SPE, washed with EtOAC (200 ml) and concentrated.  The resulting 
crude liquid was diluted in toluene (200 ml), concentrated and dried under vacuum to yield 
the desired product 1.8.4 (5.06 g, 32.2 mmol, 95%) as yellow oil. 
FTIR (neat): 3274, 1386, 1274, 1141, 1103 cm-1; 
1H NMR (500 MHz, CDCl3) δ 6.91 (dt, J = 7.0, 2.4 Hz, 1H), 6.72–6.65 (m, 1H), 4.15–4.10 
(m, 2H), 3.99 (d, J = 2.2 Hz, 2H), 2.35 (t, J = 2.5 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ 135.6, 127.1, 74.1, 51.4, 33.8; 






General procedure A for the synthesis of Library A via a one-pot Click/aza-Michael 
protocol. 
To a 1-dram vial containing 2-(prop-2-yn-1-yl)-2,3-dihydroisothiazole 1,1-dioxide 1.8.4 (50 
mg, 0.318 mmol, 1 equiv.) was added CuI (18.2 mg, 30 mol%), DBU (5 µL, 10 mol%), dry 
EtOH (0.64 ml, 0.5 M), amine (0.38 mmol, 1.2 equiv.) and azide (0.636 mmol, 2 equiv.).  
The reaction was heated at 60 ºC on a reaction block for for 12 hrs, after which time the 
reactions were cooled, filtered through SiO2 SPE into pre-weighed barcoded vials, washed 
with eluent (2 ml, EtOAc:MeOH 95:5) and concentrated.  The crude reaction was 
concentrated and QC/purified by an automated preparative reverse phase HPLC (detected by 
mass spectroscopy). 
 
General procedure B for the synthesis of Library B via two-step Click, aza-Michael 
with amines 12 – 15 and azides A – L. 
To a 1-dram vial containing 2-(prop-2-yn-1-yl)-2,3-dihydroisothiazole 1,1-dioxide 1.8.4 (50 
mg, 0.318 mmol, 1 equiv) was added CuI (18.2 mg, 30 mol%), DBU (5 µL, 10 mol%), dry 
EtOH (0.64 ml, 0.5 M), and azide (0.636 mmol, 2 equiv).  The reaction was heated at 60 ºC 
on a reaction block for for 4 hrs, after which time the reactions were cooled, filtered through 
SiO2, washed with eluent (2 mL, EtOAc) and concentrated.  The crude was transferred to a 
1-dram vial, where DBU (5 µL, 10 mol%), dry EtOH (0.64 ml, 0.5M), amine (0.38 mmol, 
1.2 equiv.) was added. The reaction was subsequently heated at at 60 ºC on a reaction block 
for for 10 hrs, after which time the reactions were cooled, filtered through SiO2 SPE and 
concentrated into pre-weighed barcoded vials, washed with eluent (2 ml, EtOAc:MeOH 
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95:5) and concentrated.  The crude reaction was concentrated and QC/purified by an 
automated preparative reverse phase HPLC (detected by mass spectroscopy). 
 
2-((1-(2-Chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-4-(4-(2-fluorobenzyl)piperazin-1-
yl)isothiazolidine 1,1-dioxide 1{M}. 
 
FTIR (neat): 2944, 1492, 1305, 1138 cm-1; 
1H NMR (DMSO-d6, 500 MHz) δ 8.15 (s, 1H), 7.42 (m, 2H), 7.37 (dt, J = 7.5, 1.5 Hz, 1H), 
7.30 (m, 3H), 7.17 (m, 2H), 5.60 (s, 2H), 4.19 (d, J = 15.0 Hz, 1H), 4.15 (d, J = 15.0 Hz, 
1H), 3.49 (s, 2H), 3.43 (m, 2H), 3.30 (m, 1H), 3.17 (m, 1H), 2.98 (m, 1H), 2.37 (br s, 8H); 
13C NMR (DMSO-d6, 125 MHz) δ 160.8 (d, JCF = 242.5 Hz), 142.1, 135.1, 132.8, 131.6 (d, 
JCF = 5.0 Hz), 129.1 (d, JCF = 8.8 Hz), 128.8, 124.4, 124.3, 124.1 (d, JCF = 3.8 Hz), 115.2 (d, 
JCF = 22.5 Hz), 56.4, 54.4, 52.2, 52.0, 49.3, 49.0, 47.8, 38.7; 
HRMS calculated for C24H29ClFN6O2S (M+H)+ 519.1746; found 519.1739 (TOF MS ES+). 
 
2-((1-Benzyl-1H-1,2,3-triazol-4-yl)methyl)-4-(4-(3-methylbenzyl)piperazin-1-
yl)isothiazolidine 1,1-dioxide 2{A}. 
 

















1H NMR (DMSO-d6, 500 MHz) δ 8.14 (s, 1H), 7.37–7.27 (m, 5H), 7.19 (t, J = 7.5 Hz, 1H), 
7.08 (s, 1H), 7.05 (d, J = 7.5 Hz, 2H), 5.59 (s, 2H), 4.17 (s, 2H), 3.44 (m, 2H), 3.38 (s, 2H), 
3.31 (m, 1H), 3.17 (m, 1H), 2.99 (m, 1H), 2.36–2.30 (m, 8 H), 2.28 (s, 3H); 
13C NMR (DMSO-d6, 125 MHz) δ 142.0, 138.0, 137.2, 136.1, 129.4, 128.7, 128.1, 128.0, 
127.8, 127.6, 125.9, 124.3, 62.0, 56.4, 52.8, 52.4, 49.3, 49.0, 47.7, 38.7; 




isothiazolidine 1,1-dioxide 2{K}. 
 
FTIR (neat): 2955, 2826, 1299, 1141 cm-1; 
1H NMR (DMSO-d6, 500 MHz) δ 8.07 (s, 1H), 7.18 (t, J = 7.5 Hz, 1H), 7.07 (s, 1H), 7.04 
(d, J = 7.5 Hz, 2H), 4.38 (t, J = 6.5 Hz, 2H), 4.18 (d, J = 15.0 Hz, 1H), 4.14 (d, J = 15.0 Hz, 
1H), 3.45 (m, 2H), 3.38 (s, 2H), 3.32 (m, 1H), 3.27 (t, J = 6.5 Hz, 2H), 3.21 (s, 3H), 3.16 
(m, 1H), 2.98 (m, 1H), 2.38–2.30 (m, 8H), 2.28 (s, 3H), 2.02 (p, J = 6.5 Hz, 2H); 
13C NMR (DMSO-d6, 125 MHz) δ 141.6, 138.0, 137.2, 129.4, 128.0, 127.6, 125.9, 124.2, 
68.4, 62.0, 58.0, 56.5, 52.4, 49.3, 49.1, 47.8, 46.7, 38.7, 29.8, 21.0; 












yl)methyl)-1H-1, 2, 3-triazol-1-yl)butanoate 2{L}. 
 
FTIR (neat): 2953, 1729, 1299, 1140 cm-1; 
1H NMR (DMSO-d6, 500 MHz) δ 8.09 (s, 1H), 7.18 (t, J = 7.5 Hz, 1H), 7.08 (s, 1H), 7.04 
(d, J = 7.5 Hz, 2H), 4.37 (t, J = 7.0 Hz, 2H), 4.18 (d, J = 14.5 Hz, 1H), 4.14 (d, J = 14.5 Hz, 
1H), 3.57 (s, 3H), 3.45 (m, 2H), 3.38 (s, 2H), 3.31 (m, 1H), 3.18 (m, 1H), 2.98 (m, 1H), 
2.39–2.29 (m, 10 H), 2.27 (s, 3H), 2.05 (p, J = 7.0 Hz, 2H); 
13C NMR (DMSO-d6, 125 MHz) δ 172.5, 141.7, 138.0, 137.2, 129.4, 127.6, 125.9, 124.2, 
62.0, 56.5, 52.4, 51.4, 49.3, 49.1, 48.6, 47.8, 38.7, 30.8, 25.1, 21.0; 
HRMS calculated for C23H35N6O4S (M+H)+ 491.2441; found 491.2389 (TOF MS ES+). 
 
2-((1-(3,5-Dimethylbenzyl)-1H-1, 2, 3-triazol-4-yl)methyl)-4-
thiomorpholinoisothiazolidine 1,1-dioxide 3{F}. 
 
FTIR (neat): 2913, 1302, 1138, 1045 cm-1; 
1H NMR (DMSO-d6, 500 MHz) 8.11 (s, 1H), 6.96 (s, 1H), 6.90 (s, 2H), 5.49 (s, 2H), 4.18 























1H), 3.21 (dd, J = 13.5, 7.5 Hz, 1H), 3.02 (dd, J = 10.0, 7.5 Hz, 1H), 2.65 (m, 4H), 2.55 (m, 
4H), 2.24 (s, 6H); 
13C NMR (DMSO-d6, 125 MHz) δ 141.9, 137.8, 135.8, 129.5, 125.3, 124.2, 57.2, 52.8, 
51.1, 48.6, 46.7, 38.5, 27.1, 20.8; 





FTIR (neat): 2912, 2821, 1434, 1301, 1044 cm-1; 
1H NMR (DMSO-d6, 500 MHz) 8.19 (s, 1H), 7.40 (m, 3H), 7.25 (m, 1H), 5.62 (s, 2H), 
4.17 (s, 2H), 3.59 (p, J = 7.5 Hz, 1H), 3.44 (dd, J = 13.0, 8.0 Hz, 1H), 3.30 (dd, 10.0, 7.5 
Hz, 1H), 3.22 (dd, J = 13.0, 8.0 Hz, 1H), 3.02 (dd, J = 10.0, 7.5 Hz, 1H), 2.65 (m, 4H), 2.54 
(m, 4H); 
13C NMR (DMSO-d6, 125 MHz) δ 142.1, 138.4, 133.3, 130.7, 128.1, 127.8, 126.6, 124.5, 
57.2, 52.0, 51.1, 48.7, 46.7, 38.5, 27.2; 















FTIR (neat): 2928, 1456, 1303, 1140, 1048 cm-1; 
1H NMR (DMSO-d6, 500 MHz) δ 8.09 (s, 1H), 4.33 (t, J = 7.0 Hz, 2H), 4.15 (s, 2H), 3.60 
(pent., J = 7.5 Hz, 1H), 3.45 (dd, J =13.0, 8.5 Hz, 1H), 3.28 (dd, J = 10.0, 8.5 Hz, 1H), 3.22 
(dd, J =13.0, 7.0 Hz, 1H), 3.01 (dd, J =10.0, 7.0 Hz, 1H), 2.66 (m, 4H), 2.56 (m, 4H), 1.79 
(pent., J = 7.0 Hz, 2H), 1.27–1.17 (m, 6H), 0.83 (m, 3H); 
13C NMR (DMSO-d6, 125 MHz) δ 141.5, 124.0, 57.2, 51.1, 49.4, 48.7, 46.8, 38.6, 30.6, 
29.6, 27.2, 25.5, 21.9, 13.9; 

























1H NMR (DMSO-d6, 500 MHz) δ 8.08 (s, 1H), 4.39 (t, J = 7.0 Hz, 2H), 4.15 (s, 2H), 3.60 
(pent., J = 7.0 Hz, 1H), 3.45 (dd, J =13.0, 8.0 Hz, 1H), 3.31–3.27 (m, 3H), 3.23 (dd, J =13.0, 
8.0 Hz, 1H), 3.22 (s, 3H), 3.02 (dd, J =10.0, 7.0 Hz, 1H), 2.67 (m, 4H), 2.56 (m, 4H), 2.03 
(pent., J = 7.0 Hz, 2H); 
13C NMR (DMSO-d6, 125 MHz) δ 141.5, 124.2, 68.5, 58.0, 57.2, 51.1, 48.7, 46.8, 46.7, 
38.6, 29.8, 27.2; 





FTIR (neat): 2914, 1305, 1132, 1045 cm-1; 
1H NMR (500 MHz, MeOD) δ 8.00 (s, 1H), 7.39–7.34 (m, 2H), 7.31 (d, J = 8.4 Hz, 2H), 
5.58 (s, 2H), 4.29 (q, J = 15.2 Hz, 2H), 3.50 (dd, J = 12.8, 7.9 Hz, 1H), 3.44 (dd, J = 9.2, 7.1 
Hz, 1H), 3.41–3.33 (m, 1H), 3.14 (dd, J = 12.8, 7.8 Hz, 1H), 3.08 (dd, J = 9.2, 7.4 Hz, 1H), 
2.50 (dd, J = 11.8, 5.2 Hz, 4H), 1.82–1.72 (m, 4H); 
13C NMR (126 MHz, MeOD) δ 135.6, 135.5, 130.8, 130.1, 125.7, 57.6, 54.1, 52.4, 52.3, 
51.8, 39.9, 24.1; 














FTIR (neat): 2910, 1300, 1136, 1047 cm-1; 
1H NMR (500 MHz, MeOD) δ 7.94 (s, 1H), 7.21 (d, J = 8.1 Hz, 2H), 7.17 (d, J = 8.2 Hz, 
2H), 5.52 (s, 2H), 4.28 (q, J = 15.1, 2H), 3.49 (dd, J = 12.8, 7.9 Hz 1H), 3.42 (dd, J = 9.2, 
7.0 Hz, 1H), 3.40–3.33 (m, 1H), 3.13 (dd, J = 12.8, 7.8 Hz, 1H), 3.07 (dd, J = 9.3, 7.3 Hz, 
1H), 2.51 (td, J = 9.1, 2.5 Hz, 4H), 2.31 (s, 3H), 1.83–1.71 (m, 4H); 
13C NMR (126 MHz, MeOD) δ 139.3, 133.4, 130.3, 128.8, 125.1, 57.2, 54.4, 51.9, 51.9, 
51.4, 39.6, 23.7, 20.8; 























1H NMR (500 MHz, MeOD) δ 8.03 (s, 1H), 7.42–7.36 (m, 2H), 7.36–7.27 (m, 2H), 5.61 (d, 
J = 15.4 Hz, 2H), 4.34–4.26 (m, 2H), 3.51–3.36 (m, 3H), 3.23–3.15 (m, 1H), 3.09 (dd, J = 
9.5, 6.7 Hz, 1H), 2.40 (s, 4H), 1.60–1.51 (m, 4H), 1.45 (dd, J = 11.2, 5.6 Hz, 2H); 
13C NMR (126 MHz, MeOD) δ δ 135.6, 135.5, 130.8, 130.1, 58.8, 54.2, 52.0, 50.7, 39.7, 
26.6, 25.1; 
HRMS calculated for C18H25ClN5O2S (M+H)+ 410.1418; found 410.1438 (TOF MS ES+). 
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Comp. HRMS Expected M/z (M)+ 
HRMS Found 
M/z (M+H)+ Mass (mg) Purity (%) 
1{A} 484.2056 485.2153 48.1 mg 97.1 % 
1{B} 518.1667 519.1739 44.2 mg 99.8 % 
1{C} 502.1962 503.2058 42.8 mg 97.5 % 
1{D} 498.2213 499.2291 38.3 mg 99.3 % 
1{E} 514.2162 515.2245 58.6 mg 95.2 % 
1{F} 512.2369 513.2458 29.3 mg 98.3 % 
1{G} 552.1930 553.2005 38.3 mg 97.4 % 
1{H} 552.1930 553.2022 41.3 mg 99.1 % 
1{I} 518.1667 519.1757 31.8 mg 99.2 % 
1{J} 478.2526 479.2626 29.1 mg 98.9 % 
1{K} 466.2162 467.2246 32.6 mg 99.6 % 
1{L} 494.2111 495.2186 28.5 mg 99.1 % 
2{A} 480.2307 481.2389 29.3 mg 99.7 % 
2{B} 514.1917 515.1992 35.8 mg 98.6 % 
2{C} 498.2213 499.2295 44.8 mg 99.1 % 
2{D} 494.2463 495.2545 44.7 mg 98.5 % 
2{E} 510.2413 511.2496 17.7 mg 60.6 % 
2{F} 508.2620 509.2706 43.0 mg 98.9 % 
2{G} 548.2181 549.2261 32.2 mg 98.5 % 
2{H} 548.2181 549.2242 37.3 mg 98.0 % 
2{I} 514.1917 515.2001 25.4 mg 99.8 % 
2{J} 474.2776 475.2872 30.7 mg 99.3 % 
2{K} 462.2413 463.2486 25.7 mg 100.0 % 
2{L} 490.2362 491.2389 29.3 mg 99.7 % 
3{A} 393.1293 394.1394 12.9 mg 89.8 % 
3{B} 427.0903 428.0991 16.8 mg 98.0 % 
3{C} 411.1198 412.1292 16.2 mg 89.9 % 
3{D} 407.1449 408.1539 16.5 mg 98.0 % 
3{E} 423.1398 424.1484 14.0 mg 93.1 % 
3{F} 421.1606 422.1705 20.9 mg 96.0 % 
3{G} 461.1167 462.1259 24.1 mg 98.5 % 
3{H} 461.1167 462.1251 22.0 mg 96.8 % 
3{I} 427.0903 428.0991 25.8 mg 98.8 % 
3{J} 387.1762 388.1851 15.0 mg 97.1 % 
3{K} 375.1398 376.1493 16.2 mg 97.5 % 
3{L} 403.1347 404.1437 8.1 mg 84.5 % 
4{A} 460.2620 461.2720 10.6 mg 94.4 % 
4{B} 494.2230 495.2325 10.8 mg 98.9 % 
4{C} 478.2526 479.2604 9.2 mg 94.8 % 
4{D} 474.2776 475.2846 20.5 mg 98.2 % 
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4{E} 490.2726 491.2820 12.8 mg 81.7 % 
4{F} 488.2933 489.3016 15.1 mg 92.6 % 
4{G} 528.2494 529.2567 16.1 mg 88.9 % 
4{H} 528.2494 529.2580 14.3 mg 90.1 % 
4{I} 494.2230 495.2308 10.6 mg 97.4 % 
4{J} 454.3089 455.3181 9.9 mg 97.2 % 
4{K} 442.2726 443.2823 9.0 mg 87.5 % 
4{L} 470.2675 471.2753 6.0 mg 92.3 % 
5{A} 359.1415 360.1506 40.0mg 92.7 % 
5{B} 393.1026 394.1125 39.5mg 93.1 % 
5{C} 377.1321 378.1426 21.9mg 90.6 % 
5{D} 373.1572 374.1666 36.6mg 89.6 % 
5{E} 389.1521 390.1592 35.9mg 95.4 % 
5{F} 387.1728 388.1819 19.9mg 85.6 % 
5{G} 427.1289 428.1374 34.9mg 86.0 % 
5{H} 427.1289 428.1368 42.1mg 95.5 % 
5{I} 393.1026 394.1121 38.4mg 94.1 % 
5{J} 353.1885 354.1969 22.8mg 87.7 % 
5{K} 341.1521 342.1595 23.7mg 87.1 % 
5{L} 369.1470 370.1554 35.2mg 92.8 % 
6{A} 361.1572 362.1671 57.3 mg 97.7 % 
6{B} 395.1182 396.1288 69.3 mg 98.3 % 
6{C} 379.1478 380.1569 51.0 mg 97.9 % 
6{D} 375.1728 376.1825 48.7 mg 98.4 % 
6{E} 391.1678 392.1744 60.5 mg 98.2 % 
6{F} 389.1885 390.1976 77.1 mg 98.0 % 
6{G} 429.1446 430.1522 69.2 mg 98.4% 
6{H} 429.1446 430.1544 67.9 mg 97.9 % 
6{I} 395.1182 396.1271 60.8 mg 98.0 % 
6{J} 355.2041 356.2140 52.4 mg 96.9 % 
6{K} 343.1678 344.1757 59.2 mg 98.4 % 
6{L} 371.1627 372.1714 53.4 mg 96.8 % 
7{A} 375.1728 376.1805 57.7 mg 98.4 % 
7{B} 409.1339 410.1438 61.8 mg 98.0 % 
7{C} 393.1634 394.1719 61.2 mg 97.9 % 
7{D} 389.1885 390.1964 46.9 mg 99.1 % 
7{E} 405.1834 406.1928 51.2 mg 98.1 % 
7{F} 403.2041 404.2126 55.1 mg 96.6 % 
7{G} 443.1602 444.1696 66.9 mg 96.9 % 
7{H} 443.1602 444.1691 67.0 mg 98.4 % 
7{I} 409.1339 410.1407 59.7 mg 98.3 % 
7{J} 369.2198 370.2278 33.6 mg 97.0 % 
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7{K} 357.1834 358.1918 49.1 mg 97.1 % 
7{L} 385.1783 386.1882 39.4 mg 97.1 % 
8{A} 335.1415 336.1514 34.9 mg 99.6 % 
8{B} 369.1026 370.1110 41.9 mg 100.0 % 
8{C} 353.1321 354.1402 35.9 mg 99.7 % 
8{D} 349.1572 350.1653 30.9 mg 100.0 % 
8{E} 365.1521 366.1608 38.0 mg 100.0 % 
8{F} 363.1728 364.1826 49.3 mg 99.8 % 
8{G} 403.1289 404.1367 45.7 mg 100.0 % 
8{H} 403.1289 404.1371 55.7 mg 100.0 % 
8{I} 369.1026 370.1119 43.9 mg 100.0 % 
8{J} 329.1885 330.1975 46.9 mg 99.5 % 
8{K} 317.1521 318.1617 13.0 mg 91.6 % 
8{L} 345.1470 346.1571 26.5 mg 98.9 % 
9{A} 349.1572 350.1661 31.4 mg 99.8 % 
9{B} 383.1182 384.1274 28.8 mg 100.0 % 
9{C} 367.1478 368.1559 32.5 mg 100.0 % 
9{D} 363.1728 364.1822 36.4 mg 100.0 % 
9{E} 379.1678 380.1761 27.8 mg 100.0 % 
9{F} 377.1885 378.1973 33.9 mg 98.9 % 
9{G} 417.1446 418.1529 34.0 mg 99.2 % 
9{H} 417.1446 418.1536 37.8 mg 99.4 % 
9{I} 383.1182 384.1261 38.3 mg 99.8 % 
9{J} 343.2041 344.2115 30.9 mg 98.2 % 
9{K} 331.1678 332.1770 28.3 mg 97.8 % 
9{L} 359.1627 360.1713 22.8 mg 98.3 % 
10{A} 363.1728 364.1814 30.8 mg 99.8 % 
10{B} 397.1339 398.1418 30.5 mg 99.7 % 
10{C} 381.1634 382.1718 30.9 mg 100.0 % 
10{D} 377.1885 378.1976 31.8 mg 96.9 % 
10{E} 393.1834 394.1907 30.6 mg 100.0 % 
10{F} 391.2041 392.2122 29.8 mg 99.2 % 
10{G} 431.1602 432.1678 28.0 mg 100.0 % 
10{H} 431.1602 432.1700 38.1 mg 100.0 % 
10{I} 397.1339 398.1406 31.4 mg 98.4 % 
10{J} 357.2198 358.2291 22.5 mg 99.3 % 
10{K} 345.1834 346.1910 27.3 mg 100.0 % 
10{L} 373.1783 374.1858 15.4 mg 99.0 % 
11{A} 492.2055 493.2166 23.5 mg 99.6 % 
11{B} 560.1276 561.1351 30.1 mg 98.5 % 
11{C} 528.1867 529.1973 29.1 mg 98.3 % 
11{D} 520.2368 521.2452 26.9 mg 97.0 % 
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11{E} 552.2267 553.2336 24.8 mg 99.0 % 
11{F} 548.2681 549.2745 20.7 mg 88.0 % 
11{G} 628.1803 629.1876 29.5 mg 96.4 % 
11{H} 628.1803 629.1880 32.0 mg 94.9 % 
11{I} 560.1276 561.1326 20.7 mg 94.5 % 
11{J} 480.2994 481.3079 18.3 mg 94.5 % 
11{K} 456.2267 457.2344 15.3 mg 99.1 % 
11{L} 512.2165 513.2237 19.4 mg 97.5 % 
12{A} 390.1837 391.1910 17.8 mg 99.3 % 
12{B} 424.1448 425.1529 12.4 mg 97.5 % 
12{C} 408.1743 409.1832 22.5 mg 99.0 % 
12{D} 404.1994 405.2089 37.4 mg 98.9 % 
12{E} 420.1943 421.2021 30.6 mg 99.8 % 
12{F} 418.2150 419.2209 12.9 mg 93.4 % 
12{G} 458.1711 459.1787 63.2 mg 99.6 % 
12{H} 458.1711 459.1795 30.2 mg 97.6 % 
12{I} 424.1448 425.1544 18.1 mg 97.7 % 
12{J} 384.2307 385.2394 52.9 mg 97.6 % 
12{K} 372.1943 373.2020 49.9 mg 97.3 % 
12{L} 400.1892 401.1975 20.9 mg 97.0 % 
13{A} 447.2416 448.2503 15.0 mg 94.8 % 
13{B} 481.2026 482.2089 12.6 mg 95.6 % 
13{C} 465.2322 466.2395 45.1 mg 98.0 % 
13{D} 461.2572 462.2646 17.2 mg 98.0 % 
13{E} 477.2522 478.2593 35.9 mg 96.3 % 
13{F} 475.2729 476.2809 13.4 mg 91.2 % 
13{G} 515.2290 516.2383 62.2 mg 98.7 % 
13{H} 515.2290 516.2368 31.0 mg 94.4 % 
13{I} 481.2026 482.2080 21.8 mg 96.4 % 
13{J} 441.2885 442.2977 28.9 mg 94.2 % 
13{K} 429.2522 430.2625 21.8 mg 95.5 % 
13{L} 457.2471 458.2586 28.7 mg 92.4 % 
14{A} 473.2572 NA NA NA 
14{B} 507.2183 508.2254 6.6 mg 95.9 % 
14{C} 491.2478 492.2542 17.7 mg 99.4 % 
14{D} 487.2729 488.2804 19.9 mg 98.6 % 
14{E} 503.2678 504.2772 17.0 mg 97.0 % 
14{F} 501.2885 502.2981 1.7 mg 92.0 % 
14{G} 541.2446 542.2553 83.6 mg 98.7 % 
14{H} 541.2446 542.2510 18.3 mg 98.7 % 
14{I} 507.2183 508.2267 24.0 mg 94.7 % 
14{J} 467.3042 468.3139 79.2 mg 97.9 % 
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14{K} 455.2678 456.2773 30.0 mg 92.3 % 
14{L} 483.2627 484.2695 17.1 mg 98.4 % 
15{A} 420.1943 421.2033 17.5 mg 95.4 % 
15{B} 454.1553 455.1652 13.5 mg 96.5 % 
15{C} 438.1849 439.1934 30.7 mg 99.4 % 
15{D} 434.2100 435.2179 14.3 mg 100.0 % 
15{E} 450.2049 451.2133 19.6 mg 98.9 % 
15{F} 448.2256 449.2339 13.2 mg 97.6 % 
15{G} 488.1817 489.1891 62.1 mg 95.8 % 
15{H} 488.1817 489.1899 42.1 mg 98.4 % 
15{I} 454.1553 455.1622 16.4 mg 97.6 % 
15{J} 414.2413 415.2501 44.1 mg 100.0 % 
15{K} 402.2049 403.2145 43.4 mg 99.2 % 























































































































































Sketched electronic versions of the library compounds were imported into the Tripos 
Molecular Spreadsheet [1] wherein standard Lipinski Rule of 5 parameters (molecular 
weight, ClogP, number of H-acceptors, and number of H-donors[2]) plus the number of 
rotatable bonds and polar surface area were computed.  Lipinski violations were specified 
according to molecular weight > 500, ClogP > 5.0, number of acceptors > 10, number of 
donors > 5, and number of rotatable bonds > 5.  The structures were then exported into SDF 
format and coverted into three-dimensional protonated structures via Concord [3].  
Absorption, distribution, metabolism and excretion (ADME) profiles of these compounds 
was then generated via Volsurf [4].  Descriptors were generated using three probes (water, 
hydrophobic and carbonyl oxygen) with a grid space distribution of 1.0 Å.  Predictions were 
then projected onto internal ADME models at the 5-component level.  Finally diversity 
analysis was carried out using DiverseSolutions [5] using standard H-aware 3D BCUT 
descriptors.  The library was then projected onto a chemical space defined by the following 
descriptors:  gastchrg_invdist2_000.550_K_L, gastchrg_invdist6_000.500_K_H, 
haccept_invdist2_001.000_K_H, tabpolar_invdist_000.250_K_H, 
tabpolar_invdist_000.500_K_L and populated (for comparison) by a recent version of the 
MLSMR screening set (ca. 7/2010; ~330,000 unique chemical structures).  Diversity scores 











where Nocc is the number of cells occupied by PubChem compounds in an evenly distributed 














































2 -3.53 -0.06 0.48 0.17 
63.6
4 -0.39 1.10 2.13 0.08 
A{2} 2.14 340.44 5 3 4 0 138.91 0.11 -0.33 -3.66 0.01 0.51 0.13 61.22 -0.43 1.00 1.78 -0.02 
A{3} 2.00 354.46 5 3 5 0 139.90 0.11 -0.56 -3.55 -0.01 0.40 0.29 67.93 -0.68 0.93 1.81 -0.03 
A{4} 2.00 354.46 5 3 5 0 139.71 0.11 -0.45 -3.88 0.08 0.42 0.19 67.06 -0.58 0.76 1.69 -0.24 
A{5} 3.09 353.48 4 3 3 0 92.51 0.11 0.43 -4.22 0.39 0.28 0.39 76.24 -0.31 0.55 1.32 -0.34 
A{6} 3.48 356.50 4 2 3 0 115.66 0.11 0.30 -3.81 0.55 0.24 0.62 78.25 -0.74 0.77 0.88 -0.24 
A{7} 5.38 443.60 4 3 5 1 89.74 0.11 -0.16 -6.14 0.71 -0.30 0.76 113.09 -0.78 -0.15 1.37 -0.72 
A{8} 2.62 328.43 5 3 6 1 144.92 0.11 -0.51 -3.53 -0.05 0.53 0.15 59.93 -0.42 1.05 2.10 -0.02 
B{1} 2.14 340.44 5 3 4 0 118.37 0.10 -0.35 -3.39 0.30 0.51 0.37 63.25 -0.42 1.17 2.21 0.03 
B{2} 2.14 340.44 5 3 4 0 118.37 0.10 -0.18 -3.65 0.36 0.49 0.33 63.32 -0.35 0.99 2.01 0.00 
B{3} 2.00 354.46 5 3 5 0 121.03 0.10 -0.21 -3.99 0.42 0.38 0.44 70.97 -0.53 0.80 1.92 -0.24 
B{4} 2.00 354.46 5 3 5 0 119.20 0.10 -0.29 -3.99 0.43 0.38 0.35 65.83 -0.51 0.73 1.84 -0.31 
B{5} 3.09 353.48 4 3 3 0 69.05 0.10 0.41 -3.93 0.67 0.28 0.62 69.35 -0.77 0.85 0.85 -0.35 
B{6} 3.48 356.50 4 2 3 0 88.85 0.10 0.70 -4.50 0.88 0.23 0.73 80.30 -0.67 0.43 1.04 -0.43 
B{7} 5.38 443.60 4 3 5 1 66.28 0.10 0.26 -6.01 1.01 -0.36 0.88 108.06 -1.03 -0.12 0.47 -0.61 
B{8} 2.62 328.43 5 3 6 1 121.28 0.10 -0.45 -3.37 0.21 0.58 0.30 60.78 -0.15 1.17 2.64 0.28 
C{1} 0.68 298.36 5 3 2 0 150.53 0.79 -0.26 -3.07 -0.10 0.62 0.04 59.93 -0.34 1.28 2.12 0.39 
C{2} 0.68 298.36 5 3 2 0 150.53 0.79 -0.28 -3.08 -0.08 0.65 -0.05 52.76 -0.41 1.15 1.82 0.24 
C{3} 0.55 312.38 5 3 3 0 151.52 0.79 -0.47 -3.13 -0.04 0.51 0.15 64.81 -0.66 1.01 1.83 0.31 
C{4} 0.55 312.38 5 3 3 0 151.33 0.79 -0.49 -3.35 -0.02 0.55 0.05 62.62 -0.54 0.86 1.86 0.11 
C{5} 1.63 311.40 4 3 1 0 104.13 0.79 0.51 -3.72 0.36 0.42 0.32 75.31 -0.23 0.79 1.46 -0.05 
C{6} 2.02 314.42 4 2 1 0 127.28 0.79 0.46 -3.26 0.55 0.36 0.58 78.34 -0.62 1.06 1.09 0.15 
C{7} 3.92 401.52 4 3 3 0 101.36 0.79 -0.16 -5.70 0.63 -0.11 0.72 112.54 -0.57 0.20 1.71 -0.47 
C{8} 1.16 286.35 5 3 4 0 156.54 0.79 -0.33 -3.25 -0.11 0.66 -0.01 55.56 -0.41 1.11 1.87 0.24 
D{1} 0.68 298.36 5 3 2 0 129.99 0.15 -0.13 -3.03 0.27 0.63 0.31 67.78 -0.39 1.20 2.14 0.45 
D{2} 0.68 298.36 5 3 2 0 129.99 0.15 -0.05 -3.24 0.31 0.62 0.25 65.89 -0.33 1.00 1.96 0.43 
D{3} 0.55 312.38 5 3 3 0 131.30 0.15 -0.01 -3.46 0.37 0.52 0.38 70.74 -0.39 0.83 1.99 0.24 
D{4} 0.55 312.38 5 3 3 0 130.82 0.15 -0.20 -3.80 0.38 0.47 0.30 70.03 -0.50 0.72 1.85 0.05 
D{5} 1.63 311.40 4 3 1 0 80.67 0.15 0.60 -3.42 0.67 0.39 0.58 70.32 -0.71 0.93 0.89 0.01 
D{6} 2.02 314.42 4 2 1 0 100.47 0.02 0.80 -4.20 0.79 0.35 0.66 84.74 -0.56 0.66 1.02 -0.21 
D{7} 3.92 401.52 4 3 3 0 79.05 0.27 0.43 -5.39 0.95 -0.22 0.75 101.95 -0.72 0.10 0.67 -0.45 
D{8} 1.16 286.35 5 3 4 0 132.90 0.20 -0.24 -3.09 0.14 0.73 0.23 64.99 -0.06 1.23 2.59 0.68 
E{1} 2.14 340.44 5 3 4 0 147.35 0.20 -0.32 -3.92 0.06 0.47 0.09 66.79 -0.46 0.88 1.81 0.07 
E{2} 2.14 340.44 5 3 4 0 147.42 0.20 -0.32 -3.96 0.06 0.46 0.14 68.83 -0.44 0.92 1.91 0.09 
E{3} 2.00 354.46 5 3 5 0 148.65 0.20 -0.49 -3.91 0.08 0.38 0.22 71.13 -0.72 0.76 1.58 -0.03 
E{4} 2.00 354.46 5 3 5 0 148.46 0.20 -0.42 -4.25 0.11 0.38 0.24 74.53 -0.52 0.75 1.90 -0.19 
E{5} 3.09 353.48 4 3 3 0 100.98 0.20 0.47 -4.64 0.50 0.27 0.36 81.13 -0.32 0.41 1.15 -0.39 
E{6} 3.48 356.50 4 2 3 0 124.15 0.20 0.23 -3.99 0.57 0.27 0.61 84.57 -0.69 0.75 1.16 -0.20 
E{7} 5.38 443.60 4 3 5 1 98.22 0.13 -0.19 -6.12 0.66 -0.32 0.79 114.83 -0.81 -0.17 1.40 -0.72 
E{8} 2.62 328.43 5 3 6 1 152.89 0.13 -0.56 -3.81 0.02 0.51 0.18 67.36 -0.57 0.98 1.91 0.00 
F{1} 2.14 340.44 5 3 4 0 126.78 0.13 -0.11 -3.89 0.35 0.44 0.31 73.49 -0.25 0.82 2.17 0.09 
F{2} 2.14 340.44 5 3 4 0 126.83 0.13 -0.25 -3.79 0.32 0.45 0.32 73.88 -0.36 1.01 2.19 0.09 
F{3} 2.00 354.46 5 3 5 0 128.10 0.13 -0.38 -4.22 0.37 0.32 0.41 78.05 -0.42 0.57 2.23 -0.16 
F{4} 2.00 354.46 5 3 5 0 127.93 0.13 -0.49 -4.34 0.35 0.32 0.42 81.45 -0.53 0.75 2.27 -0.24 
F{5} 3.09 353.48 4 3 3 0 78.08 0.13 0.30 -4.32 0.67 0.20 0.60 83.06 -0.71 0.63 1.25 -0.35 
F{6} 3.48 356.50 4 2 3 0 97.30 0.13 0.71 -5.14 0.85 0.15 0.67 95.35 -0.59 0.22 1.14 -0.62 
F{7} 5.38 443.60 4 3 5 1 76.61 0.13 0.56 -6.18 0.97 -0.46 0.89 113.00 -0.90 -0.20 0.47 -0.73 
F{8} 2.62 328.43 5 3 6 1 133.03 0.13 -0.17 -3.50 0.32 0.48 0.32 65.94 -0.35 1.03 2.06 0.06 
G{1} 0.68 298.36 5 3 2 0 150.53 0.13 -0.21 -3.32 -0.04 0.63 -0.05 54.60 -0.42 1.10 1.68 0.19 
G{2} 0.68 298.36 5 3 2 0 150.53 0.29 -0.30 -3.30 -0.03 0.63 0.02 58.36 -0.36 1.21 1.90 0.30 
G{3} 0.55 312.38 5 3 3 0 151.52 0.29 -0.46 -3.35 0.02 0.52 0.12 61.91 -0.70 0.92 1.53 0.17 
G{4} 0.55 312.38 5 3 3 0 151.33 0.29 -0.50 -3.39 -0.02 0.55 0.16 65.72 -0.46 1.05 2.07 0.19 
G{5} 1.63 311.40 4 3 1 0 104.13 0.29 0.56 -3.94 0.44 0.43 0.30 73.40 -0.25 0.71 1.14 -0.14 
G{6} 2.02 314.42 4 2 1 0 127.28 0.29 0.37 -3.51 0.64 0.40 0.56 75.02 -0.65 0.97 0.87 0.05 
G{7} 3.92 401.52 4 3 3 0 101.36 0.29 -0.19 -5.64 0.62 -0.11 0.73 112.57 -0.58 0.22 1.75 -0.43 
G{8} 1.16 286.35 5 3 4 0 156.54 0.29 -0.53 -3.03 -0.14 0.72 0.03 56.16 -0.41 1.22 2.03 0.40 
H{1} 0.68 298.36 5 3 2 0 129.98 0.29 -0.03 -3.12 0.30 0.62 0.26 65.92 -0.30 1.00 2.11 0.48 
H{2} 0.68 298.36 5 3 2 0 130.01 0.29 -0.13 -3.03 0.27 0.63 0.31 67.80 -0.39 1.20 2.14 0.45 
H{3} 0.55 312.38 5 3 3 0 130.95 0.29 -0.06 -3.28 0.36 0.52 0.39 67.90 -0.41 0.83 2.01 0.24 
H{4} 0.55 312.38 5 3 3 0 131.10 0.29 -0.20 -3.33 0.32 0.53 0.38 68.86 -0.39 0.84 2.16 0.22 
H{5} 1.63 311.40 4 3 1 0 80.68 0.17 0.59 -3.29 0.64 0.40 0.59 70.32 -0.69 0.97 1.02 0.07 
H{6} 2.02 314.42 4 2 1 0 100.50 0.17 0.70 -4.01 0.73 0.36 0.66 84.52 -0.63 0.80 1.03 -0.13 
H{7} 3.92 401.52 4 3 3 0 79.08 0.17 0.26 -5.47 0.89 -0.28 0.86 106.51 -0.82 0.18 0.80 -0.52 
H{8} 1.16 286.35 5 3 4 0 133.18 0.12 -0.26 -2.80 0.20 0.66 0.23 61.75 -0.27 1.13 2.31 0.49 
I1} 2.25 374.45 5 3 4 0 150.53 0.03 -0.34 -4.60 0.18 0.14 0.27 85.37 -0.47 0.55 1.84 0.29 
I{2} 2.25 374.45 5 3 4 0 150.53 0.03 -0.40 -4.47 0.19 0.15 0.27 84.22 -0.62 0.57 1.73 0.27 
I{3} 2.11 388.48 5 3 5 0 151.52 0.09 -0.55 -4.47 0.20 0.05 0.40 88.49 -0.86 0.45 1.54 0.16 
I{4} 2.11 388.48 5 3 5 0 151.33 0.16 -0.52 -4.70 0.23 0.07 0.33 89.10 -0.74 0.39 1.65 0.03 
I{5} 3.32 387.50 4 3 3 0 104.14 0.29 0.41 -5.10 0.59 -0.05 0.53 96.20 -0.49 0.23 1.04 -0.19 
I{6} 3.59 390.52 4 2 3 0 127.28 0.15 0.15 -4.73 0.74 -0.08 0.74 97.01 -0.86 0.43 0.80 -0.21 
I{7} 5.49 477.62 4 3 5 1 101.37 0.15 0.12 -6.79 0.70 -0.56 0.70 121.65 -0.71 -0.60 0.72 -1.27 
I{8} 2.73 362.44 5 3 6 1 156.54 0.51 -0.52 -4.38 0.16 0.16 0.29 84.05 -0.62 0.58 2.01 0.27 
J{1} 2.25 374.45 5 3 4 0 130.00 0.51 -0.41 -4.62 0.41 0.10 0.56 95.72 -0.50 0.60 2.18 0.31 
J{2} 2.25 374.45 5 3 4 0 130.00 0.51 -0.39 -4.62 0.42 0.09 0.54 94.62 -0.52 0.55 2.13 0.29 
J{3} 2.11 388.48 5 3 5 0 131.28 0.51 -0.18 -4.97 0.52 0.00 0.61 99.27 -0.58 0.30 1.71 0.03 
J{4} 2.11 388.48 5 3 5 0 130.83 0.65 -0.48 -4.88 0.49 -0.03 0.58 95.68 -0.69 0.31 1.95 0.01 
J{5} 3.32 387.50 4 3 3 0 80.68 0.65 0.16 -4.80 0.75 -0.13 0.81 98.30 -0.93 0.39 1.00 -0.09 
J{6} 3.59 390.52 4 2 3 0 100.47 0.18 0.43 -5.42 0.90 -0.16 0.82 107.46 -0.87 0.14 0.81 -0.41 
J{7} 5.49 477.62 4 3 5 1 77.91 0.18 0.41 -6.73 0.88 -0.73 0.78 119.95 -1.04 -0.76 0.00 -1.24 
J{8} 2.73 362.44 5 3 6 1 132.91 0.18 -0.37 -4.42 0.29 0.17 0.48 91.81 -0.30 0.70 2.36 0.48 
K{1} 2.25 374.45 5 3 4 0 136.88 0.18 -0.47 -4.63 0.26 0.12 0.41 88.25 -0.64 0.59 1.75 0.22 
K{2} 2.25 374.45 5 3 4 0 136.88 0.18 -0.41 -4.76 0.26 0.12 0.41 89.25 -0.47 0.56 1.83 0.23 
 184 
K{3} 2.11 388.48 5 3 5 0 137.87 0.18 -0.49 -4.85 0.29 0.04 0.53 92.07 -0.82 0.49 1.49 -0.02 
K{4} 2.11 388.48 5 3 5 0 137.68 0.31 -0.51 -5.01 0.30 0.02 0.49 94.31 -0.68 0.41 1.73 -0.15 
K{5} 3.32 387.50 4 3 3 0 90.49 0.31 0.38 -5.30 0.71 -0.09 0.63 98.96 -0.53 0.13 0.97 -0.22 
K{6} 3.59 390.52 4 2 3 0 113.63 0.43 0.35 -5.15 0.89 -0.11 0.81 100.52 -0.86 0.25 0.55 -0.35 
K{7} 5.49 477.62 4 3 5 1 87.72 0.50 0.18 -6.76 0.81 -0.62 0.75 121.07 -0.76 -0.71 0.47 -1.29 
K{8} 2.73 362.44 5 3 6 1 142.89 0.50 -0.74 -4.44 0.21 0.18 0.45 87.79 -0.65 0.68 2.01 0.35 
L{1} 2.25 374.45 5 3 4 0 116.33 0.50 -0.15 -4.61 0.50 0.10 0.52 87.31 -0.50 0.48 1.57 0.04 
L{2} 2.25 374.45 5 3 4 0 116.37 0.50 -0.15 -4.62 0.48 0.12 0.53 88.29 -0.48 0.55 1.61 0.06 
L{3} 2.11 388.48 5 3 5 0 117.30 0.37 -0.15 -4.77 0.55 0.01 0.59 88.54 -0.64 0.27 1.41 -0.17 
L{4} 2.11 388.48 5 3 5 0 121.55 0.66 -0.14 -4.78 0.53 0.02 0.60 89.88 -0.63 0.39 1.61 -0.14 
L{5} 3.32 387.50 4 3 3 0 67.03 0.38 0.41 -4.85 0.81 -0.09 0.79 92.05 -0.92 0.39 0.42 -0.36 
L{6} 3.59 390.52 4 2 3 0 86.86 0.38 0.56 -5.87 1.00 -0.17 0.81 103.10 -0.80 -0.11 0.60 -0.75 
L{7} 5.49 477.62 4 3 5 1 64.26 0.38 0.55 -7.29 1.04 -0.77 0.88 122.71 -1.04 -0.85 -0.22 -1.54 
L{8} 2.73 362.44 5 3 6 1 124.14 0.38 -0.11 -4.51 0.53 0.07 0.47 86.89 -0.44 0.37 1.88 0.09 
A-II-6 4.75 396.57 4 1 5 0 92.64 0.38 0.56 -4.36 0.72 0.16 0.72 88.28 -0.65 0.75 1.03 -0.46 
A-II-9 4.74 364.50 4 1 5 0 67.89 0.38 0.75 -4.48 0.82 0.21 0.72 87.18 -0.63 0.60 0.70 -0.58 
A-I-6 3.98 370.53 4 1 3 0 93.94 0.15 0.87 -4.98 1.01 0.08 0.78 89.43 -0.61 0.18 0.82 -0.69 
A-I-9 3.97 338.46 4 1 3 0 69.17 0.15 0.75 -4.53 1.01 0.13 0.79 86.70 -0.52 0.39 0.86 -0.53 
B-II-6 4.75 396.57 4 1 5 0 58.16 0.15 0.66 -3.67 0.70 0.25 0.68 80.88 -0.60 0.86 0.98 -0.14 
B-II-9 4.74 364.50 4 1 5 0 38.13 0.15 0.80 -3.77 0.80 0.34 0.68 79.64 -0.57 0.76 0.65 -0.27 
B-I-6 3.98 370.53 4 1 3 0 65.76 0.26 0.87 -4.80 1.02 0.20 0.76 91.30 -0.55 0.44 1.09 -0.43 
B-I-9 3.97 338.46 4 1 3 0 47.04 0.26 0.93 -4.29 1.02 0.28 0.79 87.92 -0.35 0.56 1.18 -0.29 
C-II-6 3.30 354.49 4 1 3 0 91.78 0.04 0.56 -4.42 0.83 0.09 0.75 86.21 -0.72 0.55 0.71 -0.45 
C-II-9 3.29 322.42 4 1 3 0 67.03 0.04 0.67 -4.33 0.84 0.14 0.76 87.23 -0.65 0.55 0.78 -0.45 
C-I-6 2.52 328.45 4 1 1 0 94.28 0.05 0.67 -5.15 1.01 0.04 0.78 89.86 -0.65 0.14 1.04 -0.72 
C-I-9 2.51 296.39 4 1 1 0 69.52 0.05 0.59 -4.70 0.99 0.11 0.79 88.03 -0.55 0.35 1.08 -0.55 
D-II-6 3.30 354.49 4 1 3 0 63.30 0.14 0.71 -3.93 0.76 0.29 0.66 79.22 -0.64 0.80 0.53 -0.27 
D-II-9 3.29 322.42 4 1 3 0 44.18 0.14 0.63 -3.64 0.72 0.37 0.68 80.38 -0.56 0.85 0.92 -0.22 
D-I-6 2.52 328.45 4 1 1 0 67.83 0.14 1.02 -4.38 0.99 0.26 0.76 84.42 -0.54 0.50 0.85 -0.40 
D-I-9 2.51 296.39 4 1 1 0 48.70 0.14 1.00 -3.85 1.00 0.34 0.80 81.55 -0.44 0.70 0.95 -0.31 
E-II-6 4.75 396.57 4 1 5 0 89.55 0.57 0.19 -5.25 0.87 -0.16 0.83 104.32 -0.81 0.32 0.90 -0.47 
E-II-9 4.74 364.50 4 1 5 0 64.77 0.57 0.32 -5.12 0.90 -0.12 0.86 103.89 -0.77 0.32 0.93 -0.45 
E-I-6 3.98 370.53 4 1 3 0 93.29 0.57 0.92 -5.75 1.16 -0.23 0.90 106.48 -0.76 -0.12 0.46 -0.67 
E-I-9 3.97 338.46 4 1 3 0 68.53 0.57 0.82 -5.26 1.13 -0.17 0.89 101.46 -0.65 0.08 0.51 -0.53 
F-II-6 4.75 396.57 4 1 5 0 67.25 0.08 0.44 -5.22 0.90 -0.15 0.83 102.52 -0.81 0.27 0.66 -0.43 
F-II-9 4.74 364.50 4 1 5 0 48.13 0.08 0.57 -5.10 0.93 -0.11 0.86 103.01 -0.76 0.26 0.74 -0.40 
F-I-6 3.98 370.53 4 1 3 0 67.91 0.08 0.92 -5.87 1.19 -0.26 0.89 109.48 -0.76 -0.13 0.38 -0.67 
F-I-9 3.97 338.46 4 1 3 0 48.94 0.08 0.82 -5.43 1.15 -0.19 0.88 106.17 -0.65 0.12 0.45 -0.53 
G-II-6 3.30 354.49 4 1 3 0 89.17 0.16 0.52 -4.86 0.83 0.03 0.77 92.34 -0.74 0.54 0.72 -0.66 
G-II-9 3.29 322.42 4 1 3 0 64.41 0.16 0.61 -4.75 0.90 0.08 0.79 91.64 -0.68 0.49 0.86 -0.62 
G-I-6 2.52 328.45 4 1 1 0 93.69 0.16 0.88 -5.45 1.03 -0.01 0.78 95.54 -0.65 0.07 0.80 -0.93 
G-I-9 2.51 296.39 4 1 1 0 68.93 0.16 0.81 -5.40 1.07 0.02 0.78 95.74 -0.49 0.14 1.01 -0.87 
H-II-6 3.30 354.49 4 1 3 0 67.48 0.33 0.58 -4.25 0.76 0.20 0.68 81.45 -0.63 0.68 0.74 -0.46 
H-II-9 3.29 322.42 4 1 3 0 48.98 0.33 0.68 -4.19 0.82 0.25 0.70 82.68 -0.58 0.60 0.89 -0.44 
H-I-6 2.52 328.45 4 1 1 0 67.68 0.33 0.88 -5.00 1.02 0.13 0.75 93.33 -0.65 0.26 1.01 -0.57 
H-I-9 2.51 296.39 4 1 1 0 49.30 0.33 0.87 -4.62 1.05 0.19 0.76 90.64 -0.48 0.37 1.12 -0.50 
I-II-6 4.86 430.58 4 1 5 0 89.95 0.33 0.47 -4.87 0.84 0.01 0.77 94.30 -0.80 0.49 0.66 -0.63 
I-III-9 4.85 398.52 4 1 5 0 69.15 0.33 0.64 -4.82 0.93 0.02 0.79 91.19 -0.79 0.42 0.40 -0.68 
I-II-6 4.09 404.55 4 1 3 0 94.86 0.33 0.75 -5.49 1.04 0.01 0.80 97.99 -0.72 0.11 1.03 -0.86 
I-II-9 4.08 372.48 4 1 3 0 70.08 0.33 0.73 -5.38 1.07 0.01 0.81 96.61 -0.51 0.17 1.05 -0.83 
J-II-6 4.86 430.58 4 1 5 0 58.08 0.14 0.71 -4.18 0.83 0.18 0.69 81.31 -0.70 0.67 0.59 -0.36 
J-II-9 4.85 398.52 4 1 5 0 46.00 0.14 0.84 -4.12 0.85 0.23 0.71 83.11 -0.65 0.62 0.66 -0.36 
J-I-6 4.09 404.55 4 1 3 0 68.26 0.14 0.85 -4.64 1.02 0.18 0.78 86.26 -0.63 0.36 1.04 -0.59 
J-I-9 4.08 372.48 4 1 3 0 49.24 0.14 0.89 -4.22 1.03 0.26 0.80 83.81 -0.45 0.47 1.13 -0.45 
K-II-6 4.86 430.58 4 1 5 0 83.82 0.15 0.35 -6.01 1.01 -0.39 0.89 114.99 -0.86 0.09 0.38 -0.58 
K-II-9 4.85 398.52 4 1 5 0 59.07 0.15 0.51 -5.50 1.03 -0.26 0.90 105.85 -0.80 0.19 0.57 -0.56 
K-I-6 4.09 404.55 4 1 3 0 94.52 0.15 0.60 -6.09 1.07 -0.27 0.90 105.29 -0.79 -0.22 0.59 -1.00 
K-I-9 4.08 372.48 4 1 3 0 69.76 0.15 0.33 -5.94 1.14 -0.31 0.92 108.53 -0.78 -0.02 0.68 -0.73 
L-II-6 4.86 430.58 4 1 5 0 67.65 0.02 0.06 -5.55 0.89 -0.28 0.88 105.74 -0.86 0.20 0.91 -0.53 
L-II-9 4.85 398.52 4 1 5 0 49.20 0.02 0.14 -5.32 0.92 -0.26 0.91 102.70 -0.81 0.21 0.96 -0.51 
L-I-6 4.09 404.55 4 1 3 0 68.06 0.02 0.85 -6.26 1.23 -0.40 0.96 115.93 -0.80 -0.23 0.37 -0.79 
L-I-9 4.08 372.48 4 1 3 0 49.21 0.02 0.80 -5.86 1.21 -0.35 0.95 110.73 -0.71 -0.02 0.45 -0.76 




4.1.2 Library Production of “4+4” Scaffold via Click-SNAr 
General Procedure A: Cu-catalyzed N-arylation.  To a microwave vial charged with 
solution of sultam 1.12.1 (0.132 mmol, 1.0 equiv.) in EtOH (0.4 mL), was added o-anisidine 
1.12.2 (0.330 mmol, 2.5 equiv.), CuI (0.066 mmol, 0.5 equiv.), 1,10-phenanthroline (0.0264 
mmol, 0.2 equiv.), and Cs2CO3 (0.264 mmol, 2.0 equiv.).  The reaction was heated at 100 
°C under microwave irradiation for 30 min, which upon completion was quenched with aq., 
HCl and diluted with EtOAc.  The organic layer was separated and the aqueous layer was 
extracted with EtOAc (3x).  The combined organic layers were washed with brine, dried 
over Na2SO4, concentrated under reduced pressure, and subject to automated column 
chromatography. 
 
General Procedure B: nucleophilic aromatic substitution (SNAr).  To a microwave vial 
charged with solution of sultam 1.13.1 (0.315 mmol, 1.0 equiv.) in DMSO (0.3 mL), was 
added pyrrolidine 1.13.2 (01.575 mmol, 5.0 equiv.), and DBU (0.032 mmol, 0.1 equiv.).  
The reaction was heated at 180 °C under microwave irradiation for 50 min, which upon 
completion was diluted with EtOAc and passed through SiO2 SPE.  The resulting mixture 
was concentrated under reduced pressure, and subject to automated column 
chromatography. 
 
General Procedure C: one-pot Click/SNAr.  To a microwave vial charged with solution of 
sultam 1.13.A or 1.13.B (0.158 mmol, 1.0 equiv.) in DMSO (0.2 mL), was added amine 
(0.790 mmol, 5.0 equiv.), azide (0.316 mmol, 2.0 equiv.), CuI (0.0474 mmol, 0.3 equiv.) 
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and DBU (0.0158 mmol, 0.1 equiv.).  The reaction was heated at 180 °C under microwave 
irradiation for 50 min, which upon completion was diluted with EtOAc and passed through 
SiO2 SPE.  The resulting mixture was concentrated under reduced pressure to afford the 
crude product.  The crude product was QC/purified by an automated preparative reverse 
phase HPLC (detected by mass spectroscopy). 
 
Comp. HRMS Expected M/z (M)+ 
HRMS Found 
M/z (M+H)+ Mass (mg) Yield (%) Purity (%) 
1.4.A.FN 569.1708 570.1734 134.5 mg 75 % 99.9 % 
1.4.A.DN 601.1429 602.1506 166.6 mg 88 % 99.5 % 
1.4.A.CN 598.1974 503.2058 94.0 mg 53 % 99.8 % 
1.4.A.EN 692.2193 693.2266 181.1 mg 83 % 100.0 % 
1.4.A.GN 573.1658 574.1754 116.4 mg 64 % 99.8 % 
1.4.B.GN 574.1658 574.1722 129.4 mg 72 % 99.7 % 
1.4.B.HN 571.1865 572.1985 120.5 mg 67 % 99.6 % 
1.4.B.IN 595.1501 596.1556 111.1 mg 59 % 98.5 % 
1.4.B.DN 601.1429 602.1489 144.8 mg 76 % 98.7 % 
1.4.A.FQ 535.1445 536.1111 17.0 mg 20 % 98.4 % 
1.4.A.DQ 567.1166 568.0811 54.7 mg 61 % 96.8 % 
1.4.A.CQ 564.1710 NA NA NA NA 
1.4.A.EQ 658.1929 659.2017 36.1 mg 95 % 98.6 % 
1.4.A.GQ 539.1394 540.1498 1.3 mg 2 % 91.9 % 
1.4.A.FL 519.1740 520.1812 26.5 mg 32 % 99.6 % 
1.4.A.DL 551.1461 552.1535 60.8 mg 70 % 98.3 % 
1.4.A.CL 548.2006 NA NA NA NA 
1.4.A.EL 642.2225 643.2252 29.5 mg 29 % 98.2 % 
1.4.A.GL 523.1689 524.1801 3.2 mg 4 % 98.4 % 
1.4.B.GO 573.1658 574.1739 21.7 mg 24 % 92.8 % 
1.4.B.HO 571.1865 572.1869 51.1 mg 57 % 91.9 % 
1.4.B.IO 595.1501 596.1570 25.8 mg 27 % 99.3 % 
1.4.B.JO 587.1814 588.1833 23.8 mg 26 % 95.4 % 
1.4.B.DO 601.1429 602.1476 62.7 mg 66 % 97.1 % 
1.4.B.GP 573.1658 574.1711 13.4 mg 15 % 97.1 % 
1.4.B.HP 571.1865 572.1899 34.2 mg 38 % 93.1 % 
1.4.B.IP 595.1501 596.1559 19.2 mg 20 % 99.2 % 
1.4.B.JP 587.1814 588.1867 14.2 mg 15 % 96.9 % 
1.4.B.DP 601.1429 602.1483 61.2 mg 64 % 97.2 % 
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1.4.B.JN 587.1814 588.1912 108.9 mg 59 % 98.6 % 
1.4.A.FO 569.1708 570.1855 50.6 mg 56 % 97.9 % 
1.4.A.DO 601.1429 602.1527 67.6 mg 71 % 99.4 % 
1.4.A.CO 598.1974 599.2046 34.0 mg 36 % 99.1 % 
1.4.A.EO 692.2193 693.2272 68.2 mg 62 % 99.5 % 
1.4.A.GO 573.1658 574.1766 48.5 mg 54 % 99.2 % 
1.4.A.FP 569.1708 570.1751 54.5 mg 61 % 98.0 % 
1.4.A.DP 601.1429 602.1514 71.9 mg 76 % 99.2 % 
1.4.A.CP 598.1974 599.2045 24.0 mg 25 % 99.7 % 
1.4.A.EP 692.2193 693.2317 88.9 mg 81 % 99.9 % 
1.4.A.GP 573.1658 574.1765 25.3 mg 28 % 99.1 % 
1.4.A.FM 519.1740 520.1824 41.6 mg 51 % 98.0 % 
1.4.A.DM 551.1461 552.1498 66.4 mg 76 % 98.7 % 
1.4.A.CM 548.2006 549.2073 27.5 mg 32 % 99.2 % 
1.4.A.EM 642.2225 643.2255 59.8 mg 59 % 99.6 % 
1.4.A.GM 523.1690 524.1785 14.0 mg 17 % 99.0 % 
1.4.B.GN 573.1658 574.1746 64.9 mg 72 % 97.6 % 
1.4.B.HN 571.1865 572.1919 41.4 mg 46 % 98.7 % 
1.4.B.IN 595.1501 596.1562 54.3 mg 58 % 99.8 % 
1.4.B.JN 587.1814 588.1885 54.5 mg 59 % 87.4 % 
1.4.B.DN 601.1429 602.1489 51.0 mg 54 % 99.6 % 
1.4.B.GO 523.1690 524.1763 51.4 mg 62 % 98.9 % 
1.4.B.HO 521.1897 522.1924 48.2 mg 58 % 99.8 % 
1.4.B.IO 545.1533 546.1627 53.2 mg 62 % 99.2 % 
1.4.B.JO 537.1846 538.1940 49.9 mg 59 % 98.9 % 
1.4.B.DO 551.1461 552.1542 53.4 mg 61 % 98.2 % 
1.4.B.GM 523.1690 524.1777 51.0 mg 62 % 99.1 % 
1.4.B.HM 521.1897 522.2004 43.9 mg 53 % 100.0 % 
1.4.B.IM 545.1533 546.1594 48.3 mg 56 % 98.8 % 
1.4.B.JM 537.1846 538.1949 42.5 mg 50 % 97.7 % 
1.4.B.DM 551.1461 552.1516 51.1 mg 59 % 98.1 % 
1.4.B.GQ 539.1394 540.1457 55.7 mg 65 % 98.9 % 
1.4.B.HQ 537.1601 538.1682 50.6 mg 60 % 94.9 % 
1.4.B.IQ 561.1238 562.1329 53.0 mg 60 % 99.7 % 
1.4.B.JQ 553.1551 554.1635 61.0 mg 70 % 93.1 % 











Openlynx Report - Page 2 
Sample: 1 Vial:3:1 ID:MYH-1-144A
File:MY101216WT001 Date:17-Dec-2010 Description:MDF035547
Printed: Fri Dec 17 15:31:41 2010
Sample Report:
 ID MYH-1-144A File MY101216WT001 Date 17-Dec-2010 Time 3::6::8  Description MDF035547
Time














Peak Number Time AreaAbs Area %Total Height Mass Found
1 2.26 29 0.13 1639 569.17
3 2.41 22297 99.87 1334866 569.17
Time














































Openlynx Report - Page 2 
Sample: 2 Vial:3:2 ID:MYH-1-144B
File:MY101216WT002 Date:17-Dec-2010 Description:MDF035542
Printed: Fri Dec 17 15:36:20 2010
Sample Report:
 ID MYH-1-144B File MY101216WT002 Date 17-Dec-2010 Time 3::1::3  Description MDF035542
Time














Peak Number Time AreaAbs Area %Total Height Mass Found
1 1.82 45 0.19 2798
2 2.24 25 0.11 1703 601.14
3 2.26 61 0.25 3140 601.14
4 2.31 24063 99.46 1368486 601.14
Time












































Openlynx Report - Page 2 
Sample: 3 Vial:3:3 ID:MYH-1-144C
File:MY101216WT003 Date:17-Dec-2010 Description:MDF035539
Printed: Fri Dec 17 15:40:59 2010
Sample Report:
 ID MYH-1-144C File MY101216WT003 Date 17-Dec-2010 Time 3::6::2  Description MDF035539
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 1.90 31 0.19 1663 598.20
2 2.05 16001 99.81 1010951 598.20
Time


















































Openlynx Report - Page 2 
Sample: 4 Vial:3:4 ID:MYH-1-144D
File:MY101216WT004 Date:17-Dec-2010 Description:MDF035562
Printed: Fri Dec 17 15:45:36 2010
Sample Report:
 ID MYH-1-144D File MY101216WT004 Date 17-Dec-2010 Time 3::1::1  Description MDF035562
Time














Peak Number Time AreaAbs Area %Total Height Mass Found
1 2.51 25024 100.00 1384910 692.22
Time
































Openlynx Report - Page 2 
Sample: 5 Vial:3:5 ID:MYH-1-144E
File:MY101216WT005 Date:17-Dec-2010 Description:MDF035573
Printed: Fri Dec 17 15:50:14 2010
Sample Report:
 ID MYH-1-144E File MY101216WT005 Date 17-Dec-2010 Time 3::5::8  Description MDF035573
Time














Peak Number Time AreaAbs Area %Total Height Mass Found
1 1.91 41 0.20 2898 573.17
2 1.96 20303 99.80 1235460 573.17
Time














































Openlynx Report - Page 2 
Sample: 6 Vial:3:6 ID:MYH-1-146A
File:MY101216WT006 Date:17-Dec-2010 Description:MDF035564
Printed: Fri Dec 17 15:54:51 2010
Sample Report:
 ID MYH-1-146A File MY101216WT006 Date 17-Dec-2010 Time 3::0::6  Description MDF035564
Time














Peak Number Time AreaAbs Area %Total Height Mass Found
1 2.01 66 0.29 29 8 573.17
2 2.06 22183 99.71 1278470 573.17
Time





















































Openlynx Report - Page 2 
Sample: 7 Vial:3:7 ID:MYH-1-146B
File:MY101216WT007 Date:17-Dec-2010 Description:MDF035554
Printed: Fri Dec 17 15:59:30 2010
Sample Report:
 ID MYH-1-146B File MY101216WT007 Date 17-Dec-2010 Time 3::4::4  Description MDF035554
Time














Peak Number Time AreaAbs Area %Total Height Mass Found
1 2.46 61 0.29 4078 571.19
2 2.51 25 0.12 1956 571.19
3 2.57 21364 99.60 1308845 571.19
Time













































Openlynx Report - Page 2 
Sample: 8 Vial:3:8 ID:MYH-1-146C
File:MY101216WT008 Date:17-Dec-2010 Description:MDF035560
Printed: Fri Dec 17 16:04:08 2010
Sample Report:
 ID MYH-1-146C File MY101216WT008 Date 17-Dec-2010 Time 3::9::2  Description MDF035560
Time














Peak Number Time AreaAbs Area %Total Height Mass Found
1 2.08 40 0.18 2927
2 2.22 24 0.11 2140 595.15
3 2.30 127 0.57 7731 595.15
4 2.33 134 0.60 9822 595.15
5 2.37 21933 98.54 1321752 595.15
Time













































Openlynx Report - Page 2 
Sample: 9 Vial:3:9 ID:MYH-1-146E
File:MY101216WT009 Date:17-Dec-2010 Description:MDF035630
Printed: Fri Dec 17 16:08:46 2010
Sample Report:
 ID MYH-1-146E File MY101216WT009 Date 17-Dec-2010 Time 4::4::1  Description MDF0356 0
Time














Peak Number Time AreaAbs Area %Total Height Mass Found
1 2.26 32 0.39 1973 601.14
2 2.34 71 0.87 4207 601.14
3 2.38 8097 98.74 538030 601.14
Time



















































Openlynx Report - Page 2 
Sample: 1 Vial:3:1 ID:MYH-1-154A
File:MY110112WT001 Date:12-Jan-2011 Description:MDF035311
Printed: Wed Jan 12 15:35:57 2011
Sample Report:
 ID MYH-1-154A File MY110112WT001 Date 12-Jan-2011 Time 2::6::8  Description MDF035311
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 2.02 29 0.20 1725
2 2.18 179 1.20 11422 535.14
4 2.35 37 0.25 3695 535.14
5 2.37 14646 98.35 949247 535.14
Time










































Openlynx Report - Page 2 
Sample: 2 Vial:3:2 ID:MYH-1-154B
File:MY110112WT002 Date:12-Jan-2011 Description:MDF035255
Printed: Wed Jan 12 15:36:01 2011
Sample Report:
 ID MYH-1-154B File MY110112WT002 Date 12-Jan-2011 Time 2::1::2  Description MDF035255
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 2.20 476 2.84 29341 567.12
2 2.26 20 0.12 1960 567.12
3 2.28 16228 96.80 1048307 567.12
4 2.33 40 0.24 2248 567.12
Time












































Openlynx Report - Page 2 
Sample: 3 Vial:3:3 ID:MYH-1-154D
File:MY110112WT003 Date:12-Jan-2011 Description:MDF035254
Printed: Wed Jan 12 15:36:06 2011
Sample Report:
 ID MYH-1-154D File MY110112WT003 Date 12-Jan-2011 Time 2::6::7  Description MDF035254
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 2.37 80 0.52 4408 658.19
2 2.44 75 0.49 5747 658.19
3 2.46 36 0.23 3694 658.19
4 2.49 15019 98.64 957815 658.19
5 3.22 17 0.11 1357
Time


















































Openlynx Report - Page 2 
Sample: 4 Vial:3:4 ID:MYH-1-154E
File:MY110112WT004 Date:12-Jan-2011 Description:MDF035253
Printed: Wed Jan 12 15:36:10 2011
Sample Report:
 ID MYH-1-154E File MY110112WT004 Date 12-Jan-2011 Time 2::1::0  Description MDF035253
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 1.64 27 1.18 1592 539.14
2 1.82 22 0.97 1315 539.14
3 1.87 66 2.90 3989 539.14
4 1.91 69 3.05 6912 539.14
5 1.92 2096 91.89 142955 539.14
Time











































Openlynx Report - Page 2 
Sample: 5 Vial:3:5 ID:MYH-1-156A
File:MY110112WT005 Date:12-Jan-2011 Description:MDF035268
Printed: Wed Jan 12 15:36:14 2011
Sample Report:
 ID MYH-1-156A File MY110112WT005 Date 12-Jan-2011 Time 2:: ::2  Description MDF035268
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 1.91 20 0.14 1322
3 2.22 38 0.26 2608 519.17
4 2.27 14612 99.60 946656 519.17
Time











































Openlynx Report - Page 2 
Sample: 6 Vial:3:6 ID:MYH-1-156B
File:MY110112WT006 Date:12-Jan-2011 Description:MDF035485
Printed: Wed Jan 12 15:36:18 2011
Sample Report:
 ID MYH-1-156B File MY110112WT006 Date 12-Jan-2011 Time 2::0::2  Description MDF035485
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 2.02 134 0.88 8634 551.15
2 2.18 14836 98.34 982069 551.15
3 2.22 101 0.67 7617 551.15
4 2.26 17 0.11 1319 551.15
Time




















































Openlynx Report - Page 2 
Sample: 7 Vial:3:7 ID:MYH-1-156D
File:MY110112WT007 Date:12-Jan-2011 Description:MDF035260
Printed: Wed Jan 12 15:36:22 2011
Sample Report:
 ID MYH-1-156D File MY110112WT007 Date 12-Jan-2011 Time 2::5::2  Description MDF035260
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 2.22 128 0.88 6872 642.22
2 2.27 138 0.94 8484 642.22
3 2.39 14374 98.18 933030 642.22
Time










































Openlynx Report - Page 2 
Sample: 8 Vial:3:8 ID:MYH-1-156E
File:MY110112WT008 Date:12-Jan-2011 Description:MDF035135
Printed: Wed Jan 12 15:36:26 2011
Sample Report:
 ID MYH-1-156E File MY110112WT008 Date 12-Jan-2011 Time 2::9::5  Description MDF035135
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 1.75 29 0.58 2408 523.17
2 1.78 52 1.03 4202 523.17
3 1.81 4985 98.39 349410 523.17
Time










































Openlynx Report - Page 2 
Sample: 9 Vial:3:9 ID:MYH-1-158A
File:MY110112WT009 Date:12-Jan-2011 Description:MDF035274
Printed: Wed Jan 12 15:36:31 2011
Sample Report:
 ID MYH-1-158A File MY110112WT009 Date 12-Jan-2011 Time 2::4::9  Description MDF035274
Time
















Peak Number Time AreaAbs Area %Total Height Mass Found
1 1.60 29 0.21 1524
2 1.77 31 0.23 1932 573.17
3 1.87 60 0.44 4217 573.17
4 2.01 159 1.15 11582 573.17
5 2.03 665 4.83 46856 573.17
6 2.07 12787 92.84 844091 573.17
7 2.18 28 0.20 1858 573.17
8 2.57 15 0.11 976
Time






















Openlynx Report - Page 2 
Sample: 10 Vial:3:10 ID:MYH-1-158B
File:MY110112WT010 Date:12-Jan-2011 Description:MDF035134
Printed: Wed Jan 12 15:36:35 2011
Sample Report:
 ID MYH-1-158B File MY110112WT010 Date 12-Jan-2011 Time 2::9::2  Description MDF035134
Time
















Peak Number Time AreaAbs Area %Total Height Mass Found
1 2.06 27 0.18 1604
3 2.48 1199 7.97 77273 571.19
4 2.55 13814 91.85 877399 571.19
Time










































Openlynx Report - Page 2 
Sample: 11 Vial:3:11 ID:MYH-1-158C
File:MY110112WT011 Date:12-Jan-2011 Description:MDF035432
Printed: Wed Jan 12 15:36:39 2011
Sample Report:
 ID MYH-1-158C File MY110112WT011 Date 12-Jan-2011 Time 2::3::8  Description MDF035432
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 2.09 19 0.11 1273 595.15
2 2.22 24 0.14 1627 595.15
3 2. 3 77 0.44 4683 595.15
4 2.37 17225 99.31 1125540 595.15
Time










































Openlynx Report - Page 2 
Sample: 12 Vial:3:12 ID:MYH-1-158D
File:MY110112WT012 Date:12-Jan-2011 Description:MDF035434
Printed: Wed Jan 12 15:36:44 2011
Sample Report:
 ID MYH-1-158D File MY110112WT012 Date 12-Jan-2011 Time 2::8::2  Description MDF035434
Time
















Peak Number Time AreaAbs Area %Total Height Mass Found
1 2.09 76 0.53 4706 587.18
2 2.12 18 0.13 1741 587.18
3 2.15 62 3.92 39428 587.18
4 2.19 13682 95.42 843689 587.18
Time


















































Openlynx Report - Page 2 
Sample: 13 Vial:3:13 ID:MYH-1-158E
File:MY110112WT013 Date:12-Jan-2011 Description:MDF035193
Printed: Wed Jan 12 15:36:48 2011
Sample Report:
 ID MYH-1-158E File MY110112WT013 Date 12-Jan-2011 Time 3::3::5  Description MDF035193
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 2.28 322 2.47 21359 601.14
2 2.33 32 0.24 2143 601.14
3 2.37 12647 97.08 837081 601.14
4 2.44 27 0.21 1354 601.14
Time










































Openlynx Report - Page 2 
Sample: 14 Vial:3:14 ID:MYH-1-160A
File:MY110112WT014 Date:12-Jan-2011 Description:MDF035144
Printed: Wed Jan 12 15:36:52 2011
Sample Report:
 ID MYH-1-160A File MY110112WT014 Date 12-Jan-2011 Time 3::7::4  Description MDF035144
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 1.84 13 0.13 1033 573.17
2 2.01 133 1.34 9407 573.17
3 2.04 137 1.38 9882 573.17
4 2.08 9641 97.14 646166 573.17
Time








































Openlynx Report - Page 2 
Sample: 15 Vial:3:15 ID:MYH-1-160B
File:MY110112WT015 Date:12-Jan-2011 Description:MDF035261
Printed: Wed Jan 12 15:36:57 201
Sample Report:
 ID MYH-1-160B File MY110112WT015 Date 12-Jan-2011 Time 3::2::7  Description MDF035261
Time
















Peak Number Time AreaAbs Area %Total Height Mass Found
1 2.06 31 0.21 1804
2 2.47 975 6.70 63673 571.19
3 2.56 13541 93.09 852811 571.19
Time


















































Openlynx Report - Page 2 
Sample: 16 Vial:3:16 ID:MYH-1-160C
File:MY110112WT016 Date:12-Jan-2011 Description:MDF035309
Printed: Wed Jan 12 15:37:01 2011
Sample Report:
 ID MYH-1-160C File MY110112WT016 Date 12-Jan-2011 Time 3::7::8  Description MDF035309
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 2.09 22 0.11 1338 595.15
2 2.23 52 0.27 3546 595.15
3 2.28 25 0.13 2008 595.15
4 2.34 62 0.33 4920 595.15
5 2.38 18921 99.16 1207058 595.15
Time











































Openlynx Report - Page 2 
Sample: 17 Vial:3:17 ID:MYH-1-160D
File:MY110112WT017 Date:12-Jan-2011 Description:MDF035263
Printed: Wed Jan 12 15:37:06 2011
Sample Report:
 ID MYH-1-160D File MY110112WT017 Date 12-Jan-2011 Time 3::1::8  Description MDF035263
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 2.10 49 0.44 3687 587.18
2 2.14 34 0.31 2936 587.18
3 2.15 262 2.37 17588 587.18
4 2.20 10715 96.88 682670 587.18
Time









































Openlynx Report - Page 2 
Sample: 18 Vial:3:18 ID:MYH-1-160E
File:MY110112WT018 Date:12-Jan-2011 Description:MDF035136
Printed: Wed Jan 12 15:37:10 2011
Sample Report:
 ID MYH-1-160E File MY110112WT018 Date 12-Jan-2011 Time 3::6::8  Description MDF035136
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 2.28 400 2.52 26119 601.14
2 2.33 41 0.26 2677 601.14
3 2.38 15422 97.22 1000864 601.14
Time




















































Openlynx Report - Page 2 
Sample: 19 Vial:3:19 ID:MYH-1-146D
File:MY110112WT019 Date:12-Jan-2011 Description:MDF035145
Printed: Wed Jan 12 15:37:14 2011
Sample Report:
 ID MYH-1-146D File MY110112WT019 Date 12-Jan-2011 Time 3::1::8  Description MDF035145
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 2.08 125 0.88 8636 587.18
2 2.18 14013 98.64 884185 587.18
3 2.23 69 0.48 4326 587.18
Time













































Openlynx Report - Page 2 
Sample: 7 Vial:2:6 ID:MYH-1-168A
File:MY110909WT006 Date:09-Sep-2011 Description:MDF077914
Printed: Fri Sep 09 14:21:48 2011
Sample Report:
 ID MYH-1-168A File MY110909WT006 Date 09-Sep-2011 Time 10:52:28 Description MDF077914
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 1.99 96 0.59 4876
2 2.03 253 1.55 14548 569.17
3 2.37 15944 97.86 930767 569.17
Time















































Openlynx Report - Page 2 
Sample: 8 Vial:2:7 ID:MYH-1-168B
File:MY110909WT007 Date:09-Sep-2011 Description:MDF077923
Printed: Fri Sep 09 4:21:56 2011
Sample Report:
 ID MYH-1-168B File MY110909WT007 Date 09-Sep-2011 Time 10:57:07 Description MDF077923
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 1.82 25 0.18 1392
2 2.25 64 0.46 4620 601.14
3 2.29 13622 99.36 825264 601.14
Time



















































Openlynx Report - Page 2 
Sample: 9 Vial:2:8 ID:MYH-1-168C
File:MY110909WT008 Date:09-Sep-2011 Description:MDF077909
Printed: Fri Sep 09 14:22:04 2011
Sample Report:
 ID MYH-1-168C File MY110909WT008 Date 09-Sep-2011 Time 11:01:48 Description MDF077909
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 1.90 52 0.37 2861 598.20
2 1.94 53 0.37 2481 598.20
3 1.96 24 0.17 1502 598.20
4 2.04 14182 99.10 882889 598.20
Time














































Openlynx Report - Page 2 
Sample: 10 Vial:2:9 ID:MYH-1-168D
File:MY110909WT009 Date:09-Sep-2011 Description:MDF078118
Printed: Fri Sep 09 14:22:14 2011
Sample Report:
 ID MYH-1-168D File MY110909WT009 Date 09-Sep-2011 Time 11:06:33 Description MDF078118
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 1.90 22 0.15 1224
2 2.39 48 0.34 2655 692.22
3 2.47 14116 99.51 799716 692.22
Time













































Openlynx Report - Page 2 
Sample: 11 Vial:2:10 ID:MYH-1-168E
File:MY110909WT010 Date:09-Sep-2011 Description:MDF078077
Printed: Fri Sep 09 14:22:20 2011
Sample Report:
 ID MYH-1-168E File MY110909WT010 Date 09-Sep-2011 Time 11:11:16 Description MDF078077
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 1.81 58 0.56 3169 573.17
2 1.91 13 0.12 94 573.17
3 1.95 10326 99.19 664632 573.17
4 2.06 13 0.13 1022 573.17
Time




















































Openlynx Report - Page 2 
Sample: 12 Vial:2:11 ID:MYH-1-170A
File:MY110909WT011 Date:09-Sep-2011 Description:MDF077886
Printed: Fri Sep 09 14:22:28 2011
Sample Report:
 ID MYH-1-170A File MY110909WT011 Date 09-Sep-2011 Time 11:16:00 Description MDF077886
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 2.00 80 0.49 4571
2 2.04 241 1.48 14008 569.17
3 2.37 15919 98.02 926310 569.17
Time



















































Openlynx Report - Page 2 
Sample: 13 Vial:2:12 ID:MYH-1-170B
File:MY110909WT012 Date:09-Sep-2011 Description:MDF077924
Printed: Fri Sep 09 14:22:37 2011
Sample Report:
 ID MYH-1-170B File MY110909WT012 Date 09-Sep-2011 Time 11:20:39 Description MDF077924
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 1.82 18 0.11 1285
2 2.26 107 0.67 6775 601.14
3 2.29 15889 99.22 945456 601.14
Time












































Openlynx Report - Page 2 
Sample: 14 Vial:2:13 ID:MYH-1-170C
File:MY110909WT013 Date:09-Sep-2011 Description:MDF078103
Printed: Fri Sep 09 14:22:45 2011
Sample Report:
 ID MYH-1-170C File MY110909WT013 Date 09-Sep-2011 Time 11:25:18 Description MDF078103
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 1.90 47 0.31 2791 598.20
3 2.05 15195 99.69 943373 598.20
Time



















































Openlynx Report - Page 2 
Sample: 15 Vial:2:14 ID:MYH-1-170D
File:MY110909WT014 Date:09-Sep-2011 Description:MDF078107
Printed: Fri Sep 09 14:22:56 2011
Sample Report:
 ID MYH-1-170D File MY110909WT014 Date 09-Sep-2011 Time 11:29:56 Description MDF078107
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 1.90 20 0.13 1265
2 2.48 15729 99.87 896257 692.22
Time















































Openlynx Report - Page 2 
Sample: 16 Vial:2:15 ID:MYH-1-170E
File:MY110909WT015 Date:09-Sep-2011 Description:MDF078110
Printed: Fri Sep 09 14:23:05 2011
Sample Report:
 ID MYH-1-170E File MY110909WT015 Date 09-Sep-2011 Time 11:34:39 Description MDF078110
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 1.81 53 0.35 3222 573.17
3 1.91 77 0.51 5701 573.17
4 1.95 14996 99.14 954682 573.17
Time









































Openlynx Report - Page 2 
Sample: 17 Vial:2:16 ID:MYH-1-172A
File:MY110909WT016 Date:09-Sep-2011 Description:MDF077884
Printed: Fri Sep 09 14:23:12 2011
Sample Report:
 ID MYH-1- 72A File MY110909WT016 Date 09-Sep-2011 Time 11:39:24 Description MDF077884
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 1.83 90 0.56 5111
2 1.87 223 1.40 12828
3 2.23 1 598 98.04 935649 519.17
Time



















































Openlynx Report - Page 2 
Sample: 18 Vial:2:17 ID:MYH-1-172B
File:MY110909WT017 Date:09-Sep-2011 Description:MDF078101
Printed: Fri Sep 09 14:23:19 2011
Sample Report:
 ID MYH-1-172B File MY110909WT017 Date 09-Sep-2011 Time 11:44:03 Description MDF078101
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 1.93 23 0.16 1517 551.15
2 2.08 128 0.90 7483 551.15
3 2.15 14111 98.65 872485 551.15
4 2.18 41 0.29 2598 551.15
Time








































Openlynx Report - Page 2 
Sample: 19 Vial:2:18 ID:MYH-1-172C
File:MY110909WT018 Date:09-Sep-2011 Description:MDF077972
Printed: Fri Sep 09 14:23:25 2011
Sample Report:
 ID MYH-1-172C File MY110909WT018 Date 09-Sep-2011 Time 11:48:43 Description MDF077972
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 1.21 66 0.47 4709
2 1.73 29 0.20 1648 548.20
4 1.88 14167 99.17 887474 548.20
5 1.99 24 0.17 1451 548.20
Time












































Openlynx Report - Page 2 
Sample: 20 Vial:2:19 ID:MYH-1-172D
File:MY110909WT019 Date:09-Sep-2011 Description:MDF077978
Printed: Fri Sep 09 14:23:33 2011
Sample Report:
 ID MYH-1-172D File MY110909WT019 Date 09-Sep-2011 Time 11:53:32 Description MDF077978
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 1.73 19 0.13 1170
2 2.19 39 0.27 2085 642.22
3 2.35 14320 99.60 842186 642.22
Time



















































Openlynx Report - Page 2 
Sample: 21 Vial:2:20 ID:MYH-1-172E
File:MY110909WT020 Date:09-Sep-2011 Description:MDF077950
Printed: Fri Sep 09 14:23:44 2011
Sample Report:
 ID MYH-1-172E File MY110909WT020 Date 09-Sep-2011 Time 11:58:13 Description MDF077950
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 1.01 15 0.14 963
2 1.63 13 0.13 754 523.17
3 1.72 79 0.76 5337 523.17
4 1.78 10283 98.97 651295 523.17
Time








































Openlynx Report - Page 2 
Sample: 22 Vial:2:21 ID:MYH-1-174A
File:MY110909WT021 Date:09-Sep-2011 Description:MDF077919
Printed: Fri Sep 09 14:23:53 2011
Sample Report:
 ID MYH-1-174A File MY110909WT021 Date 09-Sep-2011 Time 12:03:02 Description MDF077919
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 1.78 173 .11 10648 573.17
2 1.99 131 0.84 7993 573.17
3 2.03 15226 97.58 943099 573.17
5 2.23 73 0.47 4394 573.17
Time












































Openlynx Report - Page 2 
Sample: 23 Vial:2:22 ID:MYH-1-174B
File:MY110909WT022 Date:09-Sep-2011 Description:MDF078079
Printed: Fri Sep 09 14:24:00 2011
Sample Report:
 ID MYH-1-174B File MY110909WT022 Date 09-Sep-2011 Time 12:07:47 Description MDF078079
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 2.47 199 .31 12483 571.19
2 2.53 15018 98.69 844503 571.19
Time
















































Openlynx Report - Page 2 
Sample: 24 Vial:2:23 ID:MYH-1-174C
File:MY110909WT023 Date:09-Sep-2011 Description:MDF078004
Printed: Fri Sep 09 14:24:06 2011
Sample Report:
 ID MYH-1-174C File MY110909WT023 Date 09-Sep-2011 Time 12:12:26 Description MDF078004
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 2.14 30 0.17 1821 595.15
2 2.34 17931 99.83 1062637 595.15
Time








































Openlynx Report - Page 2 
Sample: 25 Vial:2:24 ID:MYH-1-174D
File:MY11 909WT024 Date:09-Sep-2011 Description:MDF078081
Printed: Fri Sep 09 14:24:13 2011
Sample Report:
 ID MYH-1-174D File MY110909WT024 Date 09-Sep-2011 Time 12:17:06 Description MDF078081
Time
















Peak Number Time AreaAbs Area %Total Height Mass Found
1 2.10 539 3.76 45962 587.18
2 2.11 1270 8.84 77830 587.18
3 2.15 12551 87.40 755170 587.18
Time
















































Openlynx Report - Page 2 
Sample: 26 Vial:2:25 ID:MYH-1-174E
File:MY110909WT025 Date:09-Sep-2011 Description:MDF078050
Printed: Fri Sep 09 14:24:20 2011
Sample Report:
 ID MYH-1-174E File MY110909WT025 Date 09-Sep-2011 Time 12:21:47 Description MDF078050
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 2.32 24 0.36 2479 601.14
2 2.35 6746 99.64 393256 601.14
Time

















































Openlynx Report - Page 2 
Sample: 27 Vial:2:26 ID:MYH-1-176A
File:MY110909WT026 Date:09-Sep-2011 Description:MDF078080
Printed: Fri Sep 09 14:24:27 2011
Sample Report:
 ID MYH-1-176A File MY110909WT026 Date 09-Sep-2011 Time 13:10:41 Description MDF078080
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
2 1.85 97 0.62 6644 523.17
3 1.88 15405 98.86 950978 523.17
4 2.09 81 0.52 4397 523.17
Time











































Openlynx Report - Page 2 
Sample: 28 Vial:2:27 ID:MYH-1-176B
File:MY110909WT027 Date:09-Sep-2011 Description:MDF078035
Printed: Fri Sep 09 14:24:34 2011
Sample Report:
 ID MYH-1-176B File MY110909WT027 Date 09-Sep-2011 Time 1 :15:24 Description MDF078035
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 2.21 34 0.22 1929 521.19
2 2.41 15659 99.78 912164 521.19
Time








































Openlynx Report - Page 2 
Sample: 29 Vial:2:28 ID:MYH-1-176C
File:MY110909WT028 Date:09-Sep-2011 Description:MDF077898
Printed: Fri Sep 09 14:24:41 2011
Sample Report:
 ID MYH-1-176C File MY110909WT028 Date 09-Sep-2011 Time 13:19:59 Description MDF077898
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 2.01 32 0.18 1630 545.15
2 2.12 72 0.40 4607 545.15
3 2.16 41 0.23 2335 545.15
4 2.22 17885 99.19 1076142 545.15
Time


















































Openlynx Report - Page 2 
Sample: 30 Vial:2:29 ID:MYH-1-176D
File:MY110909WT029 Date:09-Sep-2011 Description:MDF077960
Printed: Fri Sep 09 14:24:49 2011
Sample Report:
 ID MYH-1-176D File MY110909WT029 Date 09-Sep-2011 Time 13:24:39 Description MDF077960
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 1.87 104 0.67 6494 537.18
2 1.91 36 0.23 2232 537.18
3 1.96 27 0.17 1490 537.18
4 2.03 15421 98.93 891411 537.18
Time








































Openlynx Report - Page 2 
Sample: 31 Vial:2:30 ID:MYH-1-176E
File:MY110909WT030 Date:09-Sep-2011 Description:MDF077976
Printed: Fri Sep 09 14:24:56 2011
Sample Report:
 ID MYH-1-176E File MY110909WT030 Date 09-Sep-2011 Time 13:29:19 Description MDF077976
Time
















Peak Number Time AreaAbs Area %Total Height Mass Found
1 2.15 18 0.11 1127 551.15
2 2.19 280 1.72 40082 551.15
3 2.21 15979 98.17 935646 551.15
Time











































Openlynx Report - Page 2 
Sample: 32 Vial:2:31 ID:MYH-1-178A
File:MY110909WT031 Date:09-Sep-2011 Description:MDF078099
Printed: Fri Sep 09 14:25:03 2011
Sample Report:
 ID MYH-1-178A File MY110909WT031 Date 09-Sep-2011 Time 13:33:58 Description MDF078099
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
2 1.84 82 0.52 5781 523.17
3 1.88 15588 99.06 969490 523.17
4 2.08 66 0.42 3954 523.17
Time

















































Openlynx Report - Page 2 
Sample: 33 Vial:2:32 ID:MYH-1-178B
File:MY110909WT032 Date:09-Sep-2011 Description:MDF077947
Printed: Fri Sep 09 14:25:10 2011
Sample Report:
 ID MYH-1-178B File MY110909WT032 Date 09-Sep-2011 Time 13:38:42 Description MDF077947
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 2.40 15728 100.00 922848 521.19
Time



























Openlynx Report - Page 2 
Sample: 34 Vial:2:33 ID:MYH-1-178C
File:MY110909WT033 Date:09-Sep-2011 Description:MDF078037
Printed: Fri Sep 09 14:25:18 2011
Sample Report:
 ID MYH-1-178C File MY110909WT033 Date 09-Sep-2011 Time 13:43:26 Description MDF078037
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 1.87 21 0.11 1282
2 2.00 31 0.17 1790 545.15
3 2.12 52 0.28 3431 545.15
4 2.15 124 0.67 8627 545.15
5 2.21 18208 98.77 1097910 545.15
Time









































Openlynx Report - Page 2 
Sample: 35 Vial:2:34 ID:MYH-1-178D
File:MY110909WT034 Date:09-Sep-2011 Description:MDF078001
Printed: Fri Sep 09 14:25:25 2011
Sample Report:
 ID MYH-1-178D File MY110909WT034 Date 09-Sep-2011 Time 13:48:05 Description MDF078001
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 1.85 174 .09 11028 537.18
2 1.96 178 1.12 11456 537.18
3 2.02 15589 97.68 916408 537.18
4 2.08 18 0.11 1152 537.18
Time
















































Openlynx Report - Page 2 
Sample: 36 Vial:2:35 ID:MYH-1-178E
File:MY110909WT035 Date:09-Sep-2011 Description:MDF078031
Printed: Fri Sep 09 14:25:38 2011
Sample Report:
 ID MYH-1-178E File MY110909WT035 Date 09-Sep-2011 Time 13:52:49 Description MDF078031
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 1.60 44 0.29 2941
2 2.08 27 0.18 1480 551.15
3 2.13 199 1.31 11705 551.15
4 2.21 14956 98.06 895659 551.15
5 2.24 25 0.17 1895 551.15
Time











































Openlynx Report - Page 2 
Sample: 37 Vial:2:36 ID:MYH-1-180A
File:MY110909WT036 Date:09-Sep-2011 Description:MDF077997
Printed: Fri Sep 09 14:25:48 2011
Sample Report:
 ID MYH-1-180A File MY110909WT036 Date 09-Sep-2011 Time 13:57:32 Description MDF077997
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 1.96 102 0.59 7217 539.14
2 2.00 17267 98.90 1067426 539.14
3 2.20 90 0.51 5166 539.14
Time








































Openlynx Report - Page 2 
Sample: 38 Vial:2:37 ID:MYH-1-180B
File:MY110909WT037 Date:09-Sep-2011 Description:MDF077992
Printed: Fri Sep 09 14:26:00 2011
Sample Report:
 ID MYH-1-180B File MY110909WT037 Date 09-Sep-2011 Time 14:02:16 Description MDF077992
Time
















Peak Number Time AreaAbs Area %Total Height Mass Found
1 1.61 80 0.44 4707
2 2.37 515 2.82 30224 537.16
3 2.48 342 1.87 21551 537.16
4 2.51 17320 94.87 970029 537.16
Time


















































Openlynx Report - Page 2 
Sample: 39 Vial:2:38 ID:MYH-1-180C
File:MY110909WT038 Date:09-Sep-2011 Description:MDF077986
Printed: Fri Sep 09 14:26:10 2011
Sample Report:
 ID MYH-1-180C File MY110909WT038 Date 09-Sep-2011 Time 14:06:52 Description MDF077986
Time















Peak Number Time AreaAbs Area %Total Height Mass Found
1 2.11 30 0.16 1891 561.12
2 2.27 38 0.19 2481 561.12
3 2.32 19389 99.65 1145688 561.12
Time










































Openlynx Report - Page 2 
Sample: 40 Vial:2:39 ID:MYH-1-180D
File:MY110909WT039 Date:09-Sep-2011 Description:MDF077993
Printed: Fri Sep 09 14:26:21 2011
Sample Report:
 ID MYH-1-180D File MY110909WT039 Date 09-Sep-2011 Time 14:11:35 Description MDF077993
Time
















Peak Number Time AreaAbs Area %Total Height Mass Found
1 1.61 32 0.19 2050
2 2.04 1044 6.15 62625 553.15
3 2.08 90 0.53 6054 553.15
4 2.13 15814 93.13 920481 553.15
Time










































Openlynx Report - Page 2 
Sample: 41 Vial:2:40 ID:MYH-1-180E
File:MY110909WT040 Date:09-Sep-2011 Description:MDF078033
Printed: Fri Sep 09 14:26:37 201
Sample Report:
 ID MYH-1-180E File MY110909WT040 Date 09-Sep-2011 Time 14:16:11 Description MDF078033
Time
















Peak Number Time AreaAbs Area %Total Height Mass Found
1 1.79 19 0.11 1463
2 2.17 493 2.98 29134 567.12
3 2.32 16001 96.90 936938 567.12
Time
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4.2: Experimental for Chapter 2 
General Procedure A: preparation of 3-component one-pot sequential reaction 
(sulfonylation, aza-Michael, and intramolecular SNAr).  To a vigorously stirred solution 
of amine (0.564 mmol, 1.2 equiv.) and Et3N (0.940 mmol, 2 equiv.) in THF (0.94 mL, 0.5 
M) in a microwave vial was added benzenesulfonyl chloride (0.470 mmol, 1 equiv.) at room 
temperature dropwise, and the reaction was stirred for 1.5 hours.  Upon disappearance of 
sulfonyl chloride, o-siloxy benzyl acetate (0.940 mmol, 2 equiv.) and TBAF (1.410 mmol, 3 
equiv.) were added to the reaction mixture.  The vial was quickly sealed and stirred for 40 
minutes under microwave irradiation at 100 °C.  Upon completion of the reaction, the 
reaction was quenched with water and EtOAc, organic layer was separated and the aqueous 
layer was extracted with EtOAc (3x).  The combined organic layers were dried (Na2SO4), 
concentrated under reduced pressure, subject to column chromatography to afford the 
product. 
 
General Procedure B: preparation of 4-component one-pot sequential reaction 
(sulfonylation, aza-Michael, intramolecular SNAr, and intermolecular SNAr).  To a 
vigorously stirred solution of amine (0.564 mmol, 1.2 equiv.) and Et3N (0.940 mmol, 2 
equiv.) in THF (0.94 mL, 0.5 M) in a microwave vial was added benzenesulfonyl chloride 
(0.100 g, 0.470 mmol) at room temperature dropwise, and the reaction was stirred for 1.5 
hours.  Upon disappearance of sulfonyl chloride, o-siloxy benzyl acetate (0.264 g, 0.940 
mmol) and TBAF (1.410 mmol, 1.41 mL) were added to the reaction mixture.  The vial was 
quickly sealed and stirred for 40 minutes under microwave irradiation at 100 °C.  Then the 
 211 
second amine (2.350 mmol, 5 equiv.) was added to the reaction mixture.  The vial was 
quickly sealed and stirred for 1 hour under microwave irradiation at 100 °C.  Upon 
completion of the reaction, the reaction was quenched with water and EtOAc, organic layer 
was separated and the aqueous layer was extracted with EtOAc (3x).  The combined organic 
layers were dried (Na2SO4), concentrated under reduced pressure, subject to column 
chromatography to afford the product. 
 
General Procedure C: preparation of 5-component one-pot sequential reaction 
(sulfonylation, aza-Michael, intramolecular SNAr, intermolecular SNAr, and Click).  To 
a vigorously stirred solution of propargyl amine (0.564 mmol, 1.2 equiv.) and Et3N (0.940 
mmol, 2 equiv.) in THF (0.94 mL, 0.5 M) in a microwave vial was added benzenesulfonyl 
chloride (0.100 g, 0.470 mmol) at room temperature dropwise, and the reaction was stirred 
for 1.5 hours.  Upon disappearance of sulfonyl chloride, o-siloxy benzyl acetate (0.264 g, 
0.940 mmol) and TBAF (1.410 mmol, 1.41 mL) were added to the reaction mixture.  The 
vial was quickly sealed and stirred for 40 minutes under microwave irradiation at 100 °C.  
Then the second amine (2.350 mmol, 5 equiv.), azide (0.940 mmol, 2 equiv.), CuI (0.141 
mmol, 0.3 equiv.), and DBU (0.047 mmol, 0.1 equiv.) were added to the reaction mixture.  
The vial was quickly sealed and stirred for 1 hour under microwave irradiation at 100 °C.  
Upon completion of the reaction, the reaction was quenched with water and EtOAc, organic 
layer was separated and the aqueous layer was extracted with EtOAc (3x).  The combined 
organic layers were dried (Na2SO4), concentrated under reduced pressure, subject to column 





According to general procedure A, 2.28.6 (148 mg, 99%) was isolated as a yellow solid. 
mp 133–136 °C; 
FTIR (thin film): 3288, 3095, 2931, 2118, 1916, 1592, 1584, 1489, 1476, 1456, 1418, 
1341, 1326, 1269, 1156, 1077, 977, 884, 768, 666 cm-1; 
1H NMR (500 MHz, CDCl3) δ 7.66 (d, J = 8.50 Hz, 1H), 7.46 (d, J = 7.24 Hz, 1H), 7.35 
(m, 2H), 7.16 (m, 1H), 6.63 (d, J = 3.15 Hz, 1H), 6.30 (dd, J = 6.59, 2.22 Hz, 1H), 5.58 (d, J 
= 15.19 Hz, 1H), 4.19 (d, J = 15.19 Hz, 1H), 4.00 (d, J = 17.84 Hz, 1H), 2.98 (dd, J = 14.73, 
2.32 Hz, 1H), 2.24 (t, J = 2.41 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ 159.43, 156.99, 152.20, 131.83, 131.66 (d, JC-F = 21.22 
Hz), 130.24, 129.55, 125.36, 122.40, 118.12, 107.47, 105.93, 47.81, 47.74, 35.29, 25.45; 














mp 112–114 °C; 
FTIR (thin film): 3270, 3130, 2930, 2871, 1591, 1474, 1413, 1334, 1271, 1181, 1158, 
1069, 975, 763, 716, 658 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.93 (dd, J = 8.8, 6.3 Hz, 1H), 7.47 (dd, J = 8.2, 1.2 
Hz, 1H), 7.41 (td, J = 8.2, 7.7, 2.0 Hz, 1H), 7.31 (dd, J = 9.1, 2.4 Hz, 1H), 6.98 (ddd, J = 
8.8, 7.8, 2.5 Hz, 1H), 5.57 (d, J = 15.3 Hz, 1H), 3.95 (d, J = 15.3 Hz, 1H), 2.96 (dtd, J = 
13.9, 8.1, 7.4, 1.5 Hz, 1H), 2.25 (ddd, J = 13.6, 8.3, 4.8 Hz, 1H), 1.65 – 1.45 (m, 3H), 1.41 – 
1.15 (m, 2H), 0.89 (t, J = 7.4 Hz, 3H). 
13C NMR (126 MHz, Chloroform-d) δ 165.59 (d, 1JC-F = 256.0 Hz), 158.98, 156.85 (d, 2JC-
F = 11.1 Hz), 132.29 (d, 3JC-F = 10.4 Hz), 131.49, 130.78 (d, 4JC-F = 3.7 Hz), 130.61, 130.32, 
112.55 (d, 5JC-F = 21.7 Hz), 112.25 (d, 6JC-F = 23.7 Hz), 77.16, 47.58, 44.66, 29.75, 19.77, 
13.83. 





According to general procedure A, 2.28.8 (82 mg, 47%) was isolated as a white solid. 






FTIR (thin film): 3100, 3032, 2933, 1957, 1588, 1471, 1452, 1338, 1272, 1211, 1163, 
1143, 1066, 971, 885, 770, 752, 661 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 8.00 (dd, J = 8.8, 6.3 Hz, 1H), 7.52 (dd, J = 8.1, 1.1 
Hz, 1H), 7.47 – 7.42 (m, 1H), 7.41 – 7.31 (m, 6H), 7.21 (td, J = 7.4, 1.2 Hz, 1H), 7.07 – 
6.99 (m, 2H), 5.51 (dd, J = 15.3, 1.6 Hz, 1H), 4.46 (d, J = 14.7 Hz, 1H), 3.72 (d, J = 15.4 
Hz, 1H), 3.19 (d, J = 14.8 Hz, 1H). 
13C NMR (126 MHz, Chloroform-d) δ 165.60 (d, 1JC-F = 256.4 Hz), 159.00, 156.86 (d, 2JC-
F = 11.2 Hz), 135.00, 132.07 (d, 3JC-F = 10.4 Hz), 131.73, 130.69 (d, 4JC-F = 3.8 Hz), 130.58, 
129.84, 128.77, 128.40, 128.10, 125.85, 122.21, 112.58 (d, 5JC-F = 21.8 Hz), 112.20 (d, 6JC-F 
= 23.8 Hz), 48.57, 46.81. 





According to general procedure A, 2.28.9 (11 mg, 15%) was isolated as a white solid. 
mp 165–167 °C; 
FTIR (thin film): 3502, 3114, 3081, 2977, 2871, 1925, 1591, 1582, 1473, 1406, 1315, 






1H NMR (500 MHz, Chloroform-d) δ 7.93 (dd, J = 8.7, 6.3 Hz, 1H), 7.49 (dd, J = 8.2, 1.1 
Hz, 1H), 7.42 (td, J = 8.2, 7.7, 1.9 Hz, 1H), 7.34 (dd, J = 9.0, 2.4 Hz, 1H), 7.27 – 7.24 (m, 
2H), 7.21 (td, J = 7.4, 1.2 Hz, 1H), 7.00 (ddd, J = 8.8, 7.8, 2.4 Hz, 1H), 5.62 (d, J = 16.2 Hz, 
1H), 4.07 (d, J = 15.3 Hz, 1H), 3.85 – 3.71 (m, 2H), 2.96 (dddd, J = 15.0, 7.0, 4.1, 1.6 Hz, 
1H), 2.61 (ddd, J = 15.1, 5.6, 3.8 Hz, 1H), 2.18 (dd, J = 6.7, 4.2 Hz, 1H). 
13C NMR (126 MHz, Chloroform-d) δ 165.81 (d, 1JC-F = 256.8 Hz), 159.04, 157.05 (d, 2JC-
F = 11.2 Hz), 132.37 (d, 3JC-F = 10.4 Hz), 132.00, 130.83, 130.12 (d, 4JC-F = 3.7 Hz), 130.07, 
126.15, 122.37, 112.64 (d, 5JC-F = 21.8 Hz), 112.43 (d, 6JC-F = 23.8 Hz), 60.97, 49.35, 47.23. 





According to general procedure A, 2.28.10 (120 mg, 80%) was isolated as yellow solid. 
mp 180–183 °C; 
FTIR (thin film): 3081, 3024, 2988, 2950, 1934, 1586, 1471, 1412, 1336, 1275, 1212, 
1159, 1091, 974, 888, 840, 827, 759, 701, 659 cm-1; 
1H NMR (400 MHz, Chloroform-d) δ 8.00 (dd, J = 8.7, 6.3 Hz, 1H), 7.47 (d, J = 8.1 Hz, 





Hz, 1H), 5.57 (d, J = 14.8 Hz, 1H), 3.94 (d, J = 14.8 Hz, 1H), 1.37 – 1.23 (m, 2H), 0.72 – 
0.62 (m, 2H), 0.46 (tt, J = 7.1, 3.9 Hz, 1H). 
13C NMR (101 MHz, Chloroform-d) δ 165.86 (d, J = 256.5 Hz), 158.95, 157.03 (d, J = 
11.1 Hz), 133.11 (d, J = 10.4 Hz), 132.03, 130.52, 130.26, 129.80 (d, J = 3.7 Hz), 126.12, 
122.03, 112.77 (d, J = 21.7 Hz), 112.27 (d, J = 23.6 Hz), 51.12, 27.92, 10.33, 5.38. 





According to general procedure A, 2.28.11 (15 mg, 9%) was isolated as clear/yellow solid. 
mp 180–182 °C; 
FTIR (thin film): 3103, 2987, 1746, 1591, 1583, 1474, 1413, 1336, 1206, 1147, 1082, 975, 
938, 770, 745, 660 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.92 (dd, J = 8.8, 6.3 Hz, 1H), 7.49 (dd, J = 8.2, 0.8 
Hz, 1H), 7.45 – 7.40 (m, 1H), 7.34 (dd, J = 9.0, 2.4 Hz, 1H), 7.22 – 7.19 (m, 2H), 7.00 (ddd, 
J = 8.8, 7.7, 2.4 Hz, 1H), 5.71 (dd, J = 15.4, 1.5 Hz, 1H), 4.14 – 3.98 (m, 3H), 3.75 (dd, J = 







13C NMR (126 MHz, Chloroform-d) δ 168.22, 165.59 (d, J = 256.6 Hz), 158.77, 156.60 
(d, J = 11.2 Hz), 131.63 (d, J = 10.4 Hz), 131.11, 131.07 (d, J = 3.7 Hz), 130.75, 129.83, 
125.97, 121.99, 112.46 (d, J = 22.1 Hz), 112.28 (d, J = 24.1 Hz), 61.48, 49.30, 47.06, 13.99. 






According to general procedure A, 2.28.12 (17 mg, 11%) was isolated as yellow oil. 
FTIR (thin film): 3526, 3086, 2939, 1600, 1575, 1490, 1456, 1340, 1229, 1156, 1107, 
1000, 890, 808, 787, 742, 706, 652 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.58 – 7.50 (m, 2H), 7.47 (dt, J = 8.2, 1.1 Hz, 1H), 
7.42 (td, J = 7.8, 1.9 Hz, 1H), 7.29 – 7.26 (m, 1H), 7.21 (td, J = 7.4, 1.2 Hz, 1H), 7.05 (ddd, 
J = 9.7, 8.4, 1.2 Hz, 1H), 5.62 (d, J = 15.3 Hz, 1H), 4.09 (d, J = 15.3 Hz, 1H), 3.88 – 3.77 
(m, 2H), 3.12 (dddd, J = 15.1, 6.4, 4.4, 1.6 Hz, 1H), 2.67 (ddd, J = 15.0, 5.6, 4.1 Hz, 1H), 
2.21 (s, 1H). 
13C NMR (126 MHz, Chloroform-d) δ 160.12 (d, 1JC-F= 262.8 Hz), 158.85, 156.78, 134.36 
(d, 2JC-F = 10.8 Hz), 131.31 , 130.47 , 130.13 , 125.80 , 122.51 (d, 3JC-F = 11.7 Hz), 121.93 , 












According to general procedure A, 2.28.13 (276 mg, 99%) was isolated as white solid. 
mp 139–142 °C; 
FTIR (thin film): 3092, 3089, 2354, 2334, 2123, 1569, 1452, 1390, 1352, 1344, 1164 cm-1 
1H NMR (500 MHz, CDCl3) δ 7.78 (dd, J = 5.1, 6.9 Hz, 2H), 7.48 (d, J = 7.0 Hz, 1H), 
7.44 (ddt, J = 2.1, 4.2, 8.3 Hz, 2H), 7.36 (dd, J = 1.6, 7.4 Hz, 1H), 7.23 (td, J = 1.2, 7.4 Hz, 
1H), 5.60 (d, J = 15.4 Hz, 1H), 4.20 (d, J = 15.3 Hz, 1H), 3.98 (ddd, J = 1.3, 2.5, 17.3 Hz, 
1H), 3.26 (dd, J = 2.5, 17.3 Hz, 1H), 2.15 (t, J = 2. Hz, 5, 1H);  
13C NMR (126 MHz, CDCl3) δ 158.9, 155.6, 133.1, 131.6, 131.3, 130.8, 129.3, 128.7, 
128.1, 127.6, 126.0, 121.8, 76.2, 73.9, 48.1, 35.8;  









dioxide (2.29.6)  
 
According to general procedure B, 2.29.6 (115.6 mg, 67%) was isolated as yellow solid. 
mp 203–205 °C; 
FTIR (thin film): 3304, 2926, 2871, 1595, 1541, 1512, 1483, 1438, 1393, 1326, 1251, 
1218, 1182, 1139, 1076, 1037, 955, 905, 830, 756, 737, 666 cm-1; 
1H NMR (400 MHz, DMSO-d6) δ 7.84 (d, J = 8.1 Hz, 1H), 7.48 (d, J = 8.9 Hz, 1H), 7.43 
(td, J = 7.8, 1.8 Hz, 1H), 7.37 (dd, J = 7.5, 1.8 Hz, 1H), 7.25 – 7.20 (m, 1H), 6.93 (d, J = 2.3 
Hz, 1H), 6.39 (dd, J = 8.9, 2.3 Hz, 1H), 5.30 (d, J = 15.1 Hz, 1H), 4.12 (d, J = 15.1 Hz, 1H), 
3.86 (dd, J = 17.5, 1.5 Hz, 1H), 3.33 (q, J = 5.9, 5.5 Hz, 4H), 3.19 (t, J = 2.5 Hz, 1H), 2.96 
(dd, J = 17.5, 2.4 Hz, 1H), 2.01 – 1.92 (m, 4H). 
13C NMR (126 MHz, Chloroform-d) δ 159.43, 156.99, 152.20, 131.83, 131.66, 130.24, 
129.54, 125.36, 122.40, 120.14, 118.11, 116.09, 107.47, 105.93, 73.53, 47.81, 35.29, 25.45. 











According to general procedure B, 2.29.7 (174 mg, 96%) was isolated as yellow solid. 
mp 208–210 °C; 
FTIR (thin film): 3210, 3025, 2941, 1595, 1487, 1453, 1333, 1269, 1218, 1169, 1117, 
1082, 1033, 908, 756 cm-1; 
1H NMR (500 MHz, CDCl3) δ 7.75 (d, J = 9.00 Hz, 1H), 7.46 (d, J = 8.32 Hz, 1H), 7.40 
(m, 2H), 7.21 (t, J = 7.71 Hz, 1H), 7.01 (d, J = 2.47 Hz, 1H), 6.68 (dd, J = 8.63, 2.47 Hz, 
1H), 4.22 (d, J = 14.55 Hz, 1H), 4.03 (d, J = 16.98 Hz, 1H), 3.89 (t, J = 5.25 Hz, 4H), 3.33 
(t, J = 4.85 Hz, 4H), 3.08 (dd, J = 16.98, 2.83 Hz, 1H), 2.25 (t, J = 2.53 Hz, 1H);  
13C NMR (126 MHz, CDCl3) δ 159.30, 156.84, 155.73, 131.87, 131.54, 130.41, 129.52, 
125.58, 122.19, 110.05, 109.05, 77.27, 77.22, 77.02, 76.95, 76.77, 73.68, 66.43, 47.79, 
47.58, 35.43; 









dihydrodibenzo[b,g][1,4,5]oxathiazocine 5,5-dioxide (2.29.8) 
 
According to general procedure B, 2.29.8 (25 mg, 28%) was isolated as white/yellow solid. 
mp 148–150 °C; 
FTIR (thin film): 3491, 3292, 3260, 2912, 2863, 2131, 1597, 1584, 1435, 1312, 1229, 
1182, 1142, 1062, 946, 989, 842, 780, 755, 720 cm-1; 
1H NMR (400 MHz, DMSO-d6) δ 7.82 (dd, J = 8.2, 1.1 Hz, 1H), 7.48 – 7.41 (m, 2H), 7.37 
(dd, J = 7.5, 1.8 Hz, 1H), 7.27 – 7.20 (m, 1H), 7.09 (d, J = 2.5 Hz, 1H), 6.55 (dd, J = 9.0, 2.5 
Hz, 1H), 5.31 (d, J = 15.0 Hz, 1H), 4.76 (s, 1H), 4.12 (d, J = 15.1 Hz, 1H), 3.87 (ddd, J = 
17.4, 2.6, 1.2 Hz, 1H), 3.60 – 3.55 (m, 2H), 3.53 – 3.48 (m, 2H), 3.20 (t, J = 2.5 Hz, 1H), 
3.04 (s, 3H), 2.96 (dd, J = 17.4, 2.4 Hz, 1H). 
13C NMR (101 MHz, DMSO) δ 158.88, 156.41, 154.10, 131.56, 130.58, 128.88, 125.40, 
122.80, 117.49, 107.26, 106.20, 77.31, 76.05, 58.12, 53.94, 47.27, 40.43, 38.98, 34.93. 












According to general procedure B, 2.29.9 (61 mg, 64%) was isolated as yellow oil. 
FTIR (thin film): 2959, 2925, 2865, 1595, 1487, 1450, 1431, 1324, 1249, 1189, 1123, 
1037, 977, 915, 896, 762, 716, 653 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.77 (d, J = 8.8 Hz, 1H), 7.48 (dd, J = 8.2, 1.1 Hz, 
1H), 7.40 (td, J = 7.7, 1.9 Hz, 1H), 7.24 (dd, J = 7.5, 1.9 Hz, 1H), 7.19 (td, J = 7.3, 1.1 Hz, 
1H), 7.02 (d, J = 2.5 Hz, 1H), 6.68 (dd, J = 8.9, 2.5 Hz, 1H), 5.60 (d, J = 15.3 Hz, 1H), 3.94 
(d, J = 15.3 Hz, 1H), 3.91 – 3.87 (m, 4H), 3.34 – 3.30 (m, 4H), 2.99 (dtd, J = 14.1, 8.1, 7.3, 
1.4 Hz, 1H), 2.22 (ddd, J = 13.5, 8.3, 4.8 Hz, 1H), 1.66 – 1.50 (m, 2H), 1.42 – 1.21 (m, 2H), 
0.91 (t, J = 7.4 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 159.37, 156.86, 155.57, 131.73, 131.54, 130.59, 130.29, 
125.56, 123.44, 122.64, 110.14, 109.26, 66.62, 47.83, 47.61, 44.42, 29.79, 19.83, 13.87. 











According to general procedure B, 2.29.10 (62.0 mg, 68%) was isolated as yellow/brown 
oil. 
FTIR (thin film): 2960, 2921, 2869, 1592, 1487, 1433, 1320, 1251, 1190, 1121, 1036, 977, 
914, 895, 762, 716, 653 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.68 (d, J = 8.8 Hz, 1H), 7.48 (dd, J = 8.2, 1.1 Hz, 
1H), 7.35 (td, J = 7.8, 1.9 Hz, 1H), 7.20 (dd, J = 7.4, 1.9 Hz, 1H), 7.14 (td, J = 7.4, 1.1 Hz, 
1H), 6.64 (d, J = 2.3 Hz, 1H), 5.58 (d, J = 15.4 Hz, 1H), 3.91 (d, J = 15.3 Hz, 1H), 3.36 (dp, 
J = 9.2, 2.7 Hz, 4H), 2.96 (dddd, J = 13.7, 8.7, 7.3, 1.4 Hz, 1H), 2.17 (ddd, J = 13.5, 8.3, 4.8 
Hz, 1H), 2.07 – 2.03 (m, 6H), 1.64 – 1.43 (m, 3H), 1.39 – 1.13 (m, 2H), 0.88 (t, J = 7.4 Hz, 
3H). 
13C NMR (126 MHz, Chloroform-d) δ 159.49, 157.02, 152.04, 131.85, 131.45, 130.67, 
130.13, 125.33, 122.84, 119.06, 107.43, 106.00, 47.92, 47.67, 44.31, 29.80, 25.60, 19.86, 
13.90. 










According to general procedure B, 2.29.11 (34 mg, 39%) was isolated as yellow/brown oil. 
FTIR (thin film): 3395, 3284, 2958, 1602, 1567, 1458, 1335, 1313, 1227, 1179, 1110, 
1070, 1042, 902, 800, 770, 729, 673 cm-1; 
1H NMR (400 MHz, DMSO-d6) δ 7.73 (d, J = 8.2 Hz, 1H), 7.42 (td, J = 7.8, 1.7 Hz, 1H), 
7.39 – 7.30 (m, 2H), 7.25 – 7.19 (m, 1H), 7.13 (t, J = 5.3 Hz, 1H), 7.04 (d, J = 7.9 Hz, 1H), 
6.61 (d, J = 8.7 Hz, 1H), 5.27 (d, J = 15.2 Hz, 1H), 4.13 (d, J = 15.2 Hz, 1H), 3.90 – 3.82 
(m, 1H), 3.21 – 3.14 (m, 1H), 3.14 – 3.11 (m, 1H), 2.95 (t, J = 6.0 Hz, 2H), 1.86 (dp, J = 
13.2, 6.5 Hz, 1H), 0.93 (d, J = 6.7 Hz, 6H). 
13C NMR (101 MHz, DMSO) δ 159.05, 157.45, 148.94, 135.15, 131.17, 130.79, 129.59, 
125.74, 122.38, 113.84, 109.90, 109.74, 77.27, 76.54, 50.75, 48.40, 40.93, 35.82, 27.60, 
20.56. 








dihydrodibenzo[b,g][1,4,5]oxathiazocine 5,5-dioxide (2.29.12) 
 
According to general procedure B, 2.29.12 (24 mg, 27%) was isolated as brown oil. 
FTIR (thin film): 3480, 2923, 2854, 1720, 1595, 1556, 1486, 1423, 1323, 1219, 1165, 
1144, 1114, 1040, 1019, 977, 909, 765, 757, 731, 711, 655 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.57 (d, J = 9.0 Hz, 1H), 7.40 (dd, J = 8.1, 1.2 Hz, 
1H), 7.33 – 7.26 (m, 2H), 7.10 (td, J = 7.5, 1.2 Hz, 1H), 6.82 (d, J = 2.5 Hz, 1H), 6.42 (dd, J 
= 9.0, 2.5 Hz, 1H), 5.49 (d, J = 15.3 Hz, 1H), 4.12 (d, J = 15.1 Hz, 1H), 3.93 (ddd, J = 17.0, 
2.6, 1.3 Hz, 1H), 3.78 (t, J = 5.7 Hz, 2H), 3.51 (t, J = 5.7 Hz, 2H), 3.19 (s, 1H), 3.02 (s, 3H), 
2.92 (dd, J = 17.0, 2.5 Hz, 1H), 2.19 (t, J = 2.5 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 159.48, 157.08, 154.42, 131.94, 131.64, 130.49, 129.49, 
125.55, 122.49, 119.10, 107.63, 106.62, 73.76, 60.00, 54.70, 47.80, 41.03, 39.26, 35.42. 









dihydrodibenzo[b,g][1,4,5]oxathiazocine 5,5-dioxide (2.30.6) 
 
According to general procedure C, 2.30.6 (258 mg, 96%) was isolated as a yellow solid. 
mp 202–203 °C; 
FTIR (thin film): 3144, 2922, 2851, 1598, 1584, 1548, 1486, 1453, 1386, 1251, 1217, 
1142, 1041, 913, 834, 759, 714, 690 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.70 (s, 1H), 7.66 (dd, J = 8.4, 4.9 Hz, 3H), 7.49 (d, 
J = 8.0 Hz, 1H), 7.43 – 7.32 (m, 4H), 7.19 (td, J = 7.5, 1.2 Hz, 1H), 6.68 (d, J = 2.4 Hz, 1H), 
6.30 (dd, J = 8.8, 2.3 Hz, 1H), 5.71 – 5.41 (m, 3H), 4.18 (dd, J = 15.9, 1.6 Hz, 1H), 3.84 (d, 
J = 15.2 Hz, 1H), 3.61 (d, J = 15.8 Hz, 1H), 3.37 (dq, J = 6.9, 3.5 Hz, 4H), 2.06 (td, J = 6.3, 
3.0 Hz, 4H). 
13C NMR (126 MHz, Chloroform-d) δ 159.53, 157.27, 152.30, 145.67, 138.51, 132.45, 
131.46, 131.24 (d, J = 32.6 Hz), 130.34, 130.12, 128.52, 126.33 (q, J = 3.7 Hz), 125.64, 
123.93 (d, J = 272.6 Hz), 123.52, 122.65, 118.70, 107.46, 106.26, 53.78, 47.97, 47.90, 
40.29, 25.60. 











dihydrodibenzo[b,g][1,4,5]oxathiazocine 5,5-dioxide (2.30.7) 
 
According to general procedure C, 2.30.7 (36 mg, 27%) was isolated as yellow/brown oil. 
FTIR (thin film): 2915, 1594, 1582, 1486, 1329, 1217, 1183, 1141, 1045, 1016, 945, 909, 
777, 756, 729, 702 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.72 (d, J = 8.9 Hz, 1H), 7.64 (s, 1H), 7.46 (dd, J = 
8.1, 1.3 Hz, 1H), 7.42 – 7.35 (m, 4H), 7.26 – 7.24 (m, 2H), 7.22 (td, J = 7.4, 1.2 Hz, 1H), 
6.98 (d, J = 2.4 Hz, 1H), 6.62 (dd, J = 8.9, 2.5 Hz, 1H), 5.57 – 5.43 (m, 3H), 4.25 – 4.17 (m, 
1H), 3.87 (d, J = 15.2 Hz, 1H), 3.81 – 3.77 (m, 4H), 3.64 (d, J = 15.7 Hz, 1H), 2.78 – 2.71 
(m, 4H). 
13C NMR (126 MHz, CDCl3) δ 159.29, 157.23, 154.44, 145.04, 134.95, 132.88, 132.46, 
131.44, 130.32, 129.95, 129.57, 129.42, 125.69, 123.12, 122.21, 122.01, 110.38, 109.70, 
53.60, 50.62, 47.59, 40.26, 25.87. 












dihydrodibenzo[b,g][1,4,5]oxathiazocine 5,5-dioxide (2.30.8) 
 
According to general procedure C, 2.30.8 (42 mg, 30%) was isolated as yellow solid. 
mp 166–168 °C; 
FTIR (thin film): 2919, 2851, 1592, 1470, 1454, 1414, 1334, 1265, 1108, 1068, 975, 889, 
828, 789, 760, 703, 660 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.74 (d, J = 8.9 Hz, 1H), 7.70 (s, 1H), 7.67 (d, J = 
8.1 Hz, 2H), 7.48 (d, J = 8.0 Hz, 1H), 7.44 – 7.36 (m, 4H), 7.24 – 7.19 (m, 1H), 7.04 (d, J = 
2.3 Hz, 1H), 6.67 (dd, J = 9.0, 2.4 Hz, 1H), 5.67 – 5.53 (m, 2H), 5.49 (d, J = 15.2 Hz, 1H), 
4.20 (d, J = 15.8 Hz, 1H), 3.89 (d, J = 4.3 Hz, 4H), 3.87 (d, J = 6.5 Hz, 1H), 3.64 (d, J = 
15.8 Hz, 1H), 3.34 – 3.30 (m, 4H). 
13C NMR (126 MHz, Chloroform-d) δ 159.28, 156.98, 155.69, 145.21, 138.33, 132.40, 
131.18, 131.12 (q, J = 32.8 Hz), 130.37, 129.89, 128.39, 126.20 (q, J = 3.7 Hz), 125.71, 
123.77 (q, J = 271.8 Hz), 123.37, 122.87, 122.30, 109.92, 109.26, 66.44, 53.66, 47.66, 
47.59, 40.20. 












dihydrodibenzo[b,g][1,4,5]oxathiazocine 5,5-dioxide (2.30.9) 
 
According to general procedure C, 2.30.9 (46 mg, 35%) was isolated as yellow solid. 
mp 150–152 °C; 
FTIR (thin film): 3315, 3223, 3142, 2958, 2920, 2852, 1596, 1556, 1487, 1450, 1329, 
1248, 1218, 1189, 1149, 1124, 1080, 1034, 978, 911, 845, 782, 768, 733, 656 cm-1; 
1H NMR (400 MHz, DMSO-d6) δ 8.05 (s, 1H), 7.95 (d, J = 8.2 Hz, 1H), 7.60 (d, J = 8.9 
Hz, 1H), 7.50 – 7.43 (m, 4H), 7.38 – 7.33 (m, 2H), 7.28 (dd, J = 7.5, 2.0 Hz, 1H), 7.23 (t, J 
= 7.3 Hz, 1H), 6.83 (dd, J = 9.0, 2.4 Hz, 1H), 5.60 (s, 2H), 5.27 (d, J = 15.2 Hz, 1H), 4.15 
(d, J = 15.4 Hz, 1H), 3.93 (d, J = 15.1 Hz, 1H), 3.80 – 3.71 (m, 4H), 3.38 – 3.35 (m, 4H), 
3.33 (d, J = 3.4 Hz, 1H). 
13C NMR (101 MHz, DMSO) δ 158.94, 156.36, 155.58, 142.78, 134.93, 132.84, 131.94, 
130.54, 129.91, 129.21, 128.73, 125.43, 123.89, 123.06, 121.20, 109.40, 108.99, 65.76, 
51.99, 46.97, 46.83, 40.43. 












dihydrodibenzo[b,g][1,4,5]oxathiazocine 5,5-dioxide (2.30.10) 
 
According to general procedure C, 2.30.10 (45 mg, 34%) was isolated as yellow/brown oil. 
FTIR (thin film): 3395, 2960, 1602, 1569, 1460, 1323, 1228, 1161, 1112, 1066, 1044, 
1018, 910, 792, 771, 710, 674 cm-1; 
1H NMR (400 MHz, DMSO-d6) δ 7.99 (s, 1H), 7.76 (t, J = 6.2 Hz, 3H), 7.50 (d, J = 8.0 Hz, 
2H), 7.44 – 7.34 (m, 2H), 7.29 – 7.25 (m, 1H), 7.20 (t, J = 7.3 Hz, 2H), 7.07 (d, J = 7.8 Hz, 
1H), 6.62 (d, J = 8.7 Hz, 1H), 5.70 (s, 2H), 5.23 (d, J = 15.2 Hz, 1H), 4.16 (d, J = 15.5 Hz, 
1H), 3.93 (d, J = 15.3 Hz, 1H), 3.47 (d, J = 15.4 Hz, 1H), 2.95 (t, J = 5.7 Hz, 2H), 1.85 (dp, 
J = 13.5, 7.4, 6.8 Hz, 1H), 0.92 (d, J = 6.6 Hz, 6H). 
13C NMR (126 MHz, Chloroform-d) δ 159.10, 157.70, 149.07, 144.84, 138.40, 134.23, 
131.17, 131.07 (q, J = 32.40 Hz), 130.07, 129.80, 128.36, 126.13 (q, J = 3.7 Hz), 125.28, 
123.78 (q, J = 272.3 Hz), 123.24, 121.90, 114.06, 109.11, 109.08, 53.58, 51.24, 48.12, 
40.91, 27.69, 20.46. 











dihydrodibenzo[b,g][1,4,5]oxathiazocine 5,5-dioxide (2.30.11) 
 
According to general procedure C, 2.30.11 (34 mg, 27%) was isolated as red/brown oil. 
FTIR (thin film): 3387, 2949, 1593, 1543, 1490, 1474, 1455, 1352, 1326, 1230, 1182, 
1109, 1041, 1017, 912, 874, 795, 771, 725, 677 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.54 – 7.49 (m, 2H), 7.41 (td, J = 7.7, 1.7 Hz, 1H), 
7.35 – 7.32 (m, 2H), 7.28 (dd, J = 7.4, 1.7 Hz, 1H), 7.22 – 7.17 (m, 3H), 7.16 – 7.12 (m, 
1H), 6.78 (dd, J = 8.0, 0.9 Hz, 1H), 6.59 (dd, J = 8.7, 1.0 Hz, 1H), 5.50 – 5.31 (m, 3H), 3.92 
(dd, J = 16.0, 1.7 Hz, 1H), 3.82 (d, J = 15.5 Hz, 1H), 3.70 (q, J = 10.0, 9.5 Hz, 2H), 3.47 (d, 
J = 15.9 Hz, 1H), 3.34 (dd, J = 10.1, 6.7 Hz, 2H), 2.04 (t, J = 5.6 Hz, 2H), 1.84 (dd, J = 
10.7, 7.3 Hz, 2H). 
13C NMR (126 MHz, CDCl3) δ 157.92, 157.43, 152.12, 145.07, 134.90, 133.10, 132.02, 
130.77, 130.42, 129.64, 129.60, 129.41, 125.84, 123.19, 122.97, 115.39, 110.68, 106.01, 
53.55, 53.11, 48.33, 40.75, 25.96. 





























































































































































































































































































4.3: Experimental for Chapter 3 
General Procedure A: preparation of secondary sulfonamide by mesylation of amino 
esters.  A solution of amino ester (4.23 mmol, 1 equiv.) and Et3N (10.76 mmol, 2.5 equiv.) 
in CH2Cl2 (50 mL, 0.1 M) was cooled to 0 °C.  Then methanesulfonyl chloride (6.33 mmol, 
1.5 equiv.) was slowly added to the mixture at 0 °C and stirred for 10 minutes, and warmed 
to room temperature and stirred for 2 hours.  Upon completion of the reaction, the mixture 
was quenched with water and CH2Cl2, organic layer was separated, and aqueous layer was 
extracted with CH2Cl2 (x3).  The combined organic layers were dried (Na2SO4), 
concentrated under reduced pressure, subject to automated column chromatography to 
afford the product. 
 
General Procedure B: synthesis of benzylated tertiary sulfonamide via benzylation.  To 
a solution of sulfonamide (3.44 mmol, 1.0 equiv.) and benzyl bromide (5.19 mmol, 1.5 
equiv.) in CH3CN (50 mL, 0.1 M), was added K2CO3 (10.32 mmol, 3.0 equiv.).  The 
reaction was stirred and refluxed at 80 °C overnight.  Upon completion, the reaction mixture 
was cooled to room temperature, quenched with EtOAc and water, organic layer was 
separated, and aqueous layer was extracted with EtOAc (x3).  The combined organic layers 
were dried (Na2SO4), concentrated under reduced pressure, subject to automated column 
chromatography to afford the product. 
 
General Procedure C: preparation of tetramic acid sultam analog via intramolecular 
sulfa-Dieckmann cyclization.  A solution of sulfonamide (1.01 mmol, 1.0 equiv.) in THF 
 254 
(100 mL, 0.01M) was cooled to -78 °C in dry ice/acetone bath.  Then the solution was 
treated with LiHMDS (2.0 mmol, 1M in THF) slowly at -78 °C, and stirred for 2 hours.  
Then the reaction was warmed to room temperature, and quenched with 10% HCl and 
EtOAc, organic layer was separated and the aqueous layer was extracted with EtOAc (x3).  
The combined organic layers were dried (Na2SO4), concentrated under reduced pressure, 
subject to column chromatography to afford the product. 
 
General Procedure D: preparation of 3-carboxamide tetramic acid sultam analogs via 
addition into isocyanates.  To a solution of sultam (0.03 mmol, 1.0 equiv.) and phenyl 
isocyanate (0.03 mmol, 1.0 equiv.) in CH3CN (2 mL, 0.01 M) in a microwave vial, was 
added Et3N (0.03 mmol, 1.0 equiv.).  The reaction mixture was microwaved at 80 °C for 40 
minutes.  The resulting mixture was concentrated under reduced pressure and subject to 
automated column chromatography to afford the product.  
 
(S)-2-benzyl-3-isopropylisothiazolidin-4-one 1,1-dioxide (3.A.1) 
 
According to general procedure C, 3.A.1 (15 mg, 65%) was isolated as golden oil.  
[𝜶]𝑫𝟐𝟎 = -121.24 (c = 1.25, CH2Cl2);   






1H NMR (500 MHz, CDCl3) δ 7.32–7.24 (m, 3H), 7.21–7.17 (m, 2H), 4.90 (s, 1H), 4.69 (s, 
1H), 4.07 (ddd, J = 7.8, 4.9, 1.1 Hz, 1H), 3.81 (d, J = 14.8 Hz, 1H), 3.74 (d, J = 16.8 Hz, 
1H), 3.58 (dd, J = 16.8 Hz, 1.0, 1H), 3.45 (d, J = 14.8 Hz, 1H), 3.17 (dd, J = 14.2, 4.9 Hz, 
1H), 3.10 (dd, J = 14.2, 7.8 Hz, 1H), 1.58 (s, 3H); 
13C NMR (126 MHz, CDCl3) δ 198.1, 134.39, 128.95, 128.92, 128.43, 73.54, 56.2, 47.7, 
29.8, 18.8, 17.1; 
HRMS calculated for C13H17NO3SNa 290.0827 (M+Na)+; found 290.0819 (TOF MS ES+). 
 
(S)-2-(2-fluorobenzyl)-3-isopropylisothiazolidin-4-one 1,1-dioxide (3.A.2) 
 
According to general procedure C, 3.A.2 (11 mg, 72%) was isolated as reddish brown oil. 
[𝜶]𝑫𝟐𝟎 = -128.26 (c = 1.25, CH2Cl2); 
FTIR (neat): 2969, 2933, 2358, 2341, 2331, 1758, 1409, 1456, 1323, 1207, 1139, 759 cm-1; 
1H NMR (500 MHz, CDCl3) δ 7.59 (td, J = 7.6, 1.7 Hz, 1H), 7.35 (ddd, J = 15.4, 5.3, 1.8 
Hz, 1H), 7.20 (td, J = 7.5, 1.1 Hz, 1H), 7.13–7.07 (m, 1H), 4.59 (q, J = 15.8 Hz, 2H), 3.82–
3.70 (m, 2H), 3.63 (dd, J = 4.7, 1.2, Hz 1H), 2.25–2.17 (m, 1H), 1.08 (d, J = 7.0 Hz, 3H), 
0.97 (d, J = 6.9 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ 197.8, 161.8, 159.4, 131.43, 130.3, 115.5, 73.8, 56.2, 41.1, 
30.0, 18.8, 17.3;  







(S)-2-(2-chlorobenzyl)-3-isopropylisothiazolidin-4-one 1,1-dioxide (3.A.3) 
 
According to general procedure C, 3.A.3 (16 mg, 73%) was isolated as golden oil. 
[𝜶]𝑫𝟐𝟎 = -124.56 (c = 1.25, CH2Cl2);  
FTIR (neat): 3021, 2967, 2931, 1767, 1413, 1350, 1343, 1196, 1140, 1054, 843 cm-1;  
1H NMR (500 MHz, CDCl3) δ 7.62 (dd, J = 7.6, 1.7 Hz, 1H), 7.38 (dd, J = 7.7, 1.5 Hz, 
1H), 7.33–7.26 (m, 2H), 4.75 (d, J = 16.0 Hz, 1H), 4.52 (d, J = 16.0 Hz, 1H), 3.80 (s, 2H), 
3.66 (d, J = 4.7 Hz, 1H), 2.10 (qd, J = 6.9, 2.2 Hz, 1H), 1.02 (d, J = 7.0 Hz, 3H), 0.91 (d, J = 
6.9 Hz, 3H);  
13C NMR (126 MHz, CDCl3) δ 197.8, 133.5, 132.8, 130.8, 129.8, 129.6, 127.4, 75.0, 55.9, 
45.0, 30.2, 18.7, 17.1; 
HRMS calculated for C13H16ClNO3SH 302.0618 (M+H)+; found 302.0613 (TOF MS ES+). 
 
(S)-3-isopropyl-2-(4-methylbenzyl)isothiazolidin-4-one 1,1-dioxide (3.A.4) 
 
According to general procedure C, 3.A.4 (18 mg, 67%) was isolated as brownish oil.  
[𝜶]𝑫𝟐𝟎 = -125.24 (c = 1.25, CH2Cl2); 












1H NMR (500 MHz, CDCl3) δ 7.26 (d, J = 8.0 Hz, 2H), 7.15 (d, J = 7.8 Hz, 2H), 4.60 (d, J 
= 15.4 Hz, 1H), 4.27 (d, J = 15.4 Hz, 1H), 3.72 (d, J = 1.2 Hz, 1H), 3.71 (s, 1H), 3.55 (dd, J 
= 4.5 Hz, 1.2, 1H), 2.32 (d, J = 7.5 Hz, 3H), 2.16–2.05 (m, 1H), 0.99 (d, J = 7.0 Hz, 3H), 
0.91 (d, J = 7.0 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ 198.2, 138.1, 131.2, 129.6, 129.0, 73.4, 56.2, 47.2, 30.0, 
21.1, 19.0, 17.1; 
HRMS calculated for C14H19NO3SNa 304.0983 (M+Na)+; found 304.0983 (TOF MS ES+). 
 
(S)-2-(4-bromobenzyl)-3-isopropylisothiazolidin-4-one 1,1-dioxide (3.A.5) 
 
According to general procedure C, 3.A.5 (13 mg, 69%) was isolated as golden yellow oil.  
[𝜶]𝑫𝟐𝟎 = -132.29 (c = 1.25, CH2Cl2); 
FTIR (neat): 3016, 2969, 2929, 1758, 1409, 1348, 1323, 1201, 1139, 1054, 854 cm-1; 
1H NMR (500 MHz, CDCl3) δ 7.50–7.46 (m, 2H), 7.27 (d, J = 8.5 Hz, 2H), 4.47 (d, J = 
15.8 Hz, 1H), 4.35 (d, J = 15.8 Hz, 1H), 3.76–3.74 (m, 2H), 3.55 (dd, J = 4.2 Hz, 1.0, 1H), 
2.10–2.00 (m, 1H), 1.01 (d, J = 7.0 Hz, 3H), 0.90 (d, J = 6.9, 3H); 
13C NMR (126 MHz, CDCl3) δ 197.3, 133.6, 132.0, 130.3, 123.0, 73.8, 56.4, 46.7, 30.3, 
18.5, 16.6;  








(S)-2-(4-chlorobenzyl)-3-isopropylisothiazolidin-4-one 1,1-dioxide (3.A.6) 
 
According to general procedure C, 3.A.6 (0.110 g, 61%) was isolated as brown oil. 
[𝜶]𝑫𝟐𝟎 = -15.8 (c = 0.55, CH3OH); 
FTIR (thin film): 3299, 2938, 1757, 1718, 1598, 1491, 1415, 1316, 1207, 1094, 1051, 
1015, 912, 846, 798, 717, 663 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.35 (s, 4H), 4.55–4.36 (m, 2H), 3.78–3.76 (m, 2H), 
3.57 (dd, J = 4.3, 1.2 Hz, 1H), 2.12–2.03 (m, 1H), 1.03 (d, J = 7.0 Hz, 3H), 0.93 (d, J = 6.9 
Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 197.75, 134.52, 133.18, 130.31, 129.28, 73.89, 56.41, 
46.91, 30.00, 18.87, 16.99. 
HRMS calculated for C13H17ClNO3S (M+H)+ 302.0618; found 302.0583 (TOF MS ES+). 
 
(S)-3-isopropyl-2-(4-(trifluoromethyl)benzyl)isothiazolidin-4-one 1,1-dioxide (3.A.7) 
 
According to general procedure C, 3.A.7 (0.170 g, 51%) was isolated as a white solid. 












mp 95–97 °C; 
FTIR (thin film): 2968, 1638, 1621, 1595, 1535, 1447, 1328, 1232, 1117, 1032, 1016, 967, 
818 cm-1; 
1H NMR (400 MHz, Chloroform-d) δ 7.65 (d, J = 8.2 Hz, 2H), 7.55 (d, J = 8.2 Hz, 2H), 
4.53 (s, 2H), 3.81 (s, 2H), 3.60 (d, J = 4.1 Hz, 1H), 2.08 (heptd, J = 6.9, 4.4 Hz, 1H), 1.04 (d, 
J = 7.0 Hz, 3H), 0.93 (d, J = 6.9 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ 197.46, 139.02 (d, J = 1.08 Hz), 130.76 (q, J = 32.7 Hz), 
129.07, 126.04 (q, J = 3.7 Hz), 124.01 (q, J = 272.1 Hz), 74.31, 56.35, 47.08, 30.03, 18.84, 
16.93; 
HRMS calculated for C14H16F3NO3SNa+ (M+Na) 358.0695; found 358.0701. 
 
(S)-2-benzyl-3-isobutylisothiazolidin-4-one 1,1-dioxide (3.A.8) 
 
According to general procedure C, 3.A.8 (12 mg, 61%) was isolated as golden oil. 
[𝜶]𝑫𝟐𝟎 = -123.56 (c = 1.25, CH2Cl2); 
FTIR (neat): 2958, 2933 2358, 1758, 1496, 1456, 1348, 1319, 1203, 1127, 1053, 698 cm-1; 
1H NMR (500 MHz, CDCl3) δ 7.60–7.57 (m, 4H), 7.57–7.52 (m, 1H), 4.83 (d, J = 15.0 Hz, 
1H), 4.52 (d, J = 14.9 Hz, 1H), 4.02 (dd, J = 17.0, 1.2 Hz, 1H), 3.97–3.92 (m, 2H), 1.94 (tt, 






13C NMR (126 MHz, CDCl3) δ 199.5, 134.2, 129.0, 128.6, 67.0, 55.4, 47.7, 39.3, 24.5, 
22.5, 22.2; 
HRMS calculated for C14H19NO3SH 282.1164 (M+H)+; found 282.1154 (TOF MS ES+). 
 
(S)-2-(2-bromobenzyl)-3-isobutylisothiazolidin-4-one 1,1-dioxide (3.A.9) 
 
According to general procedure C, 3.A.9 (0.080 g, 37%) was isolated as yellow oil. 
[𝜶]𝑫𝟐𝟎 = +30.4 (c = 0.25, CH3OH); 
FTIR (thin film): 2958, 2871, 1759, 1468, 1441, 1318, 1202, 1025, 851, 752, 660 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.62–7.52 (m, 2H), 7.39–7.32 (m, 1H), 7.24–7.17 
(m, 1H), 4.71 (dd, J = 15.6, 2.2 Hz, 1H), 4.53 (dd, J = 15.5, 2.3 Hz, 1H), 3.87 (s, 1H), 3.85–
3.80 (m, 1H), 1.71–1.61 (m, 3H), 0.79–0.72 (m, 6H). 
13C NMR (126 MHz, CDCl3) δ 199.27, 134.28, 133.33, 130.91, 130.06, 128.15, 123.90, 
68.19, 55.09, 47.84, 39.60, 24.65, 22.66, 22.08. 
HRMS calculated for C14H19BrNO3S (M+H)+ 360.0269; found 360.0255 (TOF MS ES+). 
 













According to general procedure C, 3.A.10 (18 mg, 67%) was isolated as brownish oil.  
[𝜶]𝑫𝟐𝟎 = 129.27 (c = 1.25, CH2Cl2); 
FTIR (neat): 3029, 2940, 2855, 2359, 2335, 1768, 1470, 1321, 1225, 1145, 1127, 729, 711 
cm-1; 
1H NMR (500 MHz, CDCl3) δ 7.24 (t, J = 3.6 Hz, 2H), 7.15 (d, J = 7.9 Hz, 2H), 4.62 (d, J 
= 14.9 Hz, 1H), 4.21 (d, J = 14.9 Hz, 1H), 3.78 (dd, J = 16.9 Hz, 1.2, 1H), 3.75–3.71 (m, 
1H), 3.69 (d, J = 16.9 Hz, 1H), 2.32 (d, J = 6.7 Hz, 3H), 1.79–1.70 (m, 1H), 1.70–1.58 (m, 
2H), 0.78 (dd, J = 13.2, 6.5 Hz, 6H); 
13C NMR (126 MHz, CDCl3) δ 199.6, 138.4, 131.0, 129.6, 129.0, 66.6, 55.3, 47.7, 39.3, 
24.5, 22.5, 22.2, 21.1; 
HRMS calculated for C15H21NO3SH 296.1320 (M+H)+; found 296.1315 (TOF MS ES+). 
 
(S)-3-benzyl-2-(2-methylallyl)isothiazolidin-4-one 1,1-dioxide (3.A.11) 
 
According to general procedure C, 3.A.11 (22 mg, 63%) was isolated as yellow oil. 
[𝜶]𝑫𝟐𝟎 = -104.23 (c = 1.25, CH2Cl2); 
FTIR (neat): 3006, 2956, 2929, 2869, 1758, 1348, 1321, 1201, 1137, 1054, 1020, 811 cm-1; 
1H NMR (500 MHz, CDCl3) δ 7.32–7.24 (m, 3H), 7.21–7.17 (m, 2H), 4.90 (s, 1H), 4.69 (s, 
1H), 4.07 (ddd, J = 7.8, 4.9, 1.1 Hz, 1H), 3.81 (d, J = 14.8 Hz, 1H), 3.74 (d, J = 16.8 Hz, 
1H), 3.58 (dd, J = 16.8, 1.0 Hz, 1H), 3.45 (d, J = 14.8 Hz, 1H), 3.17 (dd, J = 14.2, 4.9 Hz, 






13C NMR (126 MHz, CDCl3) δ 198.7, 138.7, 135.5, 129.6, 128.8, 127.4, 116.8, 76.7, 69.3, 
55.4, 55.3, 50.4, 37.1, 19.9; 
HRMS calculated for C14H17NO3SH 280.1007 (M+H)+; found 280.0997 (TOF MS ES+). 
 
(S)-2-allyl-3-benzylisothiazolidin-4-one 1,1-dioxide (3.A.12) 
 
According to general procedure C, 3.A.12 (9 mg, 65%) was isolated as golden oil.  
[𝜶]𝑫𝟐𝟎 = -142.58 (c = 1.25, CH2Cl2);  
FTIR (neat): 3015, 2967, 2935, 2875, 1763, 1351, 1332, 1212, 1141, 1071, 1032, 811 cm-1;  
1H NMR (400 MHz, CDCl3) δ 7.31 (ddd, J = 8.5 Hz, 7.7, 3.6, 3H), 7.22–7.18 (m, 2H), 5.70 
(dddd, J = 17.0, 10.0, 8.6, 5.3 Hz, 1H), 5.24 (d, J = 10.0 Hz, 1H), 5.11 (d, J = 17.1 Hz, 1H), 
4.13–4.03 (m, 2H), 3.66 (d, J = 16.6 Hz, 1H), 3.46 (ddd, J = 23.9 Hz, 16.0, 4.9, 2H), 3.13 
(ddd, J = 21.5, 14.2, 5.9 Hz, 2H);  
13C NMR (101 MHz, CDCl3) δ 198.5, 135.2, 130.9, 129.7, 128.7, 126.7, 121.5, 69.1, 55.8, 
47.0, 36.3; 
HRMS calculated for C13H15NO3SNa 288.0670 (M+Na)+; found 288.0652 (TOF MS ES+). 
 







According to general procedure C, 3.A.13 (0.131 g, 96%) was isolated as yellow solid. 
[𝜶]𝑫𝟐𝟎 = +9.00 (c = 0.10, CH3OH);  
mp 123–125 °C; 
FTIR (thin film): 3010, 2937, 1748, 1604, 1510, 1492, 1329, 1224, 1119, 1035, 841, 745, 
699, 681 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.34–7.29 (m, 3H), 7.16–7.12 (m, 2H), 7.10–7.05 
(m, 2H), 7.00–6.94 (m, 2H), 4.66–4.58 (m, 1H), 3.93 (ddd, J = 8.2, 4.3, 1.4 Hz, 1H), 3.83 
(d, J = 15.0 Hz, 1H), 3.73–3.54 (m, 2H), 3.17–3.04 (m, 2H). 
13C NMR (126 MHz, Chloroform-d) δ 198.03, 162.68 (d, J = 247.9 Hz), 135.52, 130.88 
(d, J = 8.2 Hz), 129.62 (d, J = 3.3 Hz), 129.51, 128.90, 127.46, 115.89 (d, J = 21.6 Hz), 
68.94, 55.83, 47.28, 37.10. 
HRMS calculated for C17H17FNO3S (M+H)+ 334.0913; found 334.0927 (TOF MS ES+). 
 
(S)-2-(2-fluorobenzyl)-3-methylisothiazolidin-4-one 1,1-dioxide (3.A.14) 
 
According to general procedure C, 3.A.14 (0.049 g, 32%) was isolated as yellow oil. 












FTIR (thin film): 2937, 1763, 1618, 1588, 1492, 1456, 1316, 1211, 1138, 1054, 1033, 872, 
843, 820, 761, 693 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.55–7.49 (m, 1H), 7.37–7.30 (m, 1H), 7.22–7.16 
(m, 1H), 7.12–7.05 (m, 1H), 4.62–4.55 (m, 1H), 4.53–4.46 (m, 1H), 3.90–3.82 (m, 3H), 1.41 
(d, J = 6.9 Hz, 3H). 
13C NMR (126 MHz, Chloroform-d) δ 198.38, 160.95 (d, 1JC-F = 247.0 Hz), 131.35 (d, 2JC-
F = 3.5 Hz), 130.38 (d, 3JC-F = 8.1 Hz), 124.77 (d, 4JC-F = 3.6 Hz), 121.72 (d, 5JC-F = 14.1 
Hz), 115.72 (d, 6JC-F = 21.5 Hz), 64.32, 55.11, 38.41, 15.05. 
HRMS calculated for C11H13FNO3S (M+H)+ 258.0600; found 258.0582 (TOF MS ES+). 
 
(S)-3-((R)-sec-butyl)-2-(4-fluorobenzyl)isothiazolidin-4-one 1,1-dioxide (3.A.16) 
 
According to general procedure C, 3.A.16 (0.119 g, 66%) was isolated as yellow oil. 
[𝜶]𝑫𝟐𝟎 = -22.9 (c = 0.80, CH3OH); 
FTIR (thin film): 3104, 2984, 1758, 1606, 1511, 1316, 1222, 1139, 704 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.42–7.37 (m, 2H), 7.09–7.04 (m, 2H), 4.56 (d, J = 
15.7 Hz, 1H), 4.33 (d, J = 15.7 Hz, 1H), 3.78–3.75 (m, 2H), 3.67 (dd, J = 3.9, 0.9 Hz, 1H), 
1.82–1.74 (m, 1H), 1.51 (ddd, J = 14.0, 7.5, 6.5 Hz, 1H), 1.39 (dt, J = 14.0, 7.5 Hz, 1H), 







13C NMR (126 MHz, Chloroform-d) δ 197.72, 162.64 (d, 1JC-F = 247.8 Hz), 130.71 (d, 2JC-
F = 8.2 Hz), 130.09 (d, 3JC-F = 3.2 Hz), 115.87 (d, 4JC-F = 21.5 Hz), 71.73, 56.54, 45.73, 
36.21, 25.68, 13.97, 11.87. 
HRMS calculated for C14H19FNO3S (M+H)+ 300.1070; found 300.1076 (TOF MS ES+). 
 
(S)-2-(4-bromobenzyl)-3-((R)-sec-butyl)isothiazolidin-4-one 1,1-dioxide (3.A.17) 
 
According to general procedure C, 3.A.17 (10 mg, 50%) was isolated as golden oil. 
[𝜶]𝑫𝟐𝟎 = -128.25 (c = 1.25, CH2Cl2);   
FTIR (neat): 2964, 2933, 2358, 2341, 1758, 1488, 1319, 205, 1139, 1070, 1010, 796 cm-1;   
1H NMR (500 MHz, CDCl3) δ 7.62–7.47 (m, 2H), 7.41–7.19 (m, 3H), 4.57–4.31 (m, 3H), 
3.85–3.77 (m, 2H), 3.69 (dd, J = 7.4 Hz, 3.8, 1H), 1.84–1.73 (m, 1H), 1.60–1.48 (m, 1H), 
1.47–1.36 (m, 1H), 1.06–1.00 (m, 1H), 0.91 (d, J = 6.9, 3H), 0.86–0.77 (m, 4H); 
13C NMR (126 MHz, CDCl3) δ 197.6, 132.1, 130.9, 122.5, 77.1, 72.0, 45.9, 36.5, 25.7, 
14.4, 11.9; 
HRMS calculated for C13H18BrNO3SH 360.0269 (M+H)+; found 360.0255 (TOF MS ES+). 
 








According to general procedure C, 3.A.18 (3 mg, 20%) was isolated as golden oil.  
[𝜶]𝑫𝟐𝟎 = -145.26 (c = 1.25, CH2Cl2);  
FTIR (neat): 2964, 2933, 2873, 1781, 1485, 1436, 1372, 1292, 1201, 1128, 1171, 1006, 
962, 910, 883, 831, 790, 773, 526, 518, cm-1;  
1H NMR (500 MHz, CDCl3) δ 8.01 (s, 1H), 7.47–7.42 (m, 2H), 7.37–7.28 (m, 2H), 7.17–
7.13 (m, 1H), 7.08–7.01 (m, 1H), 6.96 (t, J = 6.1 Hz, 1H), 6.66 (d, J = 8.3 Hz, 2H), 4.41 (d, 
J = 15.1 Hz, 1H), 3.98 (t, J = 5.6 Hz, 1H), 3.82 (d, J = 15.1 Hz, 1H), 3.57 (dt, J = 16.7 Hz, 
8.9, 2H), 3.20 (dd, J = 10.7, 7.1 Hz, 2H);  
13C NMR (126 MHz, CDCl3) δ 198.1, 137.4, 135.8, 133.6, 130.8, 126.3, 123.4, 122.6, 
119.9, 118.3, 111.2, 108.8, 94.0, 68.3, 55.7, 48.0, 27.2;  
HRMS calculated for C19H17IN2O3SH 481.0083 (M+H)+; found 481.0074 (TOF MS ES+). 
 
(S)-tetrahydropyrrolo[1,2-b]isothiazol-3(2H)-one 1,1-dioxide (3.33.3) 
 
According to general procedure C, 3.33.3 (0.149 g, 88%) was isolated as yellow oil. 














FTIR (thin film): 3009, 2939, 1755, 1462, 1310, 1195, 1126, 1094, 1060, 986, 946, 886, 
781 cm-1; 
1H NMR (400 MHz, Chloroform-d) δ 4.28 (dd, J = 8.5, 4.0 Hz, 1H), 3.83–3.72 (m, 2H), 
3.54 (dd, J = 17.5, 1.0 Hz, 1H), 3.48 (ddd, J = 11.3, 7.9, 6.5 Hz, 1H), 2.39–2.18 (m, 2H), 
2.04–1.91 (m, 1H), 1.84–1.70 (m, 1H). 
13C NMR (126 MHz, Chloroform-d) δ 203.83, 72.29, 53.86, 51.12, 30.24, 25.36. 





According to general procedure C, 3.33.4 (10 mg, 72%) was isolated as pink dense oil.  
[𝜶]𝑫𝟐𝟎 = -142.31 (c = 1.25, CH2Cl2); 
FTIR (neat): 2952, 2929, 2856, 2358, 2343, 1762, 1348, 1340, 1201, 1143, 1026, 837, 777 
cm-1;  
1H NMR (500 MHz, CDCl3) δ 4.46 (t, J = 7.5 Hz, 1H), 4.41–4.37 (m, 1H), 3.81–3.76 (m, 
2H), 3.68–3.63 (m, 1H), 3.29 (dd, J = 11.4, 3.7 Hz, 1H), 2.24–2.11 (m, 2H), 0.84 (s, 9H), 
0.03 (s, 6H);  
13C NMR (126 MHz, CDCl3) δ 201.6, 71.4, 71.2, 56.7, 53.9, 38.5, 25.6, 18.0;  








tetrahydro-2H-isothiazolo[2,3-a]pyridin-3(3aH)-one 1,1-dioxide (3.33.5) 
 
According to general procedure C, 3.33.5 (2.121 g, 87%) was isolated as white viscous oil. 
FTIR (thin film): 2941, 2863, 1765, 1720, 1432, 1303, 1207, 1135, 1044, 945, 804, 764, 
706 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 3.82–3.76 (m, 1H), 3.76–3.73 (m, 2H), 3.62–3.54 
(m, 1H), 2.86 (td, J = 12.0, 3.0 Hz, 1H), 2.22 (dqd, J = 12.7, 3.3, 1.3 Hz, 1H), 1.99 (dqd, J = 
13.5, 3.3, 1.2 Hz, 1H), 1.91–1.82 (m, 1H), 1.65–1.53 (m, 1H), 1.52–1.45 (m, 1H), 1.40 (qt, J 
= 13.1, 3.4 Hz, 1H). 
13C NMR (126 MHz, Chloroform-d) δ 197.43, 66.40, 54.60, 40.24, 25.66, 23.46, 22.74. 
HRMS calculated for C7H12NO3S (M+H)+ 190.0538; found 190.0511 (TOF MS ES+). 
 
tert-butyl 3-oxohexahydro-5H-isothiazolo[2,3-a]pyrazine-5-carboxylate 1,1-dioxide 
(3.33.6) 
 
According to general procedure C, 3.33.6 (0.345 g, 43%) was isolated as brown oil. 
FTIR (thin film): 2975, 2867, 2844, 1685, 1414, 1367, 1240, 1132, 1055, 1033, 950, 894, 
766, 728 706 cm-1; 
1H NMR (400 MHz, Chloroform-d) δ 4.48 (s, 1H), 4.21 (s, 1H), 3.78 (s, 2H), 3.71 (dd, J = 












13C NMR (101 MHz, CDCl3) δ 153.97, 81.36, 77.21, 64.24, 54.85, 39.99, 28.30. 
HRMS calculated for C11H18N2O5SNa (M+Na)+ 313.0834; found 313.0851 (TOF MS ES+). 
 
tetrahydroisothiazolo[3,2-c][1,4]oxazin-3(2H)-one 1,1-dioxide (3.33.7) 
 
According to general procedure C, 3.33.7 (0.024 g, 56%) was isolated as light yellow 
viscous oil. 
FTIR (thin film): 2943, 2859, 1765, 1720, 1432, 1303, 1203, 1130, 1044, 950, 804, 760, 
706 cm-1; 
1H NMR (400 MHz, Chloroform-d) δ 4.22 (dd, J = 11.5, 4.0 Hz, 1H), 4.00 (dt, J = 11.7, 
2.9 Hz, 1H), 3.92 (dd, J = 9.1, 4.0 Hz, 1H), 3.77 (d, J = 1.5 Hz, 2H), 3.70–3.61 (m, 2H), 
3.56 (dt, J = 12.1, 2.7 Hz, 1H), 3.25 (ddd, J = 11.9, 10.5, 3.4 Hz, 1H). 
13C NMR (126 MHz, Chloroform-d) δ 195.07, 65.13, 65.10, 63.99, 54.23, 40.87. 



















FTIR (thin film): 3399, 2935, 2255, 1748, 1645, 1537, 1444, 1324, 1226, 1135, 1023, 997, 
824, 761, 699 cm-1; 
1H NMR (400 MHz, DMSO-d6) δ 10.92 (s, 1H), 7.59–7.38 (m, 4H), 7.35–7.14 (m, 5H), 
6.98–6.86 (m, 1H), 4.23 (s, 2H), 2.10–1.93 (m, 2H), 1.64–1.56 (m, 2H), 1.55–1.37 (m, 6H). 
13C NMR (126 MHz, DMSO) δ 185.80, 161.42, 140.54, 140.25, 128.72, 127.90, 127.52, 
126.45, 121.43, 118.40, 94.75, 64.88, 40.43, 32.29, 24.55, 22.32. 
HRMS calculated for C22H23N2O4S (M-H)- 411.1379; found 411.1393 (TOF MS ES-). 
 
1-benzyl-4-hydroxy-N-(4-methoxyphenyl)-2-thia-1-azaspiro[4.5]dec-3-ene-3-
carboxamide 2,2-dioxide (3.36.6) 
 
According to general procedure D, 3.36.6 (0.047 g, 62%) was isolated as yellow viscous oil. 
FTIR (thin film): 3420, 2934, 2252, 1643, 1511, 1455, 1415, 1242, 1141, 1052, 1007, 823, 
761 cm-1; 
1H NMR (400 MHz, DMSO-d6) δ 10.64 (s, 1H), 7.50–7.41 (m, 4H), 7.29 (t, J = 7.5 Hz, 
2H), 7.24–7.17 (m, 1H), 6.88–6.81 (m, 2H), 4.27 (s, 2H), 3.72 (s, 3H), 2.06–1.87 (m, 2H), 
1.70–1.60 (m, 2H), 1.59–1.39 (m, 6H). 
13C NMR (126 MHz, DMSO) δ 185.92, 160.89, 154.48, 140.21, 132.89, 127.96, 127.50, 
126.57, 120.33, 113.94, 93.65, 65.47, 55.14, 40.43, 32.11, 24.41, 22.26. 













According to general procedure D, 3.36.7 (0.035 g, 48%) was isolated as yellow viscous oil. 
FTIR (thin film): 3437, 2939, 2251, 2125, 1653, 1206, 1052, 1007, 822, 760 cm-1; 
1H NMR (400 MHz, DMSO-d6) δ 10.92 (s, 1H), 7.60–7.52 (m, 2H), 7.47–7.41 (m, 2H), 
7.32–7.25 (m, 2H), 7.23–7.16 (m, 1H), 7.11–7.04 (m, 2H), 4.24 (s, 2H), 2.01 (tq, J = 12.9, 
10.5, 5.4, 4.5 Hz, 2H), 1.61 (d, J = 13.7 Hz, 2H), 1.57–1.33 (m, 6H). 
13C NMR (126 MHz, DMSO-d6) δ 185.89, 161.27, 157.12 (d, 1JC-F = 237.6 Hz), 140.44, 
136.52 (d, 2JC-F = 2.9 Hz), 127.93, 127.52, 126.06, 120.03 (d, 3JC-F = 7.5 Hz), 115.20 (d, 4JC-
F = 21.8 Hz), 93.66, 65.03, 40.43, 32.24, 24.51, 22.30. 





















FTIR (thin film): 3437, 2940, 2250, 2124, 1648, 1052, 1027, 1008, 821, 758 cm-1; 
1H NMR (400 MHz, DMSO-d6) δ 10.76 (s, 1H), 7.47–7.40 (m, 4H), 7.33–7.26 (m, 2H), 
7.23–7.17 (m, 1H), 7.10–7.03 (m, 2H), 4.26 (s, 2H), 2.24 (s, 3H), 2.05–1.90 (m, 2H), 1.64 
(d, J = 12.9 Hz, 2H), 1.58–1.39 (m, 5H). 
13C NMR (126 MHz, DMSO) δ 185.80, 161.07, 140.28, 137.32, 130.70, 129.18, 127.96, 
127.51, 126.56, 118.77, 93.14, 65.30, 40.43, 32.14, 24.45, 22.28, 20.46. 





According to general procedure D, 3.36.9 (0.083 g) was isolated as brown oil. 
FTIR (thin film): 2928, 1641, 1575, 1423, 1360, 1271, 1101, 756, 700 cm-1; 
1H NMR (500 MHz, DMSO-d6) δ 10.70 (s, 1H), 7.49 (dt, J = 8.9, 1.7 Hz, 2H), 7.26–7.18 
(m, 2H), 6.90 (t, J = 7.3 Hz, 1H), 3.41 (d, J = 13.4 Hz, 1H), 3.17 (dd, J = 11.6, 3.1 Hz, 1H), 
2.57 (td, J = 12.1, 3.0 Hz, 1H), 1.96–1.88 (m, 1H), 1.82 (d, J = 12.7 Hz, 1H), 1.59 (d, J = 
12.5 Hz, 1H), 1.49–1.29 (m, 2H), 1.16 (qd, J = 12.4, 3.5 Hz, 1H). 
13C NMR (101 MHz, DMSO) δ 161.15, 128.86, 128.66, 121.20, 118.15, 61.32, 50.69, 
38.77, 26.75, 23.89, 23.27. 











carboxamide 1,1-dioxide (3.36.10) 
 
According to general procedure D, 3.36.10 (0.095 g, 53%) was isolated as brown oil. 
FTIR (thin film): 3274, 2943, 2860, 1727, 1619, 1543, 1415, 1337, 1230, 1129, 1030, 955, 
829 cm-1; 
1H NMR (400 MHz, DMSO-d6) δ 10.52 (s, 1H), 7.41 (d, J = 8.5 Hz, 2H), 6.83 (d, J = 8.5 
Hz, 2H), 3.71 (s, 2H), 3.19–3.11 (m, 1H), 2.58 (t, J = 11.9 Hz, 1H), 2.51 (s, 3H), 1.93 (d, J = 
12.5 Hz, 1H), 1.82 (d, J = 12.4 Hz, 1H), 1.64–1.55 (m, 1H), 1.40 (dq, J = 23.3, 12.7 Hz, 
1H), 1.15 (q, J = 11.8 Hz, 1H). 
13C NMR (101 MHz, DMSO) δ 154.00, 135.93, 133.67, 119.66, 113.97, 61.34, 55.15, 
26.85, 25.51, 23.94, 23.31. 
HRMS calculated for C15H19N2O5S (M+H)+ 339.1015; found 339.0979 (TOF MS ES+). 
 
3-hydroxy-N-(p-tolyl)-3a,4,6,7-tetrahydro-5H-isothiazolo[2,3-a]pyridine-2-
carboxamide 1,1-dioxide (3.36.12) 
 
According to general procedure D, 3.36.12 (0.051 g, 30%) was isolated as brown oil. 
FTIR (thin film): 3336, 3063, 2941, 2852, 1666, 1593, 1535, 1441, 1353, 1222, 1118, 
















1H NMR (400 MHz, DMSO-d6) δ 10.37 (s, 1H), 7.39 (d, J = 8.0 Hz, 2H), 7.05 (d, J = 8.0 
Hz, 2H), 3.44 (d, J = 12.9 Hz, 1H), 3.30 (dd, J = 11.7, 3.1 Hz, 1H), 3.10 (qd, J = 7.1, 4.7 Hz, 
2H), 2.62 (td, J = 12.1, 3.0 Hz, 1H), 2.23 (s, 3H), 2.00–1.90 (m, 1H), 1.82 (d, J = 11.8 Hz, 
1H), 1.59 (d, J = 11.7 Hz, 1H), 1.49–1.31 (m, 2H). 
13C NMR (101 MHz, DMSO) δ 160.41, 137.39, 130.45, 129.08, 118.49, 60.62, 45.78, 
38.77, 26.89, 23.75, 23.10, 20.36, 8.62. 
HRMS calculated for C15H19N2O4S (M+H)+ 323.1066; found 323.1026 (TOF MS ES+). 
 
tert-butyl 3-hydroxy-2-(phenylcarbamoyl)-3a,4,6,7-tetrahydro-5H-isothiazolo[2,3-
a]pyrazine-5-carboxylate 1,1-dioxide (3.36.13) 
 
According to general procedure D, 3.36.13 (0.059 g, 70%) was isolated as orange viscous 
oil. 
FTIR (thin film): 2981, 2160, 1691, 1630, 1586, 1510, 1416, 1241, 1162, 1130, 1031, 830 
cm-1; 
1H NMR (500 MHz, DMSO-d6) δ 10.60 (s, 1H), 7.52–7.47 (m, 2H), 7.27–7.21 (m, 2H), 
6.92 (tt, J = 7.3, 1.2 Hz, 1H), 4.07 (s, 1H), 3.81 (d, J = 12.4 Hz, 1H), 3.46–3.38 (m, 2H), 
3.12–3.06 (m, 2H), 2.76 (ddd, J = 12.8, 11.5, 3.5 Hz, 1H), 1.42 (s, 9H). 
13C NMR (126 MHz, DMSO) δ 177.85, 160.91, 153.79, 140.09, 128.77, 121.55, 118.28, 
97.77, 79.34, 59.55, 45.76, 40.43, 28.04, 8.66. 













isothiazolo[2,3-a]pyrazine-5-carboxylate 1,1-dioxide (3.36.14) 
 
According to general procedure D, 3.36.14 (0.054 g, 59%) was isolated as orange viscous 
oil. 
FTIR (thin film): 2985, 2161, 1692, 1634, 1584, 1543, 1512, 1413, 1239, 1166, 1128, 
1034, 832 cm-1; 
1H NMR (500 MHz, DMSO-d6) δ 10.44 (s, 1H), 7.44–7.38 (m, 2H), 6.86–6.81 (m, 2H), 
4.15–3.98 (m, 1H), 3.87–3.77 (m, 1H), 3.70 (s, 3H), 3.46–3.37 (m, 2H), 3.12–3.07 (m, 2H), 
2.76 (ddd, J = 12.8, 11.5, 3.6 Hz, 1H), 1.42 (s, 9H). 
13C NMR (126 MHz, DMSO) δ 177.58, 160.73, 154.13, 153.79, 133.28, 119.72, 113.96, 
97.59, 79.33, 59.54, 55.11, 45.77, 40.43, 28.04, 8.65. 
HRMS calculated for C19H26N3O7S (M+H)+ 440.1491; found 440.1482 (TOF MS ES+). 
 
tert-butyl 2-((4-fluorophenyl)carbamoyl)-3-hydroxy-3a,4,6,7-tetrahydro-5H-





















According to general procedure D, 3.36.15 (0.061 g, 69%) was isolated as orange viscous 
oil. 
FTIR (thin film): 2979, 1702, 1573, 1514, 1415, 1362, 1240, 1161, 1125, 1031, 901, 812, 
760 cm-1; 
1H NMR (500 MHz, DMSO-d6) δ 10.61 (s, 1H), 7.54–7.48 (m, 2H), 7.11–7.05 (m, 2H), 
4.15–3.98 (m, 1H), 3.86–3.76 (m, 1H), 3.46–3.38 (m, 2H), 3.11–3.07 (m, 2H), 2.76 (ddd, J 
= 12.9, 11.5, 3.5 Hz, 1H), 1.42 (s, 9H). 
13C NMR (126 MHz, DMSO-d6) δ 177.88, 160.77, 154.91 (d, 1JC-F = 295.1 Hz), 136.40 (d, 
2JC-F = 2.4 Hz), 119.74 (d, 3JC-F = 7.6 Hz), 115.19 (d, 4JC-F = 22.0 Hz), 97.53, 79.30, 59.50, 
45.71, 40.37, 27.98, 8.60. 
HRMS calculated for C18H23FN3O6S (M+H)+ 428.1292; found 428.1282 (TOF MS ES+). 
 
tert-butyl 3-hydroxy-2-(p-tolylcarbamoyl)-3a,4,6,7-tetrahydro-5H-isothiazolo[2,3-
a]pyrazine-5-carboxylate 1,1-dioxide (3.36.16) 
 
According to general procedure D, 3.36.16 (0.025 g, 28%) was isolated as orange viscous 
oil. 












1H NMR (500 MHz, DMSO-d6) δ 10.51 (s, 1H), 7.40–7.35 (m, 2H), 7.06–7.02 (m, 2H), 
4.14–3.97 (m, 1H), 3.86–3.75 (m, 1H), 3.46–3.37 (m, 2H), 3.10–2.85 (m, 2H), 2.75 (ddd, J 
= 12.9, 11.6, 3.5 Hz, 1H), 2.22 (s, 3H), 1.42 (s, 9H). 
13C NMR (126 MHz, DMSO) δ 177.68, 160.83, 153.79, 137.55, 130.28, 129.17, 118.30, 
97.71, 79.34, 59.53, 40.43, 38.36, 28.04, 20.40, 8.66. 





According to general procedure D, 3.36.17 (0.030 g, 37%) was isolated as dark brown 
viscous oil. 
FTIR (thin film): 3260, 2940, 2256, 1720, 1680, 1605, 1549, 1346, 1230, 1152, 1112, 954, 
830 cm-1; 
1H NMR (500 MHz, DMSO-d6) δ 10.55 (s, 1H), 7.51–7.47 (m, 2H), 7.24 (dd, J = 8.3, 7.3 
Hz, 2H), 6.93 (ddt, J = 8.3, 7.5, 1.4 Hz, 1H), 3.89 (dd, J = 11.1, 4.2 Hz, 1H), 3.70–3.63 (m, 
2H), 3.50–3.43 (m, 1H), 3.39–3.34 (m, 1H), 3.30 (t, J = 10.7 Hz, 1H), 3.01–2.93 (m, 1H). 
13C NMR (126 MHz, DMSO) δ 171.16, 160.37, 138.48, 128.96, 123.97, 119.18, 67.98, 
65.86, 59.13, 55.43, 42.17. 












carboxamide 1,1-dioxide (3.36.18) 
 
According to general procedure D, 3.36.18 (0.021 g, 30%) was isolated as dark brown 
viscous oil. 
FTIR (thin film): 3264, 2937, 2258, 1723, 1680, 1608, 1551, 1348, 1237, 1155, 1110, 
1023, 956, 829 cm-1; 
1H NMR (400 MHz, DMSO-d6) δ 10.15 (s, 1H), 7.49 (d, J = 8.5 Hz, 2H), 6.91 (d, J = 8.6 
Hz, 2H), 4.31–4.25 (m, 2H), 4.22–4.13 (m, 2H), 3.82 (d, J = 9.6 Hz, 1H), 3.73 (s, 3H), 3.65 
(dd, J = 11.7, 3.8 Hz, 1H), 3.50–3.44 (m, 1H). 
13C NMR (101 MHz, DMSO) δ 171.11, 159.81, 155.63, 131.59, 120.71, 114.02, 67.92, 
65.82, 59.05, 55.17, 42.12, 39.52. 
























FTIR (thin film): 3266, 2931, 2257, 1724, 1683, 1610, 1545, 1514, 1348, 1330, 1223, 
1155, 1109, 1048, 1023, 936, 821 cm-1; 
1H NMR (400 MHz, DMSO-d6) δ 10.19 (s, 1H), 7.46 (d, J = 8.1 Hz, 2H), 7.14 (d, J = 8.1 
Hz, 2H), 4.33–4.26 (m, 2H), 4.24–4.13 (m, 2H), 3.85–3.78 (m, 1H), 3.65 (dd, J = 11.6, 3.8 
Hz, 1H), 3.50–3.44 (m, 1H), 2.26 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 171.11, 160.07, 135.96, 132.94, 129.27, 119.17, 67.92, 
65.82, 59.12, 55.40, 42.13, 20.45. 
HRMS calculated for C14H15N2O5S (M-H)- 323.0702; found 323.0688 (TOF MS ES-). 
 
(S)-4-hydroxy-3-isopropyl-N-phenyl-2-(4-(trifluoromethyl)benzyl)-2,3-
dihydroisothiazole-5-carboxamide 1,1-dioxide (3.36.21) 
 
According to general procedure D, 3.36.21 (0.016 g, 99%) was isolated as a white solid. 
[𝜶]𝑫𝟐𝟎 = -23.41 (c = 0.44, CH3OH); 
mp 103–105 °C; 
FTIR (neat): 3393, 2985, 2968, 1626, 1587, 1538, 1448, 1421, 1325, 1233, 1161, 1141, 
1098, 1066, 1031, 1016, 966, 820 cm-1; 
1H NMR (400 MHz, DMSO-d6) δ 10.95 (s, 1H), 7.72 (d, J = 8.5 Hz, 2H), 7.67 (d, J = 8.4 










J = 16.9 Hz, 1H), 4.20 (d, J = 17.0 Hz, 1H), 3.39 (d, J = 2.3 Hz, 1H), 2.03 (ddt, J = 13.9, 7.0, 
3.6 Hz, 1H), 0.89 (d, J = 6.8 Hz, 3H), 0.83 (d, J = 7.0 Hz, 3H); 
13C NMR (126 MHz, DMSO) δ 179.51, 160.99, 144.19, 140.22, 128.75, 128.40, 127.40 (q, 
J = 31.7 Hz), 125.05 (q, J = 3.6 Hz), 124.42 (d, J = 271.9Hz), 121.46, 118.30, 97.86, 71.70, 
49.30, 30.14, 18.58, 17.28; 
HRMS calculated for C21H21F3N2O4SNa+ (M+Na) 477.1066; found 477.1072. 
 
(S)-4-hydroxy-3-isopropyl-N-(4-methoxyphenyl)-2-(4-(trifluoromethyl)benzyl)-2,3-
dihydroisothiazole-5-carboxamide 1,1-dioxide (3.36.22) 
 
According to general procedure D, 3.36.22 (0.160 g, 53%) was isolated as a white solid. 
[𝜶]𝑫𝟐𝟎 = -9.23 (c = 0.26, CH3OH); 
mp >300 °C; 
FTIR (neat): 2968, 1625, 1587, 1546, 1514, 1430, 1329, 1235, 1168, 1146, 1096, 1067, 
1033, 1015, 918, 825 cm-1 
1H NMR (500 MHz, DMSO-d6) δ 10.79 (s, 1H), 7.69 (q, J = 8.2 Hz, 4H), 7.44 (d, J = 9.0 
Hz, 2H), 6.83 (d, J = 9.0 Hz, 2H), 4.62 (d, J = 17.1 Hz, 1H), 4.19 (d, J = 16.9 Hz, 1H), 3.71 
(s, 3H), 3.36 (d, J = 2.5 Hz, 1H), 2.01 (ddd, J = 13.2, 6.6, 2.3 Hz, 1H), 0.89 (d, J = 6.8 Hz, 










13C NMR (126 MHz, DMSO) δ 179.17, 160.73, 154.01, 144.24, 133.48, 128.39, 127.37 (d, 
J = 31.7 Hz), 125.03 (q, J = 4.0, 3.5 Hz), 124.42 (d, J = 271.9 Hz), 119.64, 113.93, 97.72, 
71.67, 55.09, 49.32, 30.12, 18.60, 17.27; 
HRMS calculated for C22H23F3N2O5SNa+ (M+Na) 507.1172; found 507.1177. 
 
(S)-N-(4-fluorophenyl)-4-hydroxy-3-isopropyl-2-(4-(trifluoromethyl)benzyl)-2,3-
dihydroisothiazole-5-carboxamide 1,1-dioxide (3.36.23) 
 
According to general procedure D, 3.36.23 (0.202 g, 97%) was isolated as a yellow syrup. 
[𝜶]𝑫𝟐𝟎 = -6.67 (c = 0.90, CH3OH); 
FTIR (neat): 2975, 1638, 1579, 1541, 1508, 1412, 1324, 1208, 1117, 1065, 1016, 832, 764, 
730 cm-1; 
1H NMR (400 MHz, DMSO-d6) δ 10.38 (s, 1H), 8.23 (s, 1H), 7.09 (q, J = 8.2 Hz, 4H), 
7.00–6.89 (m, 2H), 6.48 (t, J = 8.7 Hz, 2H), 4.03 (d, J = 16.9 Hz, 1H), 3.60 (d, J = 16.9 Hz, 
1H), 2.79 (d, J = 2.5 Hz, 1H), 1.52–1.35 (m, 1H), 0.30 (d, J = 6.8 Hz, 3H), 0.23 (d, J = 7.0 
Hz, 3H); 
13C NMR (126 MHz, DMSO) δ 179.58, 160.86, 157.00 (d, J = 237.8 Hz), 144.18 (d, J = 
0.9 Hz), 136.62 (d, J = 2.3 Hz), 128.40, 127.39 (q, J = 31.5 Hz), 125.05 (q, J = 3.7 Hz), 
124.42 (d, J = 271.9 Hz), 119.74 (d, J = 7.3 Hz), 115.21 (d, J = 21.9 Hz), 97.72, 71.67, 










HRMS calculated for C21H20F4N2O4SNa+ (M+Na) 495.0972; found 495.0978. 
 
(S)-4-hydroxy-3-isopropyl-N-(p-tolyl)-2-(4-(trifluoromethyl)benzyl)-2,3-
dihydroisothiazole-5-carboxamide 1,1-dioxide (3.36.24) 
 
According to general procedure D, 3.36.24 (0.078 g, 65%) was isolated as a white solid. 
[𝜶]𝑫𝟐𝟎 = -40.36 (c = 0.28, CH3OH); 
mp 266-268 °C; 
FTIR (neat): 3384, 2968, 1635, 1599, 1561, 1533, 1443, 1421, 1326, 1234, 1157, 1147, 
1067, 1017, 1031, 914, 813 cm-1; 
1H NMR (400 MHz, DMSO-d6) δ 10.86 (s, 1H), 7.69 (q, J = 8.4 Hz, 4H), 7.41 (d, J = 8.4 
Hz, 2H), 7.04 (d, J = 8.3 Hz, 2H), 4.62 (d, J = 16.9 Hz, 1H), 4.19 (d, J = 17.1 Hz, 1H), 3.37 
(d, J = 2.5 Hz, 1H), 2.23 (s, 3H), 2.02 (td, J = 6.9, 2.5 Hz, 1H), 0.88 (d, J = 6.8 Hz, 3H), 
0.82 (d, J = 7.0 Hz, 3H); 
13C NMR (126 MHz, DMSO) δ 179.31, 160.86, 144.22, 137.71, 130.12, 129.16, 128.40, 
127.38 (d, J = 31.5 Hz), 125.04 (q, J = 3.6 Hz), 124.43 (d, J = 271.9 Hz), 118.27, 97.85, 
71.68, 49.33, 30.14, 20.42, 18.61, 17.27; 





























































































































































































































































































































































































































































































































































































































































































































































































































































































dihydroisothiazole-5-carboxamide 1,1-dioxide (3.36.24) 
 
 
N
S
HO
OO
N
H
OMe
CF3
